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Summary
This work was undertaken to molecularly clone the Nirand strain of 
the polycythaemia inducing Friend spleen focus forming virus (F-SFFVp) 
together with its replication competent helper virus. Friend murine 
leukaemia virus (F-MuLV). To this aim viral extrachromosomal DNA 
molecules (of both linear and circular nature corresponding to both of 
these viruses) which could be induced in Friend cell lines were 
molecularly characterised with respect to their quantitative increase 
during differentiation and subcellular location. One cell line, F4-6 in 
which considerable amounts of these extrachromosomal DNAs could be 
detected was utilised for the large scale production and purification 
of both SFFVp and F-MuLV extrachromosomal DNA molecules. Restriction 
enzyme analysis of such molecules in combination with Southern blotting 
enabled the construction of primary restriction enzyme maps which 
allowed the selection of a molecular cloning strategy. Both of these 
viruses were subsequently molecularly cloned and were subsequently 
shown to be biologically active after transfection into recipient 
cells.
A further aspect of this work was to construct a biologically active 
SFFVp containing a dominant selectable marker gene. A selectable 
construct was generated by joining different regions of the genome of 
the myeloproliferative sarcoma virus (MPSV) and SFFVp. A construct with 
the U3 region from the long terminal repeat (LTR) of SFFVp and the 
envelope gene region (gp55) of SFFVp (designated neo* SFFVp) was found 
to be fully active as a selectable retroviral vector with identical 
biological properties to the wild type SFFVp. Neo* SFFVp induced 
erythroid differentiation in vivo, with infected cells no longer 
requiring erythropoietin for differentiation. Furthermore neo* SFFVp 
infected spleen cells could be used to generate immortal Friend 
leukaemia cells which were selectable with geneticin (neo*).
A further construct, neo* SFFV-M, which had a U3 region originating 
from NPSV was able to cause erythropoietin independent erythroid 
differentiation. However as compared to neo* SFFVp and indeed the wild 
type SFFVp, neo* SFFV-M was able to induce the erythroproliferative 
disease with a different kinetics. All attempts to isolate transformed 
Friend cells with this construct failed.
Finally, based on the neo* SFFVp construct a retroviral vector with a 
deleted envelope gene (and a polylinker cloning site) was constructed 
in order to further examine the pathogenesis of SFFVp.
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1. RETROVIRUSES.
a) History.
Members of the retrovirus family were originally recognised by their 
capacity to induce tumours in susceptible animals, and were the first 
infectious agents found to be oncogenic. The initial retrovirus isolate 
was described by Ellerman and Bang (1908), who transmitted a form of 
chicken leukaemia to previously uninfected birds by injecting them with 
a filtered bacteriologically free extract from leukaemic cells. This 
discovery of the first tumour virus was clouded at the time for 
leukaemia was not at that time recognised as a neoplastic disease. The 
demonstration of Peyton Rous (Rous, 1911), that a filterable agent 
(Rous sarcoma virus: RSV) isolated from the spontaneous sarcoma of a 
domestic chicken could produce sarcomas in other chickens clearly 
demonstrated that infectious agents could be oncogenic. Much later 
oncogenic retroviruses were also isolated from mammals, including the 
milk born mouse mammary tumour virus (MMTV) of mammary carcinomas in 
mice (Bittner, 1942) and the transmission of lymphomas/leukaemia by 
murine leukaemia virus (MuLV, Gross, 1951).
b) Viruses and cancer.
Despite the abundant evidence from laboratory studies for the 
oncogenic potential of these viruses, many workers remained somewhat 
sceptical about their role in naturally occuring cancers and 
experiments were considered only to be interesting in vitro phenomena, 
with no real appliance to in vivo tumourigenesis.
However further studies, and the improved methods for diagnosis and 
classification of tumours and the advent of new molecular techniques
for the detection and analysis of retroviruses changed this view 
dramatically. It is now clear that horizontally transmitted viruses 
(not only oncogenic retroviruses, but also oncogenic DNA tumour 
viruses) play important causative roles in a number of major cancers of 
animals and humans. Examples of DNA tumour viruses shown to be involved 
with malignancies include Epstein-Barr virus (EBV) which is associated 
with two human malignancies, Burkitts lymphoma and nasopharyngeal 
carcinoma (Henle et al.. 1968; Epstein and Achong, 1979; Klein, 1983). 
Many adenovirus serotypes are highly oncogenic in a broad range of 
hosts with rodents being particularly susceptible (Trentin et al.,
1962; Heubner et al., 1963; Rabson and Kirschstein, 1964; Gallimore et^  
al., 1985).
Retroviruses also induce preleukaemia (leukosis) and lymphoid 
malignances in cats (Jarrett, 1984; Neil, 1985), cattle (Kettmann ejt 
al., 1975, 1976) and man (Poiesz et al., 1980, 1981; Gallo et al., 
1983). Indeed they may also cause immune deficiency syndromes, in 
animals, with the best example being Acquired Immune Deficiency 
Syndrome (AIDS), that is caused by a human T-cell leukaemia virus 
(HTLV-III, HIV1), which belongs to a family of viruses (the human T- 
cell leukaemia viruses) which have also been shown to play roles in 
other neoplasias (Ratner et al., 1985).
c) Taxonomy of Retroviruses.
All retroviruses have common morphological, biochemical and physical 
properties that justify their inclusion into a single virus family, 
(Retroviridae).
i) Subfamilies
Retroviruses are widely distributed in nature (Teich, 1982) and 
aeabers of this faaily have been found in aany vertebrate species, froa 
birds to huaans. There is also evidence for their presence in 
invertebrates (Heine et al., 1980; Shiba and Saigo, 1983).
By the Baltiaore classification scheae (Baltimore, 1971) for viruses, 
the retroviruses are aeabers of group VI as they have a single stranded 
RNA genoae of positive polarity (i.e. it is the saae sense as aRNA) and 
have a DNA intermediate during replication.
Retroviruses are divided into three subfamilies of unequal size; 
oncoviruses (Oncovirinae, oncos=tuaour), lentiviruses, (Lentivirinae, 
lente=slow), and spuaaviruses (Spuaavirinae, spuaa=foaa).
a) Spuaaviruses.
Spuaaviruses have been isolated principally as contaminants of 
primary tissue culture cells (Hooks and Gibbs, 1975). These viruses 
derive their name from the characteristic "foamy" degeneration they 
induce in cultured cells. Spuaaviruses have been found in a number of 
aaaaalian species. In feline species, feline syncytiua-foraing viruses 
(FSFV), have been isolated from both healthy cats (Hackett et al.,
1970; Jarrett et. al., 1974) as well as cats with a variety of non- 
neoplastic diseases (Ward and Pederson, 1969; Gaskin and Gillespie, 
1972) and neoplasms (McKissick and Lamont, 1970; Hackett and Nanning, 
1971). Bovine syncytial virus (BSV) has also been isolated from normal 
cattle and cattle suffering froa leukosis (Malmquist et al., 1969). 
There have also been several reports of foamy virus isolates froa human 
tissues, with the first isolate coaing froa a patient with 
nasopharyngeal carcinoma (Achong et. al., 1971; Epstein et al., 1974).
4Another isolate has been isolated from the brain of a patient with 
dialysis encephalopathy (Cameron et al., 1978).
The first foamy virus isolate was of simian origin (simian foamy 
virus, SFV, Rustigion et. al., 1955). There are now at least nine SFV 
serotypes being associated with Old World monkeys. New World monkeys, 
apes and prosimians (Johnston, 1961, 1971; Stiles et. al., 1964; Rogers 
et al., 1967; Gajdusek et. al., 1969; Hooks et al.. 1972, 1973; Rabin et 
al., 1976). These viruses induce persistant infection but they have as 
yet not been associated with a distinct pathology.
b) Lentiviruses.
The two best characterised lentiviruses are visna and maedi viruses 
(Haase et. al., 1978). These two nearly identical sheep viruses induce 
progressive neurological impairment and a chronic degeneration 
respectively, after an extremely long latent period ranging from 
several months to years. These viruses have been termed slow virus 
infections (Sigurdsson, 1954). Other closely related viruses have been 
isolated from sheep and goats, these include progressive pneumonia 
virus (PPV, Kennedy et al.., 1968) and caprine encephalitisarthritis 
virus (CAEV, Cork et al., 1974).
c) Oncoviruses.
The oncoviruses form by far the largest subfamily of retroviruses and 
indeed may be further split into several genera and subgenera. They 
have been isolated from virtually all vertebrate species in which they 
have been diligently sought, including humans. Usually members of the 
subfamily are grouped initially according to the host species from 
which they have been isolated and by the morphogenesis of their
5virions, (type A, B, C or D, as described below). Within these broad 
groups they are further classified by their host range, interference 
patterns, genetic content, antigenic relatedness, mode of transmission 
and pathogenecity. Despite their name, many oncoviruses have not been 
shown to induce disease in vivo.
The following discussion although generally applicable to all 
retroviruses, will focus mainly on specific examples of murine 
oncoviruses.
d) Criteria for retrovirus classification.
Retrovirus virions share a similar morphology (Teich, 1982). They are 
80-130 nm in diameter and consist of an inner electron-dense core 
(nucleoid) that is surrounded by a lipid containing unit membrane. The 
core consists of ribonucleoprotein, surrounded by an icosahedral 
protein capsid. An inner coat core protein is located between the core 
and the envelope. The external surface of the envelope has glycoprotein 
"knobs" that are particularly prominant in the virions of certain 
retroviruses, (Bolognesi et al., 1978). The virion envelope forms as 
the virus buds from the plasma membrane of the cell.
In addition to these morphological similarities, the virions of all 
retroviruses share many physical, chemical and enzymatic properties. 
They are composed of about 60-70% protein, 30-40% lipid, 2-4% 
carbohydrate and 1% RNA, and have a buoyant density of 1.16-1.18 g/ml. 
Their infectivity is extremely sensitive to lipid solvents and 
detergents and to elevated temperatures (56°C for 30 min). Virions 
contain the enzyme reverse transcriptase in addition to the structural 
viral proteins.
The viral RNA genome is composed of two identical positive sense
6single stranded RNAs that possess a capped 5' structure and 
polyadenylated 3' ends (as do most processed cellular mRNAs, Coffin, 
1982) . The two RNA subunits are bound non-covalently to each other near 
their 5' ends. Each RNA subunit is 3.5-9 kilobases (kb) depending on 
the virus. A specific cell-encoded tRNA that is essential for virus 
replication is non-covalently bound near the 5 ‘ end of the RNA,
(Taylor, 1977). The presence of two viral RNA copies in retrovirus 
virions implies that these viruses are diploid.
The genomes of all replication competent retroviruses contain three 
genes encoding the structural proteins; gag codes for the internal 
structural proteins, pol codes for the reverse transcriptase as well as 
a proteinase and an endonuclease which have been assigned to this 
region, and env which codes for the envelope proteins. The order of 
these genes is the same in all retroviruses being; 5'-gag-pol-env-3'.
i) Virion morphology and morphogenesis.
The first systematic classification of retroviruses after their 
species of origin was based on variation in the electron microscopic 
appearance of the viral particles associated with different viruses. 
Four major types of retrovirus particles A, B, C and D are recognised 
and the viruses are subdivided by type in accord with their particle 
morphology (Fine and Schochetman, 1978). The vast majority of these 
viruses such as RSV and NuLV have the C-type morphology. These 
particles develop only as they bud from the plasma membrane, with the 
mature extracellular C-type particle being 80-110 nm in diameter, with 
a centrally positioned core within the envelope.
MMTV is the prototype B-type particle. These particles develop their 
inner core in the cytoplasm and acquire their envelope as they bud from
7the plasma membrane. The mature particle which measures about 125 nm in 
diameter contain an eccentrically located electron-dense core.
Several primate viruses have been classified as type-D: their 
morphological development is similar to that of the B-type particles in 
that their inner core is assembled in the cytoplasm. However, the 
mature (budded) D-type particle resembles C-type particles more 
closely. They are more closely related genetically to the C-type 
particles, (Devare et al., 1978).
A-type particles are only found intracellularly and are devoid of 
infectivity. They do not bud from the membrane and lack a lipid 
containing outer envelope. There are two types of A-type particles: 
intracisternal and intracytoplasmic. The intracisternal forms are 
derived from endogenous viral genomes, that are apparently replication 
defective (Kuff et al., 1981). Little is known about their biology, 
except that they are expressed in early embryos and in murine myelomas 
and can reintegrate into new sites in the host DNA, (Ruff et. al.,
1983). The intracisternal A-type particles have been seen only in mice 
and a limited number of other mammalian species. At least some 
intracytoplasmic A-type particles are precursor forms of B- and D-type 
particles.
ii) Host range variants of murine retroviruses.
Another important concept of retrovirus classification is that of 
cell-tropism, i.e. defining properties of the virus and of those cells 
in which the virus will undergo a complete replication cycle. According 
to this scheme murine retroviruses can be classified into four 
different groups (which may be further grouped together as either 
endogenous or horizontally transmitted).
8a) Ecotropic viruses.
These are viruses that will grow in cells of the species from which 
they were originally isolated, i.e. a mouse virus which replicates well 
in mouse cells, but poorly or at an undetectable level in cells of 
other species. Most ecotropic mouse retroviruses however replicate to a 
limited level in cells from other rodents, such as rats but are usually 
incapable of replicating in cells of higher mammals. The reason for 
this is that the required receptors which interact with the 
envelope protein are not present on the surface of these cells. Both 
endogenous (i.e. the MuLV strains occuring spontaneously in laboratory 
mice being transmitted as inherited genes from one generation to the 
next) and exogenous (i.e. those viruses that are not represented as 
integrated viral copies until after infection of the animal at a 
cellular level, which if then incorporated into the germ line may 
become a stabily inherited endogenous virus) ecotropic viruses may be 
pathogenic.
Susceptible cells can be rendered resistant to specific retrovirus 
infection by pre-infection with a virus bearing the same (or very 
similar) viral env glycoprotein specificity. This phenomenon is known 
as virus interference and is caused by blocking of the cell receptor, 
(first described by Rubin, 1960). Ecotropic viruses use the same 
receptor on mouse cells and are thus subject to cross interference 
(Sarma et al., 1967) whereas ecotropic and amphotropic viruses use 
different receptors on mouse cells and ecotropic and xenotropic viruses 
use different receptors on rat cells (Bresmer and Baltimore, 1977).
b) Xenotropic viruses. (Levy, 1973).
These viruses are endogenous to one species but are unable to
9replicate efficiently in that species, due to lack of the virus 
receptor. Most mouse cells lack receptors for xenotropic MuLV. However 
because of endogenous MuLV and thus expression of their env gene 
receptors may be occupied by this protein leading to a block at the 
receptor level. Activation of such viruses in vivo is not readily 
detected because the barrier to re-infection abrogates the 
establishment of a chronic virus producing state. They do however tend 
to have a broad host range on heterologous species. The majority of 
endogenous retroviruses display a xenotropic host range, although none 
of the xenotropic viruses have yet been shown to be pathogenic in any 
animal.
c) Amphotrophic viruses.
These viruses have a broad host range and replicate well in both the 
cells in which they were originally isolated and also heterologous 
cells including those from other species. They are horizontally 
transmitted and are not endogenous. An important criterion, which 
separates this group of viruses from ecotropic and xenotropic viruses 
is that they do not show cross interference or neutralisation (by 
antibodies directed against the envelope protein gp70) with these 
viruses. This is probably due to the fact that their env glycoproteins 
are unrelated to those of the ecotropic and xenotropic viruses. This 
group of viruses have not been shown to be pathogenic.
d) Dual or Polytropic viruses.
These are endogenous viral genomes present in mice which have 
recombined between ecotropic and xenotropic strains, that also, like 
the amphotropic viruses replicate well in both homologous and
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heterologous cells. But, unlike the amphotropic viruses they are 
neutralised by antiserum to the major env glycoprotein, gp70, of both 
ecotropic and xenotropic retroviruses, and are also subject to cross 
interference with either of the two virus groups, although there are 
several classes of which some do not show cross interference. An 
example is mink cell focus-forming (MCF) virus so called because of 
their ability to induce focal growth or morphological alterations in 
monolayers of mink lung cells, (Hartley et al., 1977).
iii) Subdivisions of the ecotropic viruses.
The tropisms may be further sub-divided according to a particular 
mouse strain in which the ecotropic viruses are able to replicate. 
Inbred mouse strains have a genetic locus, designated Fv-1, that 
restricts replication of virus to varying extents (i.e. confers 
resistance or susceptiblity to the mouse, (Lilly and Pincus, 1973)). At 
this locus two alleles have been identified and denoted Fv-1“ and Fv- 
lb, where n represents the prototype NIH-Swiss mice and b the prototype 
BALB/C mice, (Hartley et al.. 1970; Pincus et al., 1971; Pincus et al.. 
1975). The mice carrying the Fv-1“ allele at both loci are designated 
Fv-1““, and are only infected by a class of naturally occuring murine 
leukaemia viruses. These are denoted N-tropic viruses and Fv-1““ mice 
are resistant to another class of naturally occuring MuLV (B-tropic) 
viruses. Mice with the Fv-lbb genotype show the reciprocal phenomenon. 
There is yet another type of ecotropic virus, the so called NB-tropic 
virus which is not regulated at the Fv-1 locus and is thus able to grow 
in both Fv-1D", Fv-lbb and Fv-lnb cells. These viruses are considered 
to be laboratory variants as they have never been isolated as naturally 
occuring viruses. Cell lines obtained from feral (i.e. SGI; Hartley and
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Rowe, 1975) and random bred mice (3T3 FI; Gisselbrecht et al., 1974) do
not exhibit any Fv-1 restriction and have thus been designated a
Fv-l-/- genotype.
The observations mentioned above are hovever not absolute and may be 
overcome by a high multiplicity of infection (as reviewed by Teich, 
1982). As opposed to the receptor restriction, which appears to be 
absolute, the tropisms described above appear to be post penetration
restrictive and have been mapped in or near the gag gene, (Schindler et
al., 1977) and is indeed the p30 protein, (as described later, Gautsch 
et al., 1978; Trees et al., 1979).
This section is summarised in Figure 1.
iv) Transmission of retroviruses.
Retroviruses, like many other infectious agents may be transmitted 
from one host to another by contact between individuals other than from 
parent to offspring (so called horizontal transmission). However a more 
frequent mode of transmission is that from parent to offspring 
(vertical transmission). The second form may be subdivided into two 
mechanisms, i.e. congenital and genetic.
Congenital transmission or infection occurs when infectious viral 
particles released by the mother infect the offspring, of which the 
best known example is the milk born infection of newborn mice with MMTV 
in C3H mice (Bittner, 1942).
During genetic transmission the viral genome is vertically 
transmitted from one generation to the next, as a DNA provirus and is 
maintained as part of the genetic complement of the gametes, the so 
called germinal provirus. The germ-line transmission is not a 
particularly important mode of viral oncogenesis for it only applies to
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Figure 1. Classification of host range categories, demonstrated by 
C-type murine retroviruses
NuLVs are restricted at two levels, either at the receptor level, in 
which either the receptor for the respective virus is either present or 
not, or at a post penetration level in which the virus may attach and 
enter the cell but viral biosynthesis is inhibited.
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particular inbred strain of mice, such as AKR mice, which have a high 
incidence of leukaemia due to their endogenous viruses, and GR mice 
which have a high incidence of mammary carcinomas due to endogenous 
MMTV.
e) Diseases caused by retroviruses.
i) Apathogenic infections.
Among the endogenous retroviruses it is a general rule that there is 
no pathogenicity. Only viruses resident in inbred strains of mice have 
high oncogenic potential, e.g. MuLV in AKR mice and MMTV in GR mice.
ii) Acute neoplasms.
Many C-type retroviruses are able to cause malignant tumours after 
only a very short incubation period, with one good example being the 
rapidly induced splenomegaly of the Friend virus complex where spleen 
enlargement is visible after 4 days.
Acutely oncogenic retroviruses induce specific kinds of leukaemias or 
solid tumours in animals and most of these viruses can also transform 
the same target cells after in vitro infection. These viruses carry 
specific transforming sequences called one genes (Martin, 1970; Vogt, 
1971; Bader, 1972; Baltimore, 1975), which usually occur as inserts 
substituting for portions of the viral structural genes thus rendering 
the virus defective for replication. The viral one genes (v-onc) 
causing cell transformation are derived from cellullar (c-onc) genes 
which normally have a regulating role in the life cycle of the cell. 
However they exert an oncogenic effect when recombined into the viral 
genome under the influence of strong promoter signals provided by the
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proviral long terminal repeat (LTR). Other acutely oncogenic viruses 
carry transforming genes derived from viral env genes, e.g. the spleen 
focus forming virus (SFFV) component of the Friend virus complex (see 
later).
iii) Slow neoplasms.
These are tumours induced by retroviruses that do not carry oncogenes 
as part of their genomes, which may be fast growing and highly 
malignant. Slow indicates the long latent period between infection and 
manifestation of the disease. However these viruses may also be 
subdivided depending on latency period. Friend-MuLV (Oliff et al.,
1980) and Rauscher-MCF virus (Van Griensven and Vogt, 1980) are able to 
cause neoplasms in newborn mice within three to six months whereas Mo- 
MuLV results in a neoplastic disease only after an incubation period of 
longer than six months.
Various models of oncogenesis by the non-acute retroviruses have 
recently been reviewed by Neil and Forrest (1987).
iv) Anaemia, wasting and autoimmune disorders.
Many C-type viruses can cause anaemia, which may be aplastic, due to 
destruction of the stem cells in the bone marrow, hyperplastic due to a 
block in haematopoietic maturation (i.e. the anaemia strain of the 
Friend virus), or haemolytic as in several auto-immune syndromes 
associated with retroviruses.
There are also certain mouse strains that after infection with 
retroviruses (notably MuLVs) give rise to an auto-immune disease, i.e. 
infection of NZBxNZW FI mice gives rise to an auto-immune disease 
that resembles systemic lupus ervthematosis in man, (Talal and
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Steinberg, 1974).
v) Neural diseases.
There is increasing evidence that various C-type viruses are also 
capable of causing neurological disorders, indeed a congenitally 
transmitted virus in feral Californian mice is able to cause both 
lymphomas and hind limb paralysis. The two diseases are not linked but 
both occur late in life, (Gardner et. al.. 1979).
In this brief overview (see Teich et al., 1982 for more detail), the 
terms acute and non-acute oncogenic retroviruses together with brief 
descriptions have been defined. Also it has been mentioned that there 
are defective (not replication competent) and non-defective 
retroviruses. Gene components of the latter may act in trans to rescue 
defective viruses thus forming a virus complex in which both viruses 
may be transmitted as infectious agents.
f) Morphological and biochemical features of retroviruses.
i) Genome RNA structure.
The descriptions given in this section are based on the non-acute, 
non-defective MuLV, which are made up of the classical retrovirus genes 
gag, pol, and env with no additional sequences such as one genes. Other 
viruses will be introduced when appropriate for comparative purposes.
Retroviral genomes are relatively small and display a number of 
features in common:
a) They replicate through a proviral DNA intermediate, which 
subsequently integrates into the host cell genome, where it serves as a 
template for mRNA transcription, using the host cell's RNA synthetic
and processing systems.
b) They have very high recombination rates (in the order of 10-4) 
with/between related viruses.
c) They have the ability to acquire new genetic material from the host 
cell genome which allows the virus to carry out neoplastic 
transformation.
d) They have close relationship with endogenous proviruses integrated 
in the cellular DNA of uninfected animals and which are passed from 
generation to generation by classical Nendelian inheritance.
Like any other viral genome, retroviruses contain nucleotide 
sequences with distinct functions, such as coding regions for specific 
viral proteins and recognition sites for the various enzyme systems 
involved in its replication and expression. Figure 2 shows these 
regions on a scale genome map of a prototype NuLV, Moloney MuLV, genome 
which was the first to be sequenced (Schinnick et al.. 1981).
The dimer structure (60-70S structures) of the retrovirus genomes 
(Duesberg, 1968) first shown for RSV, posed many problems in the 
scientific community of the day, for diploidy in a virus was until then 
unknown. The genomic RNA subunits (34-38S) of retroviruses have several 
chemical modifications similar to those of eukaryotic mRNA, in that 
they have a poly(A) sequence of approximately 200 residues at the 3' 
terminus (Gillespie et al., 1972), with the exact 3' terminus being 
AOH. As in most eukaryotic mRNAs, the 5' terminus of each RNA molecule 
is modified with a typical capping group (CAP). The terminal virus- 
coded G residue (in the case of MuLV) is methylated at the 2' position 
of the ribose and 7-methyl GTP is added via a 5'-5'triphosphate 
linkage, giving the structure m7G5'ppp5'Gm (Furuichi et al., 1975;
Keith and Fraenkel-Conrat, 1975).
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Figure 2. Structure of the non-defective Moloney-MuLV RNA genome
The map is drawn to scale and the terminal regions of the genome are 
based on their nucleotide sequences. The regions are defined and 
described in the text.
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Even in highly purified virions, only about 50% (by veight) of the 
RNA is of viral origin. The remainder is composed of small species, 
most of which are of cell origin and which include variable amounts of 
18S and 28S rRNAs as well as 5S and 7S RNAs identical with species 
found associated with ribosomes in uninfected cells (Bishop et al., 
1970; Erikson et al., 1973; Walker et al., 1974).
Of the small 70S associated RNA molecules, the one most tightly 
associated with the genome is a single molecule per genome of tRNA 
which has been identified as a primer for ONA synthesis. In the case of 
NuLVs this tRNA appears to be tRNA*ro (Peters et. al., 1977). tRNA 
molecules are associated with the genomic RNA by base pairing of the 
3'-terminal 16-19 nucleotides of the primer (Peters et al., 1977), with 
complementary sequences in the genome referred to as the primer binding 
site PB(-), which is located 100-200 nucleotides from the 5' end of the 
genome.
ii) The redundant sequences (R).
This is a short sequence 20-80 nucleotides in length, depending on 
the virus, which is repeated at both ends of the genome and is presumed 
used during replication to permit the transfer of the nascent DNA chain 
and DNA polymerase from the 5' end to the 3' end of the genome (Joho et 
al.. 1978). This process will be described in more detail later, see 
replication.
iii) The U5 region.
This is defined as the 80-100 nucleotide region of unique sequence 
which separates R from the primer binding site PB(-) and has up until 
now been assigned no functional role, although this sequence (together
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with the R sequences) is highly conserved among related viruses. 
Furthermore the predicted conformational structure in this region of 
the genome is conserved (Devare et al.. 1982).
iv) The primer binding site PB(-).
This is the binding site of the tRNA primer for negative strand DNA 
synthesis.
v) The leader region, L.
This is an untranslated region between PB(-) and the initiation codon 
for gaa and has two functions relevant to the replication cycle. In 
NuLV-related viruses, as well as NNTV, this region contains the splice 
donor for env mRNA, whereas in ALV related viruses it is found directly 
following the sixth codon of gag.
The second function performed by the L region is to provide a signal 
for packaging, as indicated by deletion mutants of ALV and NuLV related 
viruses (Mann et. al., 1983; Watanabe and Temin, 1983). The L region of 
many MuLV related viruses also contains an open reading frame preceding 
the initiation codon for gag which apparently acts as a signal sequence 
for the glycosylated version of the gag precursor, gPr80^1 (for 
explanation see; biosynthesis of viral proteins).
vi) The coding regions.
The assignment of the various gene products to the viral genome and 
also their position in the virus particle is shown in Figure 3.
a) The gag-pol region.
The gag gene of all retroviruses analysed have an overall structural
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Figure 3. Schematic representation of the arrangement of the
structural proteins and their corresponding gene location^ 
within the virion
This figure depicts the genome organisation of a type C retrovirus with 
the corresponding protein products and how they are thought to be 
arranged within the virus particle.
Adapted from Dickson et al., 1984.
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similarity and are conserved (at the amino acid level) within each 
group but no sequence homology (at the nucleic acid level) is 
discernable between groups. There is a detectable nucleotide and amino 
acid sequence relationship between the gag gene of NuLV and simian 
sarcoma virus (SSV) for example but not between NuLV and RSV. These two 
genes are grouped together here for both the gag and pol gene products 
are synthesized as a simple high molecular weight precursor polyprotein 
(either the Pr65«*« or the Pr200 ‘) which is subsequently cleaved
to give rise to the mature proteins. Cleavage of this polyprotein 
results in the formation of the pol (NH2 -pl4-p80-p46-COOH) precursor 
which is then further cleaved to give rise to the mature proteins 
(Figure 4). Since only genomic sized RNA (and not the spliced 
subgenomic RNA which was mapped to the 3'end of the genome) is able to 
direct the synthesis of gag and gag-pol precursors in vitro (von der 
Helm and Duesberg, 1975; Phillipsen et al., 1978) and in vivo (Fan and 
Verma, 1978) it was thus established that these genes must occupy the 
5' half of the genome. However the idea that pol is expressed via an 
approximately genome-sized mRNA spliced to remove the terminator that 
ordinarily generates the carboxy terminal of gag is coming more and 
more into decline, for no one has yet shown the presence of such an 
RNA. More recent evidence from the sequence of the translation products 
of the NuLV genome, in which cleavage of the Pr200»,g~P*1 , which 
generates the amino terminus of the pl4 protease, takes place at a 
position corresponding to the fourth amino acid prior to the carboxy 
terminus of Pr65«a«. The amino-terminal amino acid sequence of pl4 
reveals a precise match to the gag and pol amino acids predicted for 
the nucleotide sequence surrounding the UAG terminator.
Furthermore, at the position corresponding to the terminator a
OOZJd
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Figure 4. The predicted structure of Moloney-MuLV Pr200»,B-po1
The scale diagram shows the location of gag and pol specific peptides 
within the Pr200g,g~l><> 1 precursor. The specific regions are 
indicated by the hatched region and the pol specific region by the open 
box.
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9 lutaaine residue has been inserted. Thus the gaq-pol fusion protein 
must have been generated by suppression of termination, i.e. by 
aisincorporation of a glutamine (Yoshinaka et al., 1985).
The observation of Faller and Hopkins (1978) that p30»*« contained a 
sequence involved in abrogating Fv-1 mediated cell resistance to HuLV 
infection vas based on T1 oligonucleotide maps and protein analysis of 
biologically generated recoabinant viruses. This conclusion has been 
confirmed and extended by experiments utilising site-specific 
recombinants generated from cloned HuLV DNA (Boone et al., 1983; Des 
Groseillers and Jolicoeur, 1983; Ou et al., 1983). In all cases the 
difference between N- and B-tropic viruses mapped to the two amino acid 
regions encoded by bases 1605-1610 of the AKR-HuLV genome (1590-1595 in 
Holoney HuLV) corresponding to amino acids 109-110 of p30«,B.
The pol gene apparently encodes two or three polypeptides depending 
on the virus, in the 5'-3' order, protease-polymerase-endonuclease. 
Nucleotide sequence of a number of polymerase genes has revealed that 
pol is the most highly conserved part of the retroviral genome and is 
the only region for which detectable homology at the amino acid level 
is seen in viruses from different groups.
b) The env gene.
The env gene encodes the surface proteins of the virion that are 
required for recognition of specific cell surface receptors necessary 
for initiating infection. Because of their location and role, the env 
products determine both host range and the neutralisation antigens of 
the virion. Although not closely related to one another the env genes 
of different retroviral groups show a great deal of structural 
similarity. There is an overlap between pol and env such that the
splice acceptor delineating the 5' end of env precedes the 3' end of 
pol and translation of env is arranged so that the amino terminus of 
the primary product is within nucleotide sequences also translated to 
give the carboxyl terminus of the pol product, although in a different 
reading frame. The 5' terminal 30-100 codons of env encode a signal 
peptide cleaved off as a consequence of transmembrane processing of the 
env precursor. The resulting glycosylated precursor is cleaved into two 
proteins which remain associated via disulphide bridges. The larger 
(340-450 amino acids) aminoterminal protein contains determinants 
specifying host range. The smaller (180-230 amino acids) 
carboxyterminal protein always contains, near its carboxy terminus a 
hydrophobic domain of 23 amino acids or more, presumably constituting a 
transmembrane anchor region, followed by a basic amino acid and a small 
(approximately 20 amino acids) cytoplasmic domain which could be 
involved in recognition of capsid proteins.
vii) The 3' region.
The primer binding site, PB(+): This has been formally defined as the 
region 5' to the initiation site for positive strand DNA synthesis, 
although the precise primer binding sequence for this region is 
somewhat variable. This region is rich in purines and shows a high 
degree of sequence conservation among otherwise unrelated viruses.
viii) The U3 region.
The U3 portion of the genome forms the bulk of the LTR in the 
provirus and contains a number of short sequences near its termini that 
provide signals for integration, initiation and in some viruses 
polyadenylation (e.g. NNTV, HTLV). The function and organisation of
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these signals will be discussed in detail in the following description 
of replication.
g) Replication.
Retroviruses are unified in their Method of replication, in that they 
follow the cycle RNA-DNA-RNA-protein.
The replication cycle may be split into two phases.
1) Steps leading to the synthesis and integration of the viral DNA, 
from a copy of the viral RNA. These steps include, attachment to and 
penetration of the cell, priming and polymerisation of both strands of 
viral DNA leading to production of linear and circular forms of viral 
DNA and insertion of the viral DNA into the host chromosomal DNA.
2) Expression of the viral genes. This includes transcription of the 
viral RNA, translation, modification of the viral proteins, assembly of 
viral particles and finally maturation from the host cell. An overview 
is presented in Figure 5.
i) The provirus hypothesis.
Up until 1970, the hypothesis based on work with RSV (Temin, 1964) 
that retroviruses replicate via a DNA intermediate (the provirus) was 
not generally accepted. Most of the evidence was indirect and came from 
experiments using inhibitors of DNA synthesis such as actinomycin D, 
which interfered also with retrovirus replication. At the time 
replication of all known RNA viruses was unaffected by such inhibitors 
(Temin, 1963, 1967; Bader, 1965). However experiments using such 
inhibitors confirmed the provirus hypothesis (Boettiger and Temin,
1970; Balduzzi and Morgan, 1970; Duesberg and Vogt, 1969). The deciding 
observation came in 1970 when Baltimore (1970) and Temin and Mizutani
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Figure 5. Schematic representation of the retroviral life cycle
The processes shown represent a complete retrovirus life cycle of a 
non-defective NuLV in which the proviral DNA is integrated such that 
the viral genes may be expressed and thus give rise to infectious viral 
progeny.
The life cycle is divided into cytoplasmic and nuclear phases.
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(1970), independently demonstrated the presence of a RNA-directed DNA 
polymerase activity in purified retrovirus virions which provided the 
necessary biochemical basis for the provirus hypothesis. Further 
support came from the demonstration that retrovirus RNA hybridised 
specifically to infected cells and that DNA from infected cells was 
infectious (Baluda and Nayak, 1970; Hill and Hillova, 1972).
ii) The infection process.
Attachment and uptake: That the virus binds to specific receptors on 
the cell surface and that this is specific has been discussed earlier.
The process of uptake of virus is not well understood, but it has 
been proposed that the internalisation of retroviruses in fibroblasts 
occurs by endocytosis and that the viruses enter and infect cells 
through lysosomes or other acidic vesicles. Conceivably uncoating and 
transfer from the acidic vesicles then occurs by a low pH-dependent 
membrane fusion. This is supported by two sets of observations, in that 
the virus particles are rapidly degraded and that infection is 
inhibited by lysomotropic substances (e.g. chloroquine, amantadine, 
tributylamine, methylamine and ammonia) at a step shortly after 
internalisation (Anderson and Nexo, 1983). If the retroviruses behave 
like better studied viruses such as semiliki forest virus (SFV), then 
one could imagine that membrane fusion must occur between the virion 
membrane and the endosome membrane, delivering the virion core into the 
cytoplasm of the cell (White et al., 1983).
iii) The synthesis of viral DNA.
Within a few hours of infection the core of the virion begins to 
carry out the process of reverse transcription of the viral RNA. This
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is depicted diagraaatically in Figure 6.
All replication coapetent retroviruses carry a gene (pol) which is 
capable of transcribing RNA into DNA (RNA-directed DNA polymerase, 
reverse transcriptase or deoxynucleoside triphosphate; DNA 
deoxvnucleotidyl transferase). This aolecule is present in the aature 
virion. Initial DNA synthesis froa the RNA teaplate gives rise to a 
single strand of DNA which is called the minus strand, since virion RNA 
is the sane sense as aRNA which by definition is plus sense. This ainus 
sense DNA is synthesized as a continuous piece of DNA, however its 
synthesis in practice is performed in three discrete steps because this 
strand is synthesized froa three distinct templates. This alnus strand 
DNA then acts as a teaplate for the synthesis of coapleaentary (plus 
strand) DNA. thus leading to a linear double stranded DNA aolecule. 
These steps are discussed in more detail in the following sections.
DNA synthesis begins with extension of the paired hydroxyl terminus 
of the priaer tRNA, which is located to the right of the U5 boundary 
(Figure 6.1). When the elongating minus strand reaches the S' end of 
the RNA template it stops giving rise to the so called strong stop DNA 
(which is easily seen both in vitro and in vivo). Thus to continue with 
the ainus strand synthesis the polymerase and the strong stop DNA 
coaplex must jump froa the 5' to the 3' end of the virion RNA. a jump 
which is facilitated by the R sequences found duplicated at both ends 
of the RNA and the inherent RNAse H activity of reverse transcriptase. 
This enzymatic activity degrades the R sequences at the 5' end of the 
RNA (Figure 6.2), which enables the minus strand DNA that is 
coapleaentary to these sequences to base pair with the R sequences 
located at the 3‘ end of the viral RNA (Figure 6.3). It is however not 
clear whether the jump is selectively made to the 3' end of the same
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Figure 6. Schematic representation of the formation of the Moloney- 
MuLV double stranded DWA provirus: reverse transcription
The replication strategy depicted is shown for simplicity for a single 
RNA subunit, although it is not clear whether one or two RNA subunits 
are involved in the process.
A detailed discussion is given in the appropriate text.
Adapted from Lowy (1985).
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RNA molecule or to the second RNA subunit found within the virion. In 
both cases the minus strand synthesis, which contains only one R 
sequence can now be extended from the 3' end to the 5' end of the RNA 
(Figure 6.4). Preparations for the third step (synthesis of the minus 
strand 5' LTR) are made before the second step (elongation of the minus 
strand from the 3' end of the viral RNA) has been completed. The 3' LTR 
minus strand DNA is formed once the minus strand U3 sequences have been 
synthesized (Figure 6.5). At this stage the RNAse H presumably 
continues to degrade the RNA from the newly formed RNA:DNA hybrid 
sequences. Thus the plus strand LTR that serves as the template for the 
third step of minus strand synthesis can be synthesized (Figure 6.6, 
Gilboa et. al., 1979; Rung et. al., 1981; Mitra et. al., 1982). This plus 
strand DNA uses the minus strand LTR DNA as its template for the 
synthesis. Its synthesis apparently primed by virion RNA that remains 
just beyond the left hand boundary of U3 (PB+). Although this plus 
strand DNA is made from the 3' minus strand DNA it will eventually 
become the plus strand for the 5' LTR. This plus strand synthesis 
probably extends just beyond the LTR DNA sequences to make a copy of 
the first 18 nucleotides of the tRNA primer that is still linked to the 
minus strand DNA, since these sequences are apparently used in making 
the second template jump, described below (Taylor and Hsu, 1980) . On 
the other strand, minus strand DNA synthesis from the RNA template is 
believed to stop after copying through PB(-) the 18 nucleotides that 
represent the tRNA binding site (Figure 6.7), since the RNA sequences 
(U5 and R) 5' to this site have been degraded by RNAse H thus the 
second stage is completed.
In the third step of minus strand DNA synthesis reverse transcriptase 
switches its template a second time, this time to the plus strand LTR.
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This jump is apparently facilitated by the 18 nucleotides of this plus 
strand fragment that are complementary to the tRNA. The RNAse H 
activity then digests the tRNA from the viral RNA:DNA minus strand 
hybrid (Figure 6.8). These 18 nucleotides on the minus strand are then 
base paired with the complementary 18 nucleotides at the end of the 
plus strand DNA (Figure 6.9). The 5' minus strand LTR is then 
synthesized (Figure 6.10) thus completing this strand and displacing 
the 3' minus strand LTR from the plus strand LTR. Thus the plus strand 
LTR which was originally synthesized from the 3’ LTR becomes the plus 
strand for the 5' LTR. The remainder of the plus strand is synthesized 
by 5'-3‘ extension, (Figure 6.11) thus generating the flush ended 
linear double stranded DNA with LTRs at both ends.
iv) Integration of the viral genome.
Once completed these linear molecules are transferred to the nucleus, 
where they are circularised. Circular DNA has only been recovered from 
the nuclear fraction of infected cells (Guntaka et al., 1976; Fritsch 
and Temin, 1977) and only after sufficient time has elapsed for linear 
DNA to be synthesized and transported to the nucleus (Shank and Varmus, 
1978). These are conventionally described as circular molecules with 
two tandem LTRs or with one LTR, although various irregular forms which 
do not conform to this convention have been isolated by molecular 
cloning (Ju and Skalka, 1980; Shoemaker et al., 1981; Van Beveran et 
al., 1982). Clones with two complete LTRs in tandem are seldom found 
suggesting that they are rarely formed, or once formed are quickly 
integrated. The manner in which linear DNA is converted to the circular 
form remains conjectural, but impaired conversion in several 
experimental situations suggest that both viral and cellular factors
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■ay have a role (Yang et al.. 1980; Chinsky and Soeire. 1982; Huhleitel 
and Aboud, 1983). Which of these forms is subsequently integrated vas 
elegantly shown by Panganiban and Temin (1983), who used recoabinant 
retroviruses to demonstrate that the circular form with two tandem LTRs 
is the immediate precursor to proviral DNA. The same workers also 
showed that the point of recombination leading to integration on the 
viral DNA is specific. Recombination always occurs at specific sites 
near the outer edge of the terminal repeat sequences (the so called 
inverted repeats IRs). For the murine viruses these sequences are 13 bp 
perfect inverted repeats present at the termini of the linear DNA.
These sequences may be designated att sequences, analogous to those 
found in the bacteriophage lambda. When these termini are joined to 
form the circular DNA a perfect 26 bp (in the case of NuLV) palindrome 
is created which appears to act as a substrate for the integration 
reaction (Panganiban and Temin, 1983). The ability of these palindromic 
sequences (in ALV) to act as substrates for in vitro cleavage by the 
endonuclease activity (Duyke et al., 1983) also suggests that this 
structure is a precursor to the integrated provirus. However further 
analysis using No-NuLV in which one of the two termini of the LTR was 
altered showed that a perfect palindrome is indeed not essential and 
that the central four base pairs of the palindrome can be altered in 
sequence and in number without preventing integration (Colicelli and 
Goff. 1985).
The integration of the viral DNA into the host sequences has many 
analogies with integration by transposable elements in both prokaryotes 
and eukaryotes (Shoemaker et al., 1980; Shoemaker et al., 1981). 
Although the point of recombination on the viral DNA appears to be 
specific, the target sites on the host DNA are selected with no (or at
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most low) apparent specificity at the sequence level, and there is no 
obvious pattern common to the target sites (Shimotohno and Temin,
1980). However it should be noted that there is some good evidence that 
the host sequences are not all equally good targets. Some host genes 
for example are "cold spots" for retroviral insertion (King et al.. 
1985) and transcriptionally active areas of the host genome may be "hot 
spots" for insertion, (Vijaya et al., 1986; Rhodewohld, PhD-Thesis, 
Hamburg, 1986; Rbodewohld et al., 1987). One consequence of integration 
of the viral DNA into the host cell genome, is that the two terminal 
nucleotides from each end of the free viral DNA are deleted. For the 
host DNA, proviral insertion results in duplication of 4-6 host 
nucleotides. One copy of these sequences (that were present once in the 
pre-integration site) now flank the left and right ends of the proviral 
DNA. Very little is known about the biochemistry of this reaction, 
although an in vitro system used to analyse this, will result in rapid 
progress (Goff and Lobel, 1987). The region known to be specifically 
required for the establishment of the integrated provirus, has been 
mapped to the 3' of the pol gene, the so called p46»»* (integrase) 
(Schwartzberg et al., 1984; Dornhower and Varmus, 1984). One 
interesting aspect of this integration reaction is that integrated DNAs 
are themselves able to yield progeny virus, probably because the 
unintegrated DNAs are not exposed to the cellular synthetic machinery 
responsible for transcription, but are wrapped up in unaccessable 
structures. It has also been shown by studies in which naked DNA was 
transfected or injected into the cytoplasm of cells, that no specific 
integration occurs, which was interpreted to mean that virion proteins 
must remain associated with the viral nucleic acids after reverse 
transcriptase to afford successful integration (Luciw et al., 1984).
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Integration is thus an essential step in the replication cycle and 
normally precedes transcription and the eventual formation of progeny. 
Biochemical studies followed the genetic (mutation) studies which 
defined the 3* portion of pol as coding for the p46»*1 integrase. These 
show that this protein, although apparently cleaved from nr100»*1 . is 
found in an active form within the virion closely associated with the 
reverse transcriptase (Hu et al.. 1986). It had no endonuclease 
activity. Recently p46»** has been expressed in bacteria and shown to 
be a potent DNA binding protein with preference for single stranded 
over double stranded DNA (Roth and Goff. pers. commun.). The enzyme 
retained its binding properties in 0.2 N salt and lower concentrations 
in the presence of EDTA (stringent DNA binding conditions) although no 
endonuclease activity has been associated with the purified enzyme.
v) Expression of the proviral DNA.
The integrated provirus represents a transcriptional unit that 
contains its own regulatory sequences. However unintegrated viral DNAs 
may also be transcribed, to give rise to viral progeny although very 
inefficiently (Cooper and Okenquist, 1978). Expression of a given 
provirus depends on host specific as well as viral specific factors 
which may include the site at which the provirus is integrated, the 
physiological state of the cell and the viral LTR. The viral gene 
products do not participate in the control of viral transcription per 
se although there are exceptions to this, notably the HIV related virus 
family (Sodroski et al., 1984; Chen et al.. 1985; Felber et. al., 1985). 
However in these systems the provirus depends entirely upon the host 
encoded synthetic machinery. As is true of most cellular genes the 
transcriptionally active proviruses are usually found in hypomethylated
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regions of the DNA that are sensitive to DNAse I (Breatnach and 
Chambon, 1981; Groudine et. al., 1981; Jaenisch et al., 1981; Breindl et 
al., 1982). In vitro methylation can prevent expression of cloned 
retroviral DNA genomes (McGeady et. al., 1983; Simon et. al., 1983). 
However unexpressed non-infectious proviruses after molecular cloning 
into bacteria, are not methylated and are infectious (Harbers et al., 
1981). Conversely proviruses located at DNAse-resistant hypermethylated 
regions are usually unexpressed. Indeed integrated proviruses that are 
transcriptionally active have DNAse I hypersensitive sites within the 
5' and 3' LTRs, sites which appear to correspond to the viral CAP and 
enhancer region (Thompson and Fan, 1985). Thus otherwise normal 
proviruses may be transcriptionally silent, presumably because of the 
influence of the flanking host sequences.
Virus specific regulation of expression depends principally on the 
LTR (Blair et. al., 1980; Chang et al., 1980; Temin, 1981). These 
sequences contain signals for enhancement, promotion, initiation and 
polyadenylation of RNA synthesis and are depicted schematically in 
Figure 7. (Fuhrman et al., 1981; Gilmartin et al., 1983; Luciw et al., 
1983; Wood et al., 1983). Various gene fusion studies have been 
performed on these LTRs to identify functions (Laimens et. al., 1982; 
Levinson et al.. 1982; Laimens et al., 1984; Schulz et al.. 1985). Most 
retroviruses appear to have only one transcriptional initiation start 
site and one poly-A addition site which both lie within the LTR. The 
start site and the poly-A addition site define the R sequences found at 
both ends of the viral genome. The start sites coincide with the 5' end 
of both genomic RNA and the viral mRNAs (Cordell et al., 1978). 
Transcription of viral RNA begins at the end of the R sequences in the 
5' LTR and as is true of most eukaryotic genes is catalysed by a
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Figure 7. Organisation of control sequences in the Wolonev-WuLV LTR
Assignment of control sequences to various regions of the proviral LTR. 
The inverted repeats (vhich form a palindromic sequence) are important 
for integration.
GGAAT and TATAA boxes are important for the correct initiation of 
transcription vhich starts at the CAP site in the 5' LTR and terminates 
at the poly(A) signal in the 3* LTR.
The direct repeats (74 bp) are not depicted here but contain the 
enhancer sequences (core sequence; TGTGGTAAG) responsible for elevated 
transcription levels.
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cellular type II RNA polymerase (as shown by a-amanatin inhibition 
experiments, Dinovitz, 1975; Bishop et al., 1976). The LTRs of RSV and 
MMTV also function as good promoters in E.coli. although the 
transcriptional start sites used in bacterium are not the same as those 
used in eukaryotic cells (Mitsalis et al., 1981; Mermer et al.. 1983; 
Prakash et al., 1983).
Each RNA transcript is polyadenylated post-transcriptionally near the 
3' end of R in the 3* LTR a sequence of events that is initiated by a 
poly (A) signal (usually AATAAA) which is located in R approximately 20 
nucleotides upstream from the right hand end of the R sequences. Thus 
the viral RNA transcriptions begin downstream from the left end of the 
provirus and their poly-A tract is added to sequences located upstream 
from the right end of the provirus.
The U3 regions of all LTRs also possess CCAAT (Efstratiadis et al., 
1980) and TATAA (Corden et. al.. 1980) boxes or very similar sequences 
associated with RNA polymerase II promoter regions just upstream from 
the initiation site (Dhar et al., 1980; Shimotohno et al., 1980; 
Sutcliff et al., 1980; Yamamoto et al., 1980; van Beveren et al., 1980; 
Swanstrom et al. , 1981). In the case of MSV a TATAA homology sequence 
is found 20-30 bp upstream of the putative start site of transcription 
(CAP site, van Beveran et al., 1981; Fuhrman et al., 1981), and a 
pentanucleotide sequence that is homologous to the CCAAT box consensus 
is located in the MSV LTR approximately 80 bp upstream of the mRNA CAP 
site. LTRs also contain sequences that enhance the efficiency of 
transcription in a position and orientation independent manner, being 
able to exert their effects over a long distance of 5 kb and more, 
(Banerji et al. , 1981; Moreau et al., 1981; Fromm and Berg, 1982; 
Gluzman and Sbenk, 1983; Khourv and Gruss, 1983; Neiber et al., 1983).
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LTR enhancers, like enhancers in general, act entirely in cis and 
preferentially upon proximal promoters (de Villiers et al., 1983; 
Wasylyk et y_., 1983). One other property of the enhancers is that they 
appear to display cell specificity as shown for the mouse 
immunoglobulin heavy-chain locus (where they have been found within the 
introns, Banerji et al., 1983; Gilis et al., 1983), and more recently 
for other systems (Gorski et al., 1986). Evidence that the retrovirus 
LTRs contain enhancers came originally from many sources, including the 
fact that the U3 region of the LTR could restore partial replication 
competence to SV40 DNA or augment the frequency of morphological 
transformation of mouse cells (Levinson et al., 1982; Kriegler and 
Botchan, 1983). Attention was drawn to the finding of 50-100 bp tandem 
repeats in the functional domain of the LTR because a similar (72 bp), 
but largely non-homologous duplication, forms the enhancer region of 
SV40. Although the duplication is found within many retroviruses its 
conservation does not appear to be essential, for there are a number of 
murine retroviruses that have only one copy or various combinations 
(see later in section on the Friend virus complex).
MuLV enhancer elements also appear to play an important role in the 
biological behaviour of these viruses, for the leukaemogenic potential 
of certain NuLVs has been assigned to a region in or near to the U3 
region (Des Groseillers et al., 1983; Lenz and Haseltine, 1983; Lung et 
al.. 1984; Lenz et al.. 1984; Des Groseillers and Jolicoeur, 1984). 
Several results imply that a tissue responsive component of the LTR 
might determine pathogenicity by fostering efficient viral growth and 
expression in the target organ. Indeed Des Groseillers et ad., (1983) 
have shown that the ability of a recombinant NuLV to infect thymocytes, 
the target cell for a T-cell leukaemia-inducing virus strain, is
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conferred by the LTR and probably by a sequence vitbin tbe U3 region. 
More in detail studies using the myeloproliferative sarcoma virus 
(MPSV; Kollek et al., 1984; Stacey et al.. 1984) indicated that 
recoabinants carrying all or only tbe U3 region of the Mo-MuSV LTR 
still transform fibroblasts in vitro but do not induce haeaopoietic 
changes in sice (Stocking et al., 1985). To test whether tbe MPSV LTR 
was functionally different froa that of Mo-MuLV froa which it was 
derived, further recoabinants were constructed replacing the MPSV LTR 
with that of Mo-MuLV. The resulting recoabinant was at least two orders 
of aagnitude less active than wild-type MPSV (Stocking et al.. 1986). 
Further studies by Chatis el al., (1983) have deaonstrated that the 
erythroleukaeaic Friend-MuLV (F-MuLV) can be converted to a 
thyaoleukaeaic strain by a 621 nucleotide region, which includes the 03 
region of Mo-MuLV, with the converse also being true (Chatis et al., 
1984). These results have recently been substantiated by Holland el al. 
(1987). Evidence that the MuLV proaoter or enhancer can behave in a 
cell-dependent Banner in cell culture adds strength to the argument 
that the organotropisa and oncogenicity of NuLV aay be closely tied to 
the characteristics of the enhancer (Laiaens §1 al.. 1982; Spandidos 
and Vilkie, 1983; Linney el al., 1984).
Although the aechanisa by which long range activation of proaoter 
regions is achieved is not yet understood, several different lines of 
evidence have iaplicated the involveaent of cellular factors that act 
in trans to potentiate proaoter utilisation and that these so called 
transcription factors cause their specific effects by interacting with 
the specified DNA sequences. Most of the early work along these lines 
has been performed with various virus aodels with aeabers of the 
papovavirus and the herpesvirus faaily and has recently been reviewed
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by McKnight and Tjian (1986).
The involvement of cellular factors in enhancer activation has been 
demonstrated most clearly in the case of the glucocorticoid receptor.
In an elegant series of experiments Yamamoto and colleagues shoved that 
the LTR of MMTV behaves as an enhancer and that the hormone 
inducibility of MMTV transcription is mediated by direct binding of the 
glucocorticoid receptor protein to the MMTV enhancer (Chandler et al., 
1983; Payvar et ai-, 1983). More recent studies have indeed shown that 
a variety of nuclear transcription factors from different cell sources 
bind to the enhancer region of MSV and Mo-MuLV (Johnson et al., 1987; 
Speck and Baltimore, 1987).
One interesting aspect of retroviral transcription is that it appears 
to be blocked to a great extent in either preimplantation embryos and 
pluripotent teratocarcinoma cells (Périés et al.. 1977; Teich et al., 
1977; Stewart et al., 1982). Efforts to understand the block to 
productive infection in teratocarcinoma cells have indicated that DNA 
méthylation and probably other mechanisms are involved (Niwa et al., 
1983; Gautsch and Wilson, 1983). On the other hand, Linney et al..,
(1984) have demonstrated that the Mo-MuLV promoter functions poorly in 
undifferentiated teratocarcinoma cells and if the enhancer domain of 
Mo-MuLV is replaced by the enhancer domain of a polyoma mutant are able 
to grow in such cells then the promoter strength is restored. Thus 
these results suggested that the initial block of retroviral gene 
expression in undifferentiated cells is due to the failure of the 
enhancer sequence to function in these cells. Indeed a recently 
isolated mutant of the myeloproliferative sarcoma virus (MPSV), PCMV 
which is expressed more efficiently than Mo-MuLV and MPSV (which is 
expressed more efficiently than Mo-MuLV in F9 cells) in teratocarcinoma
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cells (F9 and PCC4) contains a mutation in the LTR (loss of one of the 
direct repeats in the enhancer) along with a further deletion in the 
gag region (Hilberg et. al., 1987). Further analysis of this LTR has 
shown that the binding of transcription factors isolated from 
undifferentiated teratocarcinoma cells is different from the binding to 
wild type MPSV and also to No-MuLV. In this system it apears that a 
putative repressor protein found in undifferentiated PCC4 cells is 
unable to bind to the PCNV proviral LTR and thus is unable to suppress 
transcription from the PCMV LTR whereas the Mo-MuLV LTR is able to 
interact with it (M. Grez, pers. comm.).
vi) Processing of the viral RNA transcripts.
The coding regions of many eukaryotic genes are interrupted by 
stretches of non-coding DNA called introns. The introns are transcribed 
into precursor RNA and are subsequently removed in a process termed RNA 
splicing, (reviewed by Breatnach and Chambon, 1981; Breitbart et. al., 
1987). A central problem in understanding the mechanism of splicing has 
been the identification of the RNA sequences responsible for the 
accurate removal of introns. A large body of evidence indicates that 
the cis acting regions required for efficient removal of introns exert 
their function through the formation of a secondary structure which 
brings the 5' and 3' splice junctions in close proximity. Retroviral 
RNA also undergoes splicing (Figure 8).
Transcription of the genome which is initiated in the 5' LTR forms a 
long transcript spanning all three genes: the 3' end of the resulting 
RNA lies within the 3' LTR and is polyadenylated like any conventional 
message. The primary transcript is in one sense polycistronic, though 
not in the conventional prokaryotic sense. A portion of this RNA is

Figure 8. Transcription of the proviral DNA of Molonev-MuLV
Two transcripts have been positively identified and correspond to full 
length genomic RNA (35S) and a spliced version from which the env gene 
is translated. Both RNA species have 5' CAPs and 3' poly(A) tails as 
well as an untranslated leader sequence designated L.
The splice donor sequence for Moloney-MuLV (GAGGUA) is found 
approximately 320 bp upstream of the gag (pl5) methionine (AUG) 
initiation codon and approximately 80 bp upstream from the start of the 
leader sequence.
The splice acceptor sequence (CUCUCCAAG) is found 280 bp upstream from 
the env AUG initiation codon, 70 bp before the end of pol (p46»*1).
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retained in intact form OSS) and another portion gives rise to a 
spliced derivative RNA consisting of an untranslated leader (L, about 
200 nucleotides long) joined to env sequences (24S in the case of 
NuLV). It appears that the two RNAs are responsible for the formation 
of all the viral proteins (Fan and Baltimore, 1973; Gielkens et al.. 
1974; Shanmugan et al., 1974; van Zaane et al., 1977; Fan and Verma, 
1978; Rothenberg et. al., 1978). Although some investigators have 
detected smaller species of about 12-14S (Gielkins et al.., 1974).
One interesting feature of the env mRNA is that its acceptor site 
and some env coding sequences are located upstream from the pol 
termination codon; the pol and env gene open reading frames are in 
different phases (Schinnick et al., 1981; van Beveren et al., 1981; 
Seiki et , 1983; Schwartz et al.., 1983; Herr, 1984). The donor 
splice site for env mRNA is located upstream from gag in MuLV, but just 
downstream from the gag. initiation codon in RSV. In RSV, env. gene 
translation is initiated from the gag initiation AUG, whereas in MuLV 
the env gene translation is initiated from an AUG located within the 
portion of env that overlaps pol (Schwartz et al., 1983).
No definitive structural differences between the viral genomic RNA 
subunit and the mRNAs that specify gag and pol proteins are known. 
However, their half-lives differ, suggesting that they are somehow 
assigned to different intracellular pools (Levin et al., 1976).
vii) Viral protein synthesis and virion assembly.
Once the viral RNA has been expressed and modified appropriately, the 
virion proteins must be synthesized and assembled into particles that 
have encapsidated the viral RNA subunits (Dickson and Peters, 1982; 
Eisenman and Vogt, 1978; Oroszlan and Gilden, 1980; Stephenson, 1980).
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The envelope of the virion is formed at the plasma membrane as the 
virus is released from the cell by a process called budding. The C-type 
viruses assemble their viral cores at or near the plasma membrane, 
whereas the B- and D-type viruses can apparently form some of their 
cores in the cytoplasm. A good deal is known about the synthesis, 
processing and modification of the individual viral proteins, however 
there is much less information on the mechanism by which virions are 
assembled.
Viral protein synthesis is quite similar among the different 
retroviruses, although the molecular weights of proteins with similar 
functions differ among the retroviruses. In the NuLVs most protein 
cleavage appears to take place after virion assembly, since rapid 
harvest virions still contain large amounts of uncleaved polyproteins 
(Bolognesi et al.. 1978). This observation suggests that the particular 
order of the different proteins within each polyprotein may help to 
orientate the polyprotein appropriately within the virion 
(see Figure 3).
The gag proteins give rise to the core proteins excluding the reverse 
transcriptase. For MuLV, the gag precursor polyprotein is Pr65g,g and 
is cleaved to four proteins whose order in Pr65g,J is NH2-pl5-ppl2-p30- 
plO-COOH. It appears that these cleavages are mediated by a viral 
encoded protease (pl4, Crawford and Goff, 1985). The MuLV gag protein 
exists in glycosylated and non-glycosylated forms (Figure 9). The 
glycosylated forms are cleaved from gPr80«,g. which is synthesized from 
a different inframe initiation AUG codon located upstream from the 
initiation AUG for the nonglycosylated Pr65g,g. Only non-glycosylated 
gag proteins are found in ALV. Deletion mutants of MuLV that do not 
synthesize the glycosylated gag are still infectious, thus raising a
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Figure 9. Molonev-MuLV gag polyprotein synthesis
Depicted are the two metabolic pathways oi glycosylated and 
non-glycosylated gag proteins.
Translation of both primary translation products occurs at different 
AUG codons, thus giving gPr80»*» an extra sequence at or near its NHa 
terminus (indicated by the shaded box). gPr80»*« is glycosylated at two 
positions in pl5 and p30. gP95»*" is further modified by addition of 
extra oligosaccharides at the same positions.
Also shown is the phosphorylation of pl2 to ppl2 (phosphorylated form) .
$denotes cleavage sites.
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question over the importance of the glycosylation events (Fan et al., 
1983; Schwartzberg et al.. 1983). Possibly they are necessary for in 
vivo infections. The pl5«*« is very hydrophobic and in the virion it is 
probably located between the envelope and the capsid. Significant 
amounts of pl5 copurify with the viral envelope (Stephenson, 1980) and 
the fatty acid, myristic acid is linked to it (Henderson et. al., 1983). 
The hydrophobicity of pl5 may enable Pr65»*B to align with the membrane 
during virion morphogenesis (Bolognesi et al., 1978). ppl2 is an acidic 
protein that is phosphorylated at serine residues. Its precise location 
within the virion is not clear. It can bind to virion RNA, but it does 
not purify with the viral cores from which the envelope has been 
stripped in vitro. It has been proposed that most ppl2 is located on 
the inner coat between the capsid and the envelope (Bolognesi et al., 
1978). p30 is the major core protein and mutations within this region 
completely abolish virion assembly (Schwartzberg et al.. 1984). It can 
self-assemble in vitro, which is consistent with its role as the 
principle capsid protein. Data concerning Fv-1 restriction would also 
suggest that p30 is possibly involved with integration of the proviral 
DNA. plO is a highly basic protein that is bound to the virion RNA, 
forming the basis of ribonucleoprotein complex.
Many aspects of the pol gene products have been discussed earlier and 
will thus not be further mentioned here.
The env gene product Pr90*av is glycosylated and cleaved to gp70 and 
pl5E, which remain bound to each other via a disulphide linkage. It is 
probable that pl5E is a transmembrane protein with its C terminus 
located internal to the lipid membrane and its N terminal located 
external to the membrane (Herr, 1984; Pinter and Honner, 1983). In 
electron micrographs pl5E probably represents the spikes on the viral
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envelope while gp70 is the knob that suraounts the spike.
It is not known how the virion selectively encapsidates the two viral 
RNA subunits, or how the diaer RNA structure is foraed. Sequences 
located between the donor splice site and the gag initiation AUG are 
required for packaging of the RNA into virions (Mann et al., 1983; 
Watanabe and Teain, 1983). Deletion of sequences between the donor 
splice site and the initiation AUG of gag results in a mutant that 
synthesizes the viral proteins noraally and can rescue replication 
defective viruses, but the deletion prevents it froa packaging its own 
RNA into virions. The binding of tRNA to the viral RNA is apparently 
aediated in part by the reverse transcriptase which binds specifically 
to the appropriate tRNA (Panet et al., 1975). However data froa Goff's 
group would suggest that the stringency of the tRNA priaer is not 
iaportant for they were able to isolate a mutant Mo-MuLV which 
contained a new priaer binding site and thus utilised a new tRNA 
(glutaaine) to priae DNA synthesis (Colicelli and Goff, 1986). The 
foraation of the diaer structure is probably aediated by the plO 
protein since it has not been possible to fora diaer structures froa 
RNA subunit aonoaers. Retroviruses like aost other viruses leave the 
host cell by a process of budding with the specific aechanisa involved 
in this reaction being at the aoaent unclear. Recently a standardised 
and siaplified noaenclature for proteins coaaon to all retroviruses has 
been proposed (Leis et al., 1988).
2. Haeaopoiesis in the aouse.
Before describing the biology of the Friend virus coaplex a very 
brief account of haeaopoiesis and erythropoiesis will be presented as a 
basis for the understanding of the disease caused by this virus
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complex.
The formation of different types of blood cells is essential for 
normal development. Nature haemopoietic cells perform a variety of 
important functions, yet are relatively short lived and therefore 
require constant replacement. This requirement for constant 
replenishment has resulted in the haemopoietic system being divided 
into three main compartments: the mature end cells, a transit 
population of progenitor and differentiating cells, and a 
multipotential stem cell compartment that produces cells for the 
transit population (Figure 10). The pluripotential stem cell (CFSI) 
seen at the top of this scheme is able to repopulate a lethally 
irradiated mouse in both the myeloid and the lymphoid systems whereas 
the multipotential stem cell (CSFII) appears only able to repopulate 
cells within the myeloid system. Because of the large cell turnover 
required there is considerable amplification, particularly within the 
transit population in order to produce the required numbers of mature 
end cells. The rapid changes in mature haemopoietic cell numbers 
observed under particular conditions (i.e. changes in oxygen tension or 
infections), compared to the relatively constant numbers of such cells 
during steady state haemopoiesis, suggest constant and complex 
regulatory systems. Abnormalities in the normal development programme 
for blood cell formation result in various types of haematological 
disease.
a) Haempoietic progenitor cells.
Haemopoietic progenitor cells are the immediate progeny of 
multipotential cells and are primarily characterised by being committed 
to one, or at most two, haemopoietic lineages. The majority of
0 
0
Ma
cr
op
ha
ge
s
49
Figure 10. The pattern of differentiation in the murine 
lvmphohaemopoietic system
Adapted from Ostertag et al. (1987). For discussion see text (reviewed 
by Ostertag et al.. 1987).
The pluripotential stem cell, CFU-SI is only assayable in vivo, being 
the most primitive stem cell defined.
CFU-SII is defined as being multipotential, in that it has a limited 
repopulation capacity and is confined to the myeloid lineage. The other 
cells are defined below.
Ervthroid progenitor cells;
BFU-E; burst forming unit-erythroid.
CFU-E; colony forming unit-erythroid.
Neutrophil-macrophage progenitor cells.
GM-CFC; granulocyte-macrophage colony-forming cell.
Eosinophil and megakaryocyte progenitor cells.
Eo-CFC; eosinophil colony-forming cell.
Meg-CFC; megakaryocyte colony-forming cell.
Mast progenitor cell.
Mast-CFC; mast colony forming cell.
Multi-CSF; multipotential colony stimulating factor is able to 
stimulate proliferation and differentiation of many of the cells seen 
in Figure 10. However it is only shown here for its stimulating 
activity within the erythroid pathway.
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progenitor cells for the erythroid, eosinophil and megakaryocyte 
lineages appear to exist as unipotential cells, although some evidence 
has been presented to suggest that there may be minor subpopulations of 
bipotential/tripotential erythroid and megakaryocyte progenitors.
b) Ervthropoiesis.
The cells which are capable of clonal differentiation within the 
erythroid compartment exist as heterogeneous populations, as can be 
seen in Figure 10. This heterogeneity is evident from the incubation 
period required in the in vitro colony assay system (methods reviewed 
by Till and McCulloch, 1980; Metcalf, 1984) for haemoglobin containing 
progeny to appear within a clone and by the number of cell divisions 
occuring prior to haemoglobinisation.
The relatively mature erythroid progenitor cells, termed CFU-E form 
colonies of haemoglobinised cells (of 80-200 cells) after a 48 h 
incubation period in vitro (Stephenson et al., 1971). After longer 
incubation periods (up to 21 days) larger multicentric haemoglobinised 
colonies appear in cultures, and these colonies are produced by 
erythroid progenitor cells termed BFU-E (Axelrad et al., 1974; Gregory, 
1976). BFU-E may be further sub-divided according to the day of 
incubation at which they produce recognisable haemoglobinised progeny 
(Gregory and Eaves, 1978). The BFU-E which appear to be haemoglobinised 
after long incubation periods are considered to be tbe most primitive 
(these cells also form the most progeny of up to 20,000 cells in one 
colony). The available evidence would suggest that the more primitive 
BFU-E are direct progeny of multipotential stem cells, whereas the 
later BFU-E give rise directly to CFU-E. Analysis of enriched CFU-E 
fractions have shown that these cells are basophilic blast cells and
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their immediate progeny are most likely proerythroblasts (Nicola et 
al., 1981).
Manipulation of the circulating levels of erythrocytes and subsequent 
studies of BFU-E and CFU-E numbers in the spleen and bone marrow has 
suggested that these two populations of cells are directly regulated. 
CFU-E are maximally stimulated by erythropoietin (epo) whereas epo 
(which is mainly produced by an as yet unknown cell type in the kidney, 
Bauer, 1986; Caro et al., 1986, and in some cases in the liver, 
Goldwasser et al., 1986, and recently in a well defined in vitro 
hepatocyte system, Goldberg et al.., 1987) has no effect upon the 
primitive BFU-E differentiation and minor effects on the mature BFU-E 
although insulin like growth factor 1 (IGF1) can replace epo for 
maximal stimulation of CFU-E cells (Kurtz et al., 1982, 1985). In 
addition a subset of CFU-E may also be stimulated by a non-epo molecule 
(Iscove, 1978; Fagg, 1981).
BFU-E proliferation and differentiation is maximally stimulated by 
multi-CSF. with smaller subsets of multi-CSF responsive BFU-E being 
also responsive to GM-CSF and G-CSF (Metcalf et al.. 1980; Metcalf and 
Nicola, 1983). This two tiered model of erythropoietic stimulation 
observed in vitro agrees with the in vivo data, since in those 
situations where circulating epo levels are reduced (i.e. 
hypertransfusion) CFU-E numbers decline whereas BFU-E numbers remain 
unaffected (Iscove, 1978).
3. The Friend virus complex. 
a) Isolation and history.
Electron microscopic observations on Ehrlich ascites carcinoma cells 
which demonstrated the presence of virus like particles (Selby et. al.,
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1954) led C. Friend to attempt to isolate these virus like particles 
and assay them for biological activity. Cell-free filtrates prepared 
from these tumour cells were inoculated into newborn Swiss mice. After 
an incubation period of 14 months it was discovered that none of the 
mice had developed carcinomas. However a splenomegaly was observed in a 
few of the mice and subsequently the Friend virus complex was isolated 
from one of the spleens that was identified as being leukaemic upon 
histological examination (Friend, 1957).
b) Pathogenesis of the original virus isolate.
Filtrates of the leukaemic spleens inoculated into adult Swiss mice 
induced hepatosplenomegaly and profound anaemia after a short 
incubation period of 2-3 weeks. The early phase of the disease was 
characterised by erythroblastosis. All leukaemic mice died within 1-3 
months (Friend, 1957). Examination of the bone marrow, spleen and the 
liver showed extensive infiltration with large mononuclear 
hyperbasophilic cells, with the lymph nodes and thymus not being 
involved. The white cell count (normally 7000-10,000/ml) usually 
remained under 50,000 in the first few weeks p.i. with an increase 
occuring between the 5th and 7th week p.i. and then finally reached a 
count of 300,000. As the white cell count rose the red cell count 
decreased markedly and nucleated red cells were present in the 
peripheral blood. The cells of leukaemic tissues from the mice in the 
terminal stages of the disease formed tumours upon subcutaneous 
implantation into syngeneic mice which were transplantable (Friend and 
Haddad, 1960). The erythroid nature of the tumour cells was revealed 
after propagation in vitro (Friend et al., 1966; Friend et al., 1971) 
and after the formation of spleen colonies in irradiated mice (Rossi
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and Friend, 1967). These cells, predominantly proerythroblasts which 
exhibited erythroid maturation, as demonstrated by both morphologic and 
functional criteria such as 9'Fe uptake and synthesis of haemoglobin. 
Friend leukaemia cells which had been tissue culture adapted produced 
haemoglobin after induction with DNSO or other agents (Friend et al., 
1971; Steinheider et al., 1971; Ostertag et al., 1972).
After passage of the original anaemia-inducing strain from C. Friend 
to other laboratories Mirand (1967) noticed that certain stocks of the 
Friend virus were able to induce marked erythropoiesis in susceptible 
(set genetic control of Friend virus infection) mouse strains 
suggesting the direct effect in vivo of Friend virus upon erythroid 
precursor cells.
Distribution of the original strain of Friend virus to a number of 
laboratories throughout the world led to the selection of distinct 
lines of Friend virus. For example Mirand noticed that certain 
preparations of Friend virus induced a marked polycythaemia (i.e. an 
increase in the number of immature erythroid cells in the blood) and 
not anaemia, in inoculated mice and referred to these virus 
preparations as polycythaemia inducing strains of Friend virus (FV-P) 
as opposed to the anaemia inducing strains (FV-A: Mirand, 1967; Mirand 
et al., 1968). Mirand observed that FV-P strains markedly stimulated 
erythropoiesis in hypertransfused polycvthaemic mice, as determined by 
radioactive " Fe incorporation, whereas FV-A strains and Rauscher 
murine leukaemia virus were unable to induce such autonomous 
erythropoiesis (Mirand et al., 1971; Mirand, 1976).
A number of virus stocks which were obtained independently from Dr. 
Friend and have been passaged in different laboratories such as those 
of Axelrad (Axelrad and Steeves, 1964), Mirand (Mirand, 1968), Lilly
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(Lilly, 1970) and Ikawa (Ikawa et al., 1976) were also found to induce 
polycythaemia following inoculation of susceptable mice. In spite of 
the differences in the haemopoietic changes induced by different 
preparations of the Friend virus, both the FV-P and FV-A strains 
exhibit several properties by which the Friend virus can be 
distinguished from previousely studied murine leukaemia viruses:
1) A short latent interval.
2) Pathogenicity for adult as well as newborn mice.
3) Lack of thymic or lymph node involvement.
4) Predominant involvement of cells of the erythroid series in the 
leukaemic process.
c) Two viral components involved in the Friend disease.
From a variety of genetical and biological studies (by physical 
methods and by isolation of non-producer cell lines upon end point 
dilution) using FV-P it was suggested that most if not all Friend virus 
preparations contain at least two discrete viral entities (Fieldsteel 
et al., 1969; Steeves and Nirand, 1969; Bentvelzer et al.. 1972; 
Steeves, 1975; Troxler et al., 1977; Pragnell et al., 1978; Bilello et 
al., 1980; Ruta and Kabat, 1980; Troxler et al., 1980). The two 
component nature of the FV complex was also established by analysis of 
the viral RNA (Naisel et al.. 1973) with the RNA molecules coding for 
the helper virus and for SFFV functions, being associated as homodimers 
in the virions, of the FV complex, (Dube et al.. 1976).
a) Replication defective, rapidly transforming virus which was 
designated spleen focus forming virus (SFFV) either SFFVp for the 
polycythaemia inducing strain or SFFVa for the anaemia inducing strain.
b) Replication competent type-C helper virus (F-MuLV) which was
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necessary for the successful transnission and spread of SFFV.
Thus the Friend virus is often referred to as the Friend virus 
complex.
d) Effects of SFFVp on haemopoietic cells.
Infection of susceptable mice with the SFFVp viral complex results in 
a rapid and massive proliferation in the spleen of hyperbasophilic 
proerythroblast like cells. Friend leukaemia cells (FLC, Tambourin and 
Wendling, 1971). If low doses of the virus are used then one can see 
individual macroscopic spleen foci after 9-16 days p.i. an observation 
which led Axelrad and Steeves (1964) to use this criteria as a 
titration system for SFFV (also Nirand et al., 1968). The spleen and 
liver become greatly enlarged by three weeks p.i. and due to active 
erytbropoiesis, a polycythaemia develops (Nirand et_ al., 1961;
Tambourin and Wendling, 1971). The disease proves fatal in 3-6 weeks.
Erythropoiesis is greatly affected in that the erythroid 
differentiation which is normally under the control of epo is seemingly 
uncontrolled. The infected mice continue to produce mature red cells 
under conditions where epo levels are undetectable and erythropoiesis 
should thus cease (Nirand, 1967; Nirand et al., 1968; Sassa et al., 
1968; Tambourin and Wendling, 1971). When haemopoietic cells from these 
mice are tested in the in vitro CFU-E assay then one sees a large 
increase in the number of these colonies (mostly in the spleen but 
also, depending on the strain, in the bone marrow) beginning at 
approximately 3 days p.i. (Horoszwicz et al., 1975; Liao and Axelrad, 
1975; Hankins and Krantz, 1975; Fagg et al., 1980; Fagg and Ostertag, 
1982). While normal cells require epo for CFU-E formation, cells from 
SFFVp infected mice are able to form CFU-E in the absence of an
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exogenous epo source. Further in vitro studies have shown that 
infection of bone narrow cells with SFFVp that had been pseudotyped 
with any of a number of NuLVs and then grown in seni-solid media in the 
absence of epo resulted in the growth of large erythroid clusters 
(bursts) after approxinately 7-10 days (Hankins et al., 1978). These 
bursts are the progenitor cells of the CFU-E, the BFU-E. These virally 
induced BFU-E (vBFU-E) are again epo independent. From such in vitro 
studies it has also been shown that the pool size and self renewel 
capacity of pluripotential haemopoietic sten cells increases after 
continuous culture of bone marrow cells with SFFV (Eckner et al., 1982; 
Greenberger et al.. 1983) although haemopoietic cell line isolated from 
such stem cell cultures have been shown only to contain F-MuLV and no 
SFFV (Kluge et al., 1986).
Although SFFVp is able to infect a variety of haemopoietic cells (and 
also expresses in these cells, Colletta et al., 1983) it appears from a 
variety of studies that the target cell is indeed an epo responsive 
erythroid cell (Tambourin and Wendling, 1971; Opitz and Seidel, 1978; 
Kost et. al., 1979, 1981). In the studies by Kost and co-workers it was 
suggested that the target cell is a relatively late committed erythroid 
precursor cell that is located between the day 8 BFU-E and the day 2 
CFU-E. In these studies it was also shown that the target cell for SFFV 
must be in a state of active cellular DNA synthesis in order for the 
virus to have its effect. However the exact target cell of SFFVp has 
not been conclusively shown even in studies using sorted and enriched 
erythroid precursor cells for SFFVp infection in vitro (Johnson and 
Ostertag, pers. commun.). However such studies have not been easy to do 
since until recently no biologically active SFFVp virus containing a 
selectable marker gene has been available to monitor the infection
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process (Hunt et al.. 1987, and unpublished data).
e) Effects of SFFVa on haemopoietic cells.
SFFVa infected mice in contrast to SFFVp infected mice do not become 
polycythaeaic but develop a mild anaemia (Steinheider et al., 1979). 
Unlike in SFFVp infected mice, erythropoiesis in SFFVa infected mice is 
sensitive to the normal physiological controls in that the CFU-Es 
(although increased in number) are not able to form in vitro without an 
exogenously added epo source (Tambourin et. al., 1979; Steinheider et 
al.. 1979; MacDonald et al., 1980). Interestingly SFFVa infected 
erythroid cells show an increase (two orders of magnitude) in the 
number of epo receptors on their cell surface (Krantz et al., 1987). As 
with SFFVp, infection of normal bone marrow cells in vitro with SFFVa 
also leads to the development of vBFU-E (i.e. those BFU-Es seen after 
viral infection and thus induced by the infection, Hankins and Troxler, 
1980; Koury et. al., 1982). However such bursts do not differentiate 
into mature erythroid cells unless a small amount of epo is added.
Although SFFVa appears to interfere less than SFFVp with 
erythropoiesis both viruses increase the proliferative capacity of 
erythroid precursor cells and enable them to differentiate under 
conditions that are suboptimal for uninfected cells. The target cell 
for SFFVa is thus probably very close to or identical to that for 
SFFVp.
f) Pathogenesis of the helper virus.
Steeves and Lilly (1971) and others (reviewed by Tambourin, 1979; 
Troxler et. al., 1980; Ostertag and Pragnell, 1981) have shown that the 
ecotropic F-MuLV is able to induce a splenic leukaemia after
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inoculation of susceptible newborn mice (Troxler and Scolnick, 1978; 
MacDonald et al., 1980; Oliff et al., 1980; Troxler et al., 1980; 
Ishimoto et al., 1981; Ruscetti et al., 1981). Two types of F-MuLV have 
been closely analysed after biological cloning: One has been termed the 
Friend lymphatic leukaemia virus (F-LLV, Fieldsteel et al., 1969) which 
induces a lymphatic leukaemia 2-4 months p.i. of newborn animals. The 
second type F-MuLV, induces an erythroid hyperplasia after a somewhat 
shorter latency period after inoculation of newborn mice (6-9 weeks, 
compared to that induced by other ecotropic helper viruses, such as Mo- 
MuLV (Troxler et al., 1980). F-MuLV induces erythroleukaemia associated 
with a rapid increase in BFU-E (Niho et al., 1982). Permanent erythroid 
lines isolated from such mice can be induced to differentiate in vitro 
(Oliff et al.., 1981), some of which may be blocked earlier in 
differentiation than F-SFFV transformed cell lines (Shibuya and Mak, 
1983a). In accordance with the slower onset of disease as compared to 
that induced by SFFV, infection of newborn mice with MuLV generated a 
new recombinant virus, the mink cell focus-inducing virus (MCFV). This 
virus is characterised by its dual tropism (Hartley et al.. 1977). 
Friend MCFV (F-MCFV) causes an accelerated erythroid hyperplasia 
(compared to F-MuLV) when injected into newborn mice (Troxler et al., 
1978). The induction of erythroblastosis was analysed in detail by 
using different mouse strains inoculated with F-MuLV. MCFV appears to 
interfere with helper virus-induced disease, since mice which express 
endogenous MCFV env proteins (C57BL/6 and DBA/2) are remarkably 
resistant to F-MuLV induced disease (Ruscetti et al., 1981, 1985). 
Indeed a strong correlation between cellular resistance to F-MuLV 
infection and expression of a glycoprotein has been reported (Kai et 
al., 1986).
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Inoculation of adult rats or sice with F-MuLV results in tbe 
development of a lymphoid leukaemia after a latent interval of up to 6 
months.
F-MuLV may be assayed in vitro by either of two assays:
a) The reverse transcriptase assay.
b) The XC plaque assay, both of which are described in the Materials 
and Methods section.
The disease specificity of tbe helper viruses appears to be 
determined by the viral LTR (Bdsze et al., 1986), since recombinants 
between F-MuLV and Mo-MuLV as well as between F-MuLV and other MuLVs 
constructed by exchanging fragments containing the 3‘ end of the 
genomes demonstrate that the LTR is responsible for the tropism of the 
viruses (Chatis et al., 1983, 1984; Oliff et al., 1984; Holland et al., 
1985).
In a more recent paper is has indeed been demonstrated by the use of a 
retroviral vector that the LTR of F-MuLV, or to be more precise the 
enhancer, determines erythroid specific gene expression (Holland et 
al., 1987).
g) Transformation of cells in vivo by Friend virus.
While it is possible to establish transplantable cell lines from 
diseased tissues of SFFV-infected mice late in the course of the 
disease the majority of the proliferating cells early in the diseased 
animal have a limited self renewal capacity and fail to grow in either 
syngeneic donor mice or as established cell lines in vitro. It has thus 
been postulated that the disease induced by SFFV has multiple stages.
i) An early stage in which the accumulating erythroid precursor cells 
have a finite life span but the size of the compartment of erythroid
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precursor cells is uncontrolled.
ii) A late stage (after three weeks p.i.) which represents the 
proliferation of truly malignant cells that are capable of autonomous 
growth and extensive proliferation and tumourigenic growth in vivo 
(Tambourin et al., 1979, 1980; Levy et al., 1979).
It is not known whether the cells proliferating in the first stage 
are the progenitors of the malignant cells in the latter stage or 
whether the two populations of cells arise independently. Most of the 
cell lines derived from the malignant stage are more or less blocked in 
their ability to differentiate although they can be induced to 
differentiate with certain chemicals such as DMSO (Friend et al.,
1971). Both SFFV and helper viral proteins can be detected at all 
stages of the disease, although several groups have shown in a variety 
of Friend leukaemia cells (FLC) alterations in expression (Ruscetti and 
Scolnick, 1983; Shen et al., 1983; Rovinski et al., 1987) and structure 
of the p53 locus (Rovinski et al., 1987) an oncogene thought to be 
involved in the cell cycle. This could possibly be due to integration 
of SFFV near to one of the alleles, thus leading to dysfunction of p53, 
which is thought to be important in the control of the cell cycle 
(Rovinski et. al.. 1987). However a second fraction of FLC are not 
altered in the expression of p53. Thus the question remains whether p53 
activation is the primary event in causing malignancy or just a 
consequence of later mutational changes in the course of malignant 
progression. Very recent data presented by Tambourin's group (Moreau- 
Gachelin et al., 1988) have shown that in 95% of the tumours induced by 
SFFVp then this virus (although the helper is also present) is 
integrated adjacent to a putative oncogene Spi-1 thus activating this 
gene (or increasing its expression) by insertional mutagenesis.
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h) Genetic control of Friend virus infection.
Genetic loci have been described that interfere with the rapid 
induction of erythroblastosis in nice by the Friend virus complex, Fv-1 
and Fv-2. The Fv-1 locus can selectively inhibit infection by and 
replication of particular NuLVs as described earlier. Other loci that 
determine resistance to helper virus infection and/or replication also 
include the Fv-4 locus (Odaka et al.. 1983; Yoshikura and Odaka, 1982; 
Ikeda e£ al.. 1985) and also possibly the Rmcfr locus (Ruscetti et al.. 
1985).
The Fv-2 locus, as first described by Odaka's group (Odaka and 
Yamamoto, 1962; Odaka, 1969; Odaka, 1973; Lilly and Pincus, 1973; 
Steeves, 1975), has two allelic forms, Fv-2* and Fv-2r (for absolute 
sensitivity and absolute resistance, respectively to in vivo induction 
of spleen foci and erythroleukaemia by SFFV, Odaka, 1970; Lilly and 
Pincus, 1973). The prototype Fv-2 resistant mouse strain is C57B1/6 
(Fv-2rr); mice of most other inbred strains (e.g. BALB/c, DBA/2) are 
Fv-2“*. Fv-2* is the dominant allelic form, so that mice that are 
genetically heterozygous at this locus (Fv-2*/Fv-2r) are completely 
sensitive to Friend viral erythroleukaemogenesis (Odaka, 1969; Lilly, 
1970). Fv-2 differs from Fv-1 in several aspects.
a) Unlike Fv-1 restriction, which can be overcome with increasing 
m.o.i., resistance or susceptibility conferred by the Fv-2 locus is 
absolute.
b) Susceptibility (Fv-2*) is dominant over resistance (Fv-2r) at the 
Fv-2 locus, in contrast to the effect of the Fv-1 gene.
c) Whereas Fv-1 restriction is active in murine fibroblast cells in 
culture, SFFV is able to replicate well in murine fibroblasts of Fv-2r 
mice (Eckner and Hettrick, 1977; Evans et al., 1980). The action of
6:
Fv-2r seems restricted to haemopoietic or even possibly erytbroid 
cells. Other loci which determine resistance to SFFVs include W/W* and 
Sl/Sld (only for the SFFVp/F-MuLV complex; Russell, 1979), the mpsv 
resistance locus (specific for MPSV and R-SFFV/MuLV; Ostertag et al., 
1981; Hess et §!•, 1984) and the putative Fv-5 locus determining 
specificity to the Friend virus complex (Shibuya and Nak, 1982a,b; 
Kitagawa et al., 1983).
i) Genome organisation of F-MuLV and SFFV.
The genome organisation of F-MuLV will not be described here because 
of its similarity to that of Mo-MuLV (except for various point 
mutations and several recombinations in the env gene) which has been 
described earlier. However the genome organisation of F-SFFV because of 
unique structure will be described in detail.
After the SFFVp had been biologically cloned free from its helper 
virus (Troxler et al., 1977; Bernstein et al., 1977) its genome was 
compared with that of its natural ecotropic helper F-MuLV. Such studies 
have been carried out on several different strains of SFFV, all which 
had been derived from the original Friend virus stock and it appears 
that SFFV arose by recombination between F-MuLV and endogenous mouse 
genetic sequences (Troxler et al., 1977 a,b). These latter sequences 
are closely related to the env genes present in MCF viruses which have 
also arisen by a similar manner (Famulari, 1983).
Consistent with their replication defectiveness, both SFFVa and SFFVp 
contain a smaller genomic RNA (depending on the strain analysed, 32S 
RNA; Maisel et al., 1973; Dube et al., 1976; Evans et al., 1979) than 
F-MuLV (38S) and sequences encoding a functional RNA dependent DNA 
polymerase are deleted (Bernstein et al.., 1977). SFFV RNA contains
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sequences related to the 5‘ end of the gag gene of F-MuLV (Bernstein et 
al., 1977; Barbacid ejt al., 1978; Ruscetti et al., 1980), however this 
appears to vary from strain to strain, resulting in the production of a 
15,000-45,000 dalton protein as compared with the 65,000 dalton 
prototype precursor gag protein. It also contains env gene related 
sequences that encode a 52,000-55,000 dalton envelope glycoprotein 
(Racevskis and Koch, 1977, 1978; Ikawa et al., 1978; Ruscetti et al., 
1978, 1979; Dresler et al., 1979) that is immunologically related to 
the gp70 of MCF viruses (Ruscetti et al., 1978, 1979). A 21S subgenomic 
spliced RNA codes for this SFFV envelope protein (Bilello et al., 1980; 
Ruscetti et al., 1980; Yoshida and Yoshikura, 1980). The env gene of 
SFFVp also contains information that results in the inefficient 
processing of the primary env gene product to a higher molecular weight 
form which appears on the cell surface (Ruscetti et al., 1979, 1980; 
Ruta and Kabat, 1980). Thus Friend SFFVp appears to have arisen by 
deletion and recombination between F-MuLV and envelope genetic 
sequences endogenously present in the mouse.
The 30S genome of SFFVa is slightly smaller than that of SFFVp but 
like SFFVp it also contains sequences that are closely related to the 
envelope gene of MCF viruses (Evans et al., 1980; Troxler et al.,
1980). SFFVa encodes a 52,000-55,000 dalton envelope glycoprotein and a 
45,000 dalton gag related protein (Troxler et al., 1980; MacDonald et 
al., 1980a). The level of membrane bound gp55 in SFFVa is below 
detectable levels (Ruscetti et al., 1981; Wolff et al., 1985).
Like other retroviruses the integrated SFFV genome contains two LTRs, 
514 bp each, at either end (Clark and Mak, 1982). These sequences 
contain various signals involved in transcriptional control of the 
provirus as described earlier. However one striking difference in the
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U3 region of SFFV compared to ecotropic MuLV is the deletion of one 
copy of the direct tandem repeat containing an enhancer sequence 
(Bestvick et al., 1984; Clark and Mak, 1984; Wolff et al., 1985). 
Several of the NCFs have either the same or different deletion also in 
this region (Adachi et al., 1984; Koch et al., 1984; Vogt et al., 1985) 
thus suggesting that those with identical deletions may well be the 
putative precursors to SFFV. Comparison of several SFFV LTR sequences 
reveals only very few variations. In fact, the differences between the 
LTRs of all SFFVs (about 95% homology, Bestwick et. a^., 1984; Wolff et. 
al.. 1985) are most likely random.
Unlike other defective acute leukaemia inducing retroviruses no 
unique cellular sequences have been found within the SFFV genome 
although SFFV do contain sequences that may be detected in the mouse 
genome (Chattopadhyay et. al., 1982). These are viral env sequences 
related to those that have been acquired by NCF viruses. Using 
molecularly cloned SFFVp (of which four strains have been cloned, and 
range in size between 6.0 and 6.6 kb: Linemeyer et. al., 1980; Yamamoto 
et al., 1981; Amanuma et al., 1983; Hunt and Ostertag, unpublished 
data), various studies have been able to determine which sequences are 
responsible for the pathogenesis of SFFV.
Heterogeneity of the genome size of different SFFVp is mainly due to 
deletion within the qaq-pol region of the genome. Restriction map 
comparisons are presented later in the results.
j) Studies using genetically engineered mutants.
Studies by Linemeyer et. al. (1981) demonstrated that a 2.4 kb 
subgenomic fragment from SFFVp was able, in a two stage transfection 
assay using either F-MuLV, Mo-MuLV or an amphotrophic helper virus, to
65
retain its biological activity. This fragment contained 2.0 kb from the 
3' end (env) the LTR and 400 bp of non-coding 5' sequences. Studies 
using specific fragments and mutants showed that biological activity 
was coincident with gp52 expression (Lineaeyer et al., 1982). Similar 
studies using molecularly cloned SFFVa showed also that the biological 
activity was confined to the env region (Kaminchik et al., 1982). 
Spontaneous mutants of SFFVp isolated by Ruta et al.. (1983) had 
mutations within the env gene which inhibited their correct processing 
and transport to the plasma membrane and were also non-leukaemogenic, 
as was also found for analogous mutants of Rauscher-SFFV (Machida e£ 
al., 1984).
k) Similarity of the SFFV and MCF envelope genes.
Since the envelope genes of both Friend and Rauscher SFFVs appear to 
be crucial for the pathogenicity of these viruses, it is important to 
understand the structure of their env genes and gene products. The 
location of the MCF related sequences within the envelope region of 
SFFV was determined by comparisons of SFFV with MCF viruses at both the 
genetic and the protein level. Indeed an antiserum capable of 
precipitating MCF, but not ecotropic gp70 was able to precipitate a 
glycoprotein of 52,000-55,000 daltons from fibroblasts non-productively 
infected with Friend-SFFVp (Ruscetti et al.. 1979), Friend SFFVa 
(Troxler et al., 1980), and Rauscher SFFV (Ruta and Rabat, 1980). 
Cas-SFFV, derived from wild mouse ecotropic virus was also shown to 
encode an MCF gp70 related protein of 50,000 daltons (Langdon et al., 
1983).
Localisation of the MCF gp70 related region within the SFFV gp55
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molecule itself was accomplished through the use of monoclonal antibody 
to gp55 in conjunction with partial protease digestion. Both Friend MCF 
gp70 and gp55 contain a 23K V8 protease fragment that is precipitated 
by a monoclonal antibody to SFFV gp55 (Wolff et al., 1984). The 23K 
fragment in Friend NCF gp70 was localised to the N-terminus (Wolff et 
al., 1982), suggesting that the NCF related region of gp55 was also at 
the N-terminus.
Published nucleotide sequences of the envelope genes of several SFFVs 
(Amanuma et al., 1983; Wolff et al., 1983; Clark and Nak, 1983) have 
made it possible to make detailed comparisons of these with a number of 
NCF envelope genes. For three isolates of the polycythaemia inducing 
variants of SFFV it has been found that the NCF related region of the 
SFFV env gene codes for more than two thirds of the gp55 molecule. This 
includes the leader peptide and amino terminus of the glycoprotein 
itself. For all of the isolates, the amino acid homology with No-NCF 
(Bosselman et al., 1982), AKR NCF 247 (Holland et al., 1983), or Friend 
NCF (Koch et. al., 1984) gp70 in the analogous amino terminal region is 
greater than 90%. Interestingly there is a 67 amino acid region 
(starting at amino acid residue number 60 from the amino terminus) 
which is similar for all of these SFFV and NCF viruses (Figure 11).
1) The SFFV env gene product.
There are several features of the SFFV env gene product gp55 which 
are unique only to this retroviral protein. These features are obvious 
when gp55 is compared with the env proteins of other retroviruses 
(reviewed by Weiss et. al., 1982). The primary translational product of 
the prototype envelope gene is a polyprotein containing gp70 and Prl5E 
(see Figure 12a). Due to a large deletion (approximately 600 bp) in the
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Figure 11. Aaino acid sequence of SFFV and other related env proteins
env amino acid sequences of all the viruses depicted, were deduced from 
the nucleotide sequences and compared to the env amino acid sequence of 
F-MCF virus using the standard single letter code.
Symbol code.
missing residues.
*»»; possible common glycosylation sites.
For alignment and comparison part of the sequence was omitted (/). 
Recombination between xenotropic and ecotropic sequences are enclosed 
within the horizontal boxes (amino acid 270-300).
The sequence data are taken from:
Koch et al., 1984: F-HuLV, pF-MuLV57;
Koch et al., 1984: F-MCFV, pFMS4B and pFMl/pFM2;
Adachi et al., 1984: F-MCFV, FrNx;
Wolff et al., 1985: F-SFFVa;
Bestwick et al., 1984: R-SFFV;
Wolff et al., 1983: F-SFFVpLS;
Amanuma et al.. 1983: F-SFFVpIK, K-l;
Clark and Mak, 1983: F-SFFV Ax;
Vogt et al., 1985: R-MCFV-1;
Bosselman et al., 1982: M-MCFV, cllb.
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Figure 12. The SFFV env gene
a) Comparison of SFFV gp55 with the MuLV precursor env protein Pr90*"v. 
to demonstrate the deletion of the gp70-pl5E cleavage site.
CHO represents glycosylation sites.
b) Structure of the gp55 env gene as based on the nucleotide sequence 
of a molecularly cloned SFFVp strain (Wolff et al.. 1983).
Open areas represent regions that are homologous to F-MuLV. The shaded 
area is non-homologous to F-NuLV but highly related to xenotropic and 
MCF viruses. The hatched area represents sequences where no nucleotide 
sequence relationship to F-MuLV was seen.
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■iddle of the SFFV envelope gene which includes the cleavage site 
between gp70 and Prl5E, the aaino terminal gp70 and carboxy terminal 
pl5E sequences are joined and remain covalently linked (Figure 12b). 
This deletion was only discovered after sequencing the genomes of these 
SFFVs although heteroduplex analysis of SFFV and F-MuLV had previously 
indicated that a large deletion existed in the envelope gene of SFFV 
(Bosselman et al., 1980). However it was thought that SFFV was simply a 
truncated gp70 since it was not possible to precipitate gp55 with an 
antiserum prepared against pl5E (Schultz et. al., 1980). Evidence 
supporting the sequence data has come from tryptic peptide analysis of 
gp55 and pl5E from both F-NuLV and Friend MCF (Vollf et al., 1984). The 
carboxy terminal domain of pl5E which is translated as part of gp55 
contains the transmembrane sequence of non-polar amino acids (Lenz et 
al., 1982; Pinter and Honnen, 1983; Koch et al., 1983) and presumably 
also provides a transmembrane anchor for the SFFV envelope 
glycoprotein, which is associated with membranes and is not secreted 
from the cell (Ruscetti et. al.. 1979; Dresler et. al.. 1979; Lyles and 
McConnell, 1981; Srinivas and Compans, 1983). This view is supported by 
the labelling of the membrane form of gp55 with 3H palmitic acid 
(Srinivas and Compans, 1983) as this and other fatty acids are 
incorporated post-translationally into a wide variety of membrane 
glycoproteins and may serve to increase the affinity of glycoproteins 
for membranes (Schmidt and Schlesinger, 1980; Schmidt, 1982). The pl5E 
related domain of gp55 is different from the prototype pl5E in that its 
C-terminus is shorter and has a unique set of amino acids. This is 
caused by a single base pair insertion that shifts the reading frame. 
Such an insertion has been found in every SFFV env gene sequenced to 
date, including the env genes of three SFFVp and also SFFVa and
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Rauscher SFFV (Bestvick et al., 1984; Hess et al., 1984). Interestingly 
neither the exact position of the insertion nor the particular base 
inserted is identical for each isolate, although the effects of the 
insertion in every case are to shorten the reading frame by 99 base 
pairs (33 amino acids) and produce a unique five to six amino acid 
sequence. Since all of these isolates have been passaged independently 
for many years it appears that these alterations must be critical for 
the generation of pathogenic SFFV.
The glycosylation pattern of gp55 is unique in that it has fever 
glycosylation attachment sites than other env proteins. Sugar 
attachment at these sites is for the most part incomplete and 
heterogenous. Studies by several investigators have shown that the 
predominant form of gp55 that accumulates intracellularly contains 
immature oligosaccharides of the mannose type (Ruscetti et §!•, 1979; 
Dresler et al., 1979). This form of the protein has the same 
glycopeptide profile as the envelope precursors of F-MuLV and Friend 
MCF virus (Kemp et al.. 1981) consisting of two major size classes of 
2200 and 1500 daltons. Gp55 differs from these envelope precursors in 
the number of oligosaccharide attachment sites.
Although the majority of the gp55 accumulates intracellularly, as if 
unable to enter the golgi apparatus where the final sugar processing 
occurs, a small proportion passes through the entire pathway used for 
the processing of glycoproteins. The processed protein which 
incorporates a variety of complex sugars such as galactose, fucose and 
glucosamine has a molecular weight of 65,000 and can be detected on the 
cell surface (Ruscetti et al.. 1979; Gillis et al., 1979; Ruta and 
Kabat, 1980).
The 65K SFFV envelope glycosylation pattern resembles more closely
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the related Friend NCF gp70 than F-NuLV gp70 (Srinivas and Compans, 
1983).
m) Molecular comparison of SFFVp and SFFVa.
Both SFFVp and SFFVa encode 52,000-55,000 dal ton MCF gp70 related env 
proteins, which when analysed by tryptic fingerprinting, showed various 
differences (MacDonald et al.. 1980a). These differences were also seen 
after oligonucleotide fingerprints of SFFVp and SFFVa RNAs (Evans et 
al., 1980). From these studies it could be seen that SFFVa specific 
oligonucleotides (as compared to SFFVp, F-MuLV and MCF viruses) were 
related at the 5' end of the genome, at a region 3' to pol and 5' to 
env. Further analysis using recombinant virus, constructed between 
molecularly cloned SFFVp and SFFVa strains have defined the env gene as 
being responsible for the disease caused by both SFFVp and SFFVa 
(Kaminchik et al.. 1982).
At the nucleotide sequence level, all SFFVp have a 6 bp duplication 
at the 3' end of the env gene. This feature is not shared by R-SFFV and 
SFFVa, both of which induce anaemia, and do not confer complete 
independence to erythropoietin interaction of infected erythroid 
precursor cells.
There are a series of other shared features of the env region of the 
SFFVp which distinguishes them from SFFVa and which may have functional 
consequences.
a) All SFFVp have the same mutations in position 328 and 348 which lead 
to an altered change (glutamine to lysine) in the env SFFVp.
b) The above mentioned duplication of two codons in SFFVp leads to an 
insertion of two leucine residues in position 388/389 in the 
hydrophobic domain of the env protein of SFFVp.
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c) A serine residue in position 367 replaces a leucine residue in 
SFFVp. This replacement could alter the attachment of fatty acids, 
which may alter the membrane of the env protein of SFFVp as compared to 
that of SFFVa or R-SFFV.
Construction of a recombinant virus between SFFVp and SFFVa has 
clearly demonstrated that the 3' end of the env gp52 of SFFVp 
determines the biological differences (Ruscetti and Wolff, 1985). 
However these studies did not demonstrate whether sequences in either 
the gag or pol region do in fact play a minor role in the pathogenesis 
of SFFV as indeed has been shown for F-NuLV.
There are a whole series of coordinate changes in the 3' half of the 
env gene of all SFFVp, which sets SFFVp apart from the R-SFFV and the 
SFFVa. All of these changes which result in amino acid alterations 
could be of significance to the specific feature of SFFVp, i.e., its 
unique property to completely replace the requirement for 
erythropoietin in infected erythroid precursor cells.
The progressive change from a MCFV-type env region to a SFFVp like 
env gene would suggest that SFFVa is a precursor of SFFVp and thus the 
ancestral FV-A. This has been repeatedly pointed out by the late C. 
Friend (Brown et. al.. 1985). Further alterations of SFFVa (smaller 
genome size, as well as other alterations), must have followed in the 
divergent evolution of SFFV. It appears that secondary recombinations 
were important for the evolution of SFFV as indicated by different 
points of crossover of SFFVp and SFFVa. The different crossover points 
in R-SFFV could either indicate its independent evolution or secondary 
recombination as has been shown for SFFVp with related viral sequences 
(Mol et al., 1982).
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Source of Chemicals
Amersham Buchler, Braunschweig, F.R.G.,
Beckmann, Munich, F.R.G.,
Belco, Tecnomara, Ruhberg, F.R.G.,
Boehringer Mannheim, Mannheim, F.R.G.,
BRL/Gibco, Eggerstein, F.R.G.,
DuPont, De Nemours, New England Nuclear Research Products, 
Dreieich, F.R.G.,
Flow, Irvine, Scotland,
Greiner, Nürtingen, F.R.G.,
Kulzer, Hehrheim, F.R.G.,
Merck, Darmstadt, F.R.G.,
New England Biolabs, Schwalbach/Taunus, F.R.G.,
Nunc, Wiesbaden/Biebrich, F.R.G,
Pharmacia, Uppsala, Sweden,
Serva, Heidelberg, F.R.G.,
Sigma Chemie GmbH, Diesenhofen, F.R.G.,
Schleicher and Schüll, Dassel, F.R.G..
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Cells
F4-6 Krieg et al.,, 1978
F4+ Krieg et al., 1978
F4N+2 Eisen et al., 1978
B8/3 Krieg et al., 1978
PA317 Miller and Buttimore, 1986
U2 (psi-2) Mann et al., 1983
RATI 643/22N Pragnell et al., 1978
RATI Topp, 1981
NIH 3T3 Botcban et al.., 1976
A31 (BALBC/3T3) Aaronson and Todaro, 1968.
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Bacterial strains used.
1) CMK603: thr, leu, thi, SupE, recBc, T»rT9r , r~m*, LacZ «15,ALac Y, 
F', pro*.
2) DH1: F", endAl, hsd R17, (rJr, ■*♦>, supE44, thi-1, A ", resAl, 
gyrA96, relAl.
3) HB101: Hsd S 20 (r»-, ■»*), F~ , proAZ, galI2, rpSL20, WwT), 
rec A13.
4) MM522: Hsd - rec-, A(Lac-proAB), thi, SupE, F’, proAB lac« Z All5.
5) DH5a: F~, endAl. hsd R17 (rR- «R M  SupE44. thi, recAl, gyrA96, 
relAl, s80d, LacZ 115.
6) LE392: F~. hsd R514 (rn-, ■*♦) supE44, supF58. LacYl orAiLac 
IZY)6. galR2, galT22, MtBl. trpR55, A
7) JH1Q1: SupE, thi, A (Lac proA.B) /F', tra D36, proA.B (rk*.
*) lacI«Z .115.
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Plasaids
PÜC9 (8) Vieira and Messing, 1982
PBR322 Bolivar et a!., 1977
pSFFVp Lineaeyer et al., 1980
pF-MuLV 57 Oliif et al.. 1980
PÜC19 (18) Yanisch-Perron et al., 1985
M13apl9 (18) Vieira and Messing, 1982
pAG60 Colböre-Garapin et al.. 1981
pCDMneo (paos-2) Stocking et. al., 1986
Stocking et al., 1985PMPSV3 * LTR
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Eukaryotic cell culture.
Mammalian cells were generally grown at 37#C in an incubator gassed 
with 5% (v/v) CO* in air of relative humidity greater than 95%. All 
cells were cultured in GMEM (Glasgows Modified Eagles Medium, Flow 
Laboratories) supplemented with 10% (v/v) foetal calf serum (FCS,
Flow Laboratories), 500 units/ml penicillin and 100 ug/ml streptomycin 
sulphate.
Cells were grown in either plastic tissue culture flasks (25 cm3 or 
75 cm1; Greiner) or tissue culture petri dishes (Greiner).
For large scale production of extrachromosomal DNA cells were grown 
in glass roller bottles (Belco) with a sealed cap at 37*C. Roller 
bottles were rotated at 0.25 rpm on a Belco roller bottle machine.
Confluent monolayers were prepared for subculturing by removing the 
culture medium and washing the cells with warm PBS (without Mg1* and 
Ca1*). Adherent cells were then detached from the culture surface by 
incubation in PBS (without Mg1* and Ca1*) containing 0.5% trypsin 
(Seromed) at 37°C. Cells were gently dispersed by continual pipetting 
before being seeded at the required concentration into new culture 
flasks containing prewarmed growth medium.
Storage of frozen cells.
Cells were frozen in GMEM containing 20% (v/v) FCS and 10% (v/v)
DMSO. Glass ampoules were placed in polystyrene containers to ensure 
that the temperature decreased slowly and placed at -70*C overnight and 
then stored in liquid nitrogen.
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Transfection of mammalian cells. The calcium phosphate method.
(Graham and van der Eb, 1973).
This method can be used very efficiently for either transient 
expression of introduced genes or construction of stable transformants. 
The DNA for transfection was prepared as follows:
5-10 pg of the test plasmid (eventually for 2 transfections, T75 
flasks) together with 20-25 ug (and 0.5-1 pg of selection plasmid in 
co-transfection experiments) of carrier DNA (usually sonicated salmon 
sperm DNA) was ethanol precipitated overnight at -20°C. The washed, 
dried DNA pellet was then dissolved in 875 pi sterile deionized HaO and 
125 pi 2 M CaCli (sterile filtered and stored at 4°C). To a second tube 
was added 1 ml of 2x MBS (made from a lOx stock solution: 8.18% (w/v) 
NaCl, 5.94% (w/v) HEPES, 0.2% (w/v) NaaHPO« sterile filtered and stored 
at 4°C) which had been adjusted to pH 7.12 (very important) just before 
use. The DNA solution was added dropwise to the 2x HBS with constant 
agitation upon which a translucent precipitate immediately formed. This 
precipitate was used for the transfection.
On the day before transfection (designated day 1) the cells to be 
transfected were plated at a density of 10*/cm2 in GMEM containing 
10% FCS. Twelve hours later the cells were fed and after a further 
4 h the DNA precipitate was added to the medium and the cells were 
returned immediately to the incubator to ensure that the pH did not 
change. After 4-6 h the cells were washed in serum free medium and 
glycerol shocked as follows: 1-2 ml per flask of 15% glycerol in HBS 
was added and incubated for 0.5-2 min at 37#C (depending on the cell 
type). Cells were then washed once with GMEM containing 10% FCS, before 
being further incubated in the same medium at 37°C and 5% CO2 in air.
When it was necessary to select transfected cells for resistance to
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Geneticin (G418, Gibco/BRL), cells were cultivated in GMEM, 10% FCS 
containing 400-2000 pg/al Geneticin 48 h after transfection. For fast 
growing cells, flasks were split 1:4 before Geneticin selection. G418 
resistant clones usually appeared 10-20 days after beginning selection. 
Individual clones were picked either with ground glass cloning 
cylinders or with Q-Tips, depending on the cells being used. Individual 
clones were grown up in 24 well plates (Greiner) before being 
transferred to T25 flasks for further culture.
Geneticin transfer assay (GTU-assav).
Forty eight hours prior to the assay RATI fibroblasts were seeded at 
a density of 103 cells/well into 24 well tissue culture plates in 1 al 
GMEM containing 10% FCS. After 24 h the aediua was replaced with GMEM 
containing 5% FCS, 1% DMSO and 6 pg/al polybrene. The next day aediua 
was reaoved and replaced with 1 ml diluent, GMEM containing 2% FCS 
(which had been filter sterilised (0.45 pa-filter). Flow). After 24 h 
the virus diluent was reaoved and the cells were fed with 1 al GMEM 
containing 10% FCS and incubated at 37*C, 5% CO* in air, for a further 
24 h, after which tiae the aediua was replaced with selection aediua 
containing 400 pg/al G418. Cells were fed every two days until distinct 
resistant colonies could be recognized 14-21 days following infection. 
Titres were expressed as Geneticin transfer units/al (GTU/al).
Cloning of cells in seai-solid aediua.
GMEM containing 30% FCS (37°C) was aixed with aelted (50*0 20% agar 
(w/v, Gibco/BRL) to give an end concentration of 0.4% agar and 
incubated at 45°C. Cells to be cloned were resuspended at various 
densities in the agar cloning aediua (45*0 before being plated out (3
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ml) into 6 well plates (Greiner). The plates were incubated at 48C for 
5-10 min to allow the agar to set before being incubated at 37°C, 5%
COt in air in a humid incubator. After 10-20 days the clones were 
counted and picked with sterile 100 pi capillary tubes. Cloning 
efficiency or efficiency of infection of resulting G418 resistant cells 
was determined in G418 concentrations ranging from 1-2 mg/ml in the 
above medium.
DMSO induction of Friend cells.
Log phase Friend cells were seeded at 2 x 10° cells/ml in GMEM 
containing 10% FCS at day 0. Twenty four hours later (day 1) 50% of the 
culture (cells and medium) was replaced with GMEM containing 10% FCS 
and DMSO (1-1.5% end concentration). On day 3, 50% of the culture was 
removed and replaced with the above DMSO medium. At this point the cell 
density was approximately 10*/ml. On day 5 the cells were stained with 
benzidine (0.5% benzidine, 15% acetic acid, 8% H2O2 ) to determine the 
presence of haemoglobin.
Isolation of nuclei from Friend cells.
Log phase cells (1 x 10*) were washed twice in ice cold PBS (without 
Caa* and Mg2*), before being resuspended in 1 ml ice-cold 10 mM Tris- 
HC1 (pH 7.4), 1 mM EDTA and 100 mM NaCl, and gently pipetted to give a 
single cell suspension. NP40 (Nonidet P-40, Sigma) was added (from a 
10% stock solution) to give a final concentration of 0.5% and the cells 
were incubated for 5 mins on ice. The lysis procedure was monitored by 
phase contrast microscopy to determine the percentage of non-lysed 
cells. When whole cells could still be seen then the incubation was 
repeated until >90% of the cells were lysed. The lysed cells were
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centrifuged for 5 min at 500g in a Sorvall HB4 rotor at 4#C to pellet 
the nuclei. To the supernatant (the crude cytoplasmic fraction) was 
added SDS to a final concentration of 1% and NaCl to 1 M. The nuclei 
were gently resuspended in 1 ml TE solution (10 mM Tris-HCl (pH 8.0),
1 mM EDTA) before adding SDS and NaCl as above.
These fractions were further processed as described for Hirt 
supernatants (small scale).
Haemopoietic colony assays. (Fagg and Ostertag, 1982).
Virus-infected mice were used for experiments at 4-16 days post 
infection when the enlarged spleen was easily detected by palpation. 
Uninfected animals of a similar age were used as controls. Mice were 
killed by cervical dislocation, the spleen and both femurs were removed 
under sterile conditions and the wet weight of the spleen was recorded. 
The marrow was flushed from both femurs into Iscove's Modified 
Dulbecco's Medium (IMDM, Boehringer Mannheim) containing 2% FCS and 
dispersed by repeated passage through a syringe with a 22 gauge needle. 
The resultant single cell suspension was plated in IMDM containing 
10% FCS.
Similarly single cell suspensions from spleen were prepared by gently 
teasing the spleen apart in IMDM containing 2% FCS. Bone marrow cells 
were plated out at 1-2 x 108 cells/ml and spleen cells at 1-8 x 10® 
cells/ml in the absence or presence of erythropoietin (0.2-0.5 U/ml). 
The erythropoietin source was a lOx concentrated cell culture 
supernatant from the cell line IV32, which overproduces this hormone 
(Tambourine et al.. 1983), multi-CSF (5-10% supernatant lOx concen­
trated) from the cell line WEHI3B (Ymer et al., 1985) and G418 (1.5-2 
mg/ml). Cells were plated in a mixture of 1% methylcellulose containing
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human transferrin (300 ug/ml, Boehringer Mannheim) and 1% FCS 
(specially selected as CSF free) together with the above factors.
After 2 days incubation at 37*C in 5% CO* the number of colonies 
arising from CFU-E cells (CFU-E colonies) were counted microscopically. 
The colonies were confirmed as erytbroid by staining with benzidine. 
Nonstained cultures were further incubated until day 9-14 when CFU-M,
G, GM, mixed erytbroid and BFU-E colonies were scored.
XC assay.
(Heidi Stuhlmann, pers. comm., Vhitehead Institute, Boston, USA, after 
Rowe et al., 1970).
Virus titration on NIH3T3 or BALB/3T3 cells. On day 1 cells (either 
NIH3T3 or BALB/3T3) were seeded out in 24 well plates at 0.3 to 1 x 10« 
cells in 1 ml of GMEM containing 10% FCS and 2 ug/ml polybrene. Twenty 
four hours later the medium was removed and replaced with 0.1 ml of 1:5 
dilutions of the viral supernatant to be titrated in PBS containing 
2% FCS. The plates were incubated at 37*C, 5% CO* in air for 30 min, 
before 1 ml GMEM containing 10% FCS was added and further incubated for 
24 h at 37*C, 5% CO* in air. After this period cells were fed by 
aspirating medium and replacing with an equal volume of the same 
medium. After a further 48 h the medium was fully aspirated and the 
cells were irradiated for 20-30 seconds with a UV source placed 60 cm 
above the cells. To the irradiated cells were added 2 x 10s XC cells in 
1 ml GMEM containing 10% FCS and incubated for 24 h at 37*C and 5% CO* 
in air after which time the cells were fed as above. After a further 24 
h to 48 h the XC-cells were stained. The medium was removed and the 
cells were washed once with methanol before being fixed for 10 min with 
methanol. The cells were then washed once with water before being
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stained for 10 min in a lx Giemsa solution (lOx solution: 1 g Giemsa 
stain, Merck, in 54 ml glycerin and 84 ml methanol and filtered through 
fine filter paper, diluted with water).
Cells were then washed once with water and allowed to dry. Syncytia 
were monitored either macro- or microscopically according to size.
Virus titres were expressed as XC plaques/ml.
Reverse transcriptase assay. (Pragnell et al., 1977).
1 ml of a log phase cell culture supernatant (which had been fed 24 h 
previously) was centrifuged in an Eppendorf centrifuge to remove cells 
and either directly assayed or stored at -20°C, a treatment which does 
not seem to affect reverse transcriptase activity: 10 pi of sample (in 
duplicate) was pipetted into a microtitre plate to which 20 pi of "Mix" 
was added before being incubated at 37°C for 1 hour in a moist 
atmosphere.
The "Mix" comprised 0.3% (v/v) NP40 (Sigma), 0.25 OD units/ml poly(A) 
(dT)io (Boehringer Mannheim), 0.0125 mM dTTP, 25 pCi/ml, 3H-dTTP 
(Amersham, 20 Ci/mM), 12.5 mM Tris-HCl (pH 8.0), 2.5 mM dithiotbreitol, 
0.0125% Triton X 100 (Serva), 25 mM KC1, 6.25 mM Mg-acetate, 0.625 mM 
Mn-acetate. After the incubation period 22.5 pi of the mixture was 
pipetted onto a 2 cm diameter DEAE cellulose (Whatman DE/81) filter, 
and allowed to dry for 5 min at room temperature. The filters were then 
washed in 5% w/v Na*HPO< four times for 5 min each (10 ml/filter), once 
for 5 min in H2O (10 ml/filter) and finally twice for 2 min each in 96% 
ethanol (1-2 ml/filter). Filters were again allowed to dry at room 
temperature on aluminium foil before being counted in 5 ml of 
toluene base scintillation fluid for 5 min.
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Spleen focus formation assay.
Nice were injected i.v. with 0.5 ml of the virus diluent into the 
lateral tail vein. After 11-20 days, animals were sacrificed and the 
spleens were removed, weighed and then fixed in 70% ethanol.
Macroscopic spleen foci were counted and virus titres were expressed as 
spleen focus forming units (SFFU)/ml. Foci were only counted at the 
dilution where approximatly 50-100 individual foci could be easily 
distinguished. Titres were then calculated by multiplying by the 
appropriate dilution factors.
Histological and cvtological techniques.
Nice were killed by cervical dislocation and spleens were dissected. 
The tissue blocks were fixed with Bouin's or Carnoy's solution.
Semi-thin (1pm) sections were embedded in methacrylate (Technovit, 
Kulzer, Wehrheim) and were stained with toluidine blue, hematoxylin and 
eosin or Giemsa.
Preparation of competent bacterial cells for transformation by the 
calcium chloride procedure. (Nandel and Higa, 1970. Hanahan, 1983) .
100 ml of L. Broth (1% (w/v) NaCl, 1% Bactotryptone and 0.5% yeast 
extract (pH 6.8)) in a 500 ml flask was inoculated with 1 ml of an 
overnight bacterial culture (HB101 or CMK 603, DH5) and incubated at 
37*C with vigorous shaking until the cell density had reached 
approximately 5 x 107 cells/ml. The bacteria were then chilled on ice 
for 10 min and centrifuged at 1000 rpm in a GSA Sorvall rotor for 15 
min at 4°C before being resuspended in half of the original culture 
volume of ice-cold sterile 50 mM CaCli and 10 mM Tris-HCl (pH 8.0). The 
gently resuspended cells were then incubated for 15 min in an ice bath
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and pelleted by centrifugation as above. The pellet was gently 
resuspended in 1/15 of the original volume of ice-cold 50 mM CaClx and 
10 mM Tris-HCl (pH 8.0) and dispersed in 0.2 ml aliquots into 
prechilled Eppendorf tubes and stored at 4®C for 12 h. Cells were 
either used for transformation or snap frozen in liquid nitrogen after 
adding glycerol to form a 20% solution before being stored at -70*C.
Transformation of competent cells.
Ligation reactions containing generally 100 ng of vector DNA and 
equivalent molar ratios of insert were diluted 1:4 before being used 
for transformation. In general 1-10 ng of DNA were added to 10 pi of TE 
and pipetted gently into either fresh (or ice thawed-frozen) competent 
cells, gently mixed and then incubated on ice for 30 min. The cells 
were then heat shocked at 42°C for 2 min before being cooled on ice for 
2 min. At this point the bacteria could either be plated onto 
antibiotic agar plates (i.e. when subcloning) or incubated at 37*C for 
1 hour in 1 ml of SOC medium (2% bactotryptone, 0.5% yeast extract. 10 
mM NaCl, 2.5 mM KC1, 10 mM MgCls, 10 mM MgSO«, and 20 mM glucose) 
before plating (for preparing libraries).
Hanahan procedure for the preparation of competent cells.
(Hanahan, 1983, 1985)
This method is very convenient and efficient, giving an average 
transformation frequency of 107-10* colonies per microgram of pBR322 
DNA. This method is an adaptation of the standard transformation 
protocol (Hanahan, 1983) to prepare frozen competent cells for storage, 
except glycerol has been added and potassium acetate substituted for 
2(N-morphino)ethone sulphonic acid (MES), along with DTT, which are
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inhibitory in the preparation of frozen competent cells.
This method, for the construction of ■BNA-plasmid libraries, was used 
in conjunction with the bacteria, DH1 and DH5a.
Bacteria were plated out on SOB agar plates (2% Bacto tryptone, 0.5% 
Bacto yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM MgCl2 , 10 mM .MgS0<) 
and incubated overnight at 37°C. Single colonies were picked and grown 
up overnight in 10 ml of SOB medium. This overnight culture was then 
used to inoculate 100 ml of SOB medium in a 1 1 Erlenmeyer flask 
(1:100). The bacteria were incubated at 37°C with moderate agitation 
until the cell density was approximately 6-9 x 107 cells/ml (ODsso of 
0.4-0.5). The culture was then transferred to 50 ml polypropylene 
centrifuge tubes and cooled on ice for 15 min. Cells were pelleted at 
750g for 15 min at 4#C. After removing all traces of media, the cells 
were resuspended in 33 ml of 100 mM KC1, 45 mM MnCl2-4H20, 10 mM 
CaCl2 - 2H20, 3 mM HAC0CI3 , 10 mM K-Acetate, 10% (w/v) glycerol (pH 6.2), 
by gently vortexing on a vortex mixer. The resuspended cells were 
incubated on ice for 15 min, before being pelleted as before, and then 
resuspended in 8 ml of the above buffer. DMSO was added to a final 
concentration of 3-5%, mixed gently, and then incubated on ice for 5 
min. A second aliquot of DMSO giving an end concentration of 7% was 
added as before and the cells were incubated for 15 min on ice. 200 pi 
aliquots were pipetted into chilled 1.5 ml Eppendorf tubes, before 
flash freezing in liquid nitrogen. The cells were stored at -70°C until 
use.
Use of competent cells.
Tubes were removed from -70°C and allowed to thaw on ice, until the 
cell suspension was just liquid. DNA was added (in a volume of <10 pi),
and the cells were gently nixed, before incubating on ice for 45 min. 
Cells were heat shocked in a 42®C water bath for 90 sec, and then 
chilled on ice. 800 pi of SOC medium was added and incubated at 37°C 
with noderate agitation (150 rpn) for 60 nin before plating.
Preparation of bacteriophage laabda stocks.
Bacteriophage from a single plaque were transferred with a sterile 
Pasteur pipette into 1 ml of phage buffer SM (50 mM Tris-HCl (pH 7.5), 
0.01% gelatin, 0.58% NaCl, 0.2% MgSO«-7HaO), 1 drop of chloroform was 
added, and the solution was nixed on a vortex nixer. After removal of 
the chloroform by low speed centrifugation, 0.1 to 0.2 nl of phage 
suspension was mixed with 0.1 ml of fresh cells (prepared by growing a 
1:20 dilution of an overnight culture for 2 h and then resuspending the 
cells in a half volume of 10 mM MgSO«). After allowing the phage to 
adsorb to the cells for 10 min at room temperature, 2.5 ml of TOP agar 
(L. broth + 0.8% agar) were added and the mixture was poured onto a 
fresh agar plate. Confluent lysis was observed after 6-10 h at 37®C.
The agar was overlaid with 3 ml of phage buffer for 4-6 h at 2®C. This 
was then decanted, 2 drops of chloroform were added and the 
suspension titred and stored at 4®C. Titres varied from 5 x 10* to 
5 x 1011/ml depending on the phage and the bacterial host used.
Packaging of recombinant DNA into phage heads in vitro.
Packaging extracts were prepared essentially as described by 
Maniatis et al. (1982). Packaging in vitro was carried out as follows: 
the frozen packaging extracts (stored at -70®C) were thawed on ice. The 
freeze/thaw lysate, which thaws first, was transferred to the still 
frozen sonicated lysate and then the DNA to be packaged (up to 1 ug in
88
TE and 10 mM MgCls) was added to the Mixture. This was incubated at 
room temperature for 60-120 mins. After this time 0.5-1 ml of phage 
storage buffer (SN) and a drop of chloroform was added and gently mixed 
on a vortex mixer. Debris was removed by brief centrifugation in an 
eppendorf centrifuge (30 sec). Titres of packaged phage were determined 
as described previously.
Plasaid PNA preparation.
Plasmid DNA was isolated using an adaptation of the method described 
by Clewel and Helinski (1969). E.coli strains carrying plasmids were 
plated onto appropriate antibiotic agar plates so as to obtain single 
colonies. 10 ml cultures from a single colony were grown to saturation 
overnight at 37*C and then used to inoculate 500 ml of the appropriate 
antibiotic containing medium in a 2 liter Erlenmeyer flask. These 
cultures were then grown at 37*C for 12 h with vigourous shaking. The 
cells were harvested by centrifugation at 6000 rpm for 5 min at 4°C in 
a Sorvall GS-3 rotor. The cell pellet was resuspended in 6 ml of 
ice cold 25% sucrose, 50 mM Tris-HCl (pH 8.0), and transferred to a 
polypropylene Oak Ridge tube on ice. 0.6 ml of freshly prepared 
lysozyme (5 mg/ml, Sigma) in 50 mM Tris-HCl (pH 8.0) and 10 mM EDTA 
were added, mixed gently by inversion and incubated for 5 min on ice. 
2.25 ml of 250 mM Tris-HCl (pH 8.0), 250 mM EDTA stop buffer were 
added, gently mixed and incubated for a further 5 min on ice. After 
addition of 9 ml 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5% Triton X- 
100, and gentle mixing, lysis of the bacterial spheroplasts was 
indicated by an increase in viscosity at which point mixing was 
stopped. The lysate was cleared by centrifugation at 20,000 rpm for 1 
hour at 4°C in a Sorvall SS34 rotor. The supernatant was decanted
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carefully into a 50 ml polyallomer tube containing 29 g CsCl 
(Gibco/BRL). The volume was made up to 27 ml with H2O and 0.5 ml 
ethidium bromide (5 mg/ml) was added and the solution was transferred 
to a 39 ml quickseal vti tube (Beckman) through a large bore syringe. 
The tube was filled up with 0.984 g/ml CsCl in H*0, sealed and 
centrifuged for 18 h at 45,000 rpm at 20°C in a Beckman vti 50 rotor. 
Supercoiled plasmid DNA was collected in a 5 ml syringe by side 
puncture and transferred to a small (6 ml) Beckman quick seal vti tube 
and filled up with the CsCl solution described above. Tubes were sealed 
and centrifuged at 65,000 rpm for 5 h at 20°C in a Beckman vti 65 
rotor. Supercoiled plasmid DNA was removed by side puncture and the 
ethidium bromide was removed by repeated extraction with isobutanol 
partially saturated with water and the aqueous phase was dialysed 
against several changes of TE solution. The DNA was precipitated by 
addition of 0.1 volume 3 M Na-acetate (pH 5.6) and 2.5 volumes of 
ethanol. After at least 2 h at -20°C the precipitate was collected by 
centrifugation at 10,000 rpm for 10 min at 4°C in a Sorvall HB-4 rotor. 
Following brief drying under vacuum, the pellet was resuspended in 
0.5-1 ml TE solution.
Small scale preparation of plasmid DNA^
The rapid small scale preparation of plasmid DNA from recombinant 
clones was that of the alkaline lysis method described by Naniatis et 
al. (1982), except for minor modifications.
2 ml cultures of E.coli strains containing plasmids were grown for 
6 h to overnight at 37°C in L. Broth containing the appropriate 
antibiotic. The cells were pelleted by centrifugation in an Eppendorf 
microfuge for 2 min at room temperature and then resuspended in 100 pi
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of 50 mM glucose, 25 mM Tris-HCl (pH 8.0), 10 mM EDTA at room 
temperature. 200 pi of freshly prepared 0.2 N NaOH, 1% (w/v) SDS were 
added and the mixture gently mixed. 150 pi of precooled 5 H K' 3M 
acetate- solution was added immediatly and after brief gentle mixing 
was incubated for 5 min on ice. The resulting precipitate was removed 
by centrifugation for 5 min in an Eppendorf microfuge at room 
temperature and the supernatant was transferred to a fresh tube. This 
aqueous phase was then extracted with an equal volume of 
phenol/chloroform (1:1) and after centrifugation for 2 min in an 
Eppendorf microfuge was removed to a fresh tube. The plasmid DNA was 
precipitated by addition of 800 pi of absolute ethanol and allowed to 
stand at room temperature for 5 min. The DNA was collected by 
centrifugation for 5 min at room temperature in an Eppendorf microfuge. 
The supernatant was carefully aspirated and the pellet was washed with 
70% (v/v) ethanol, dried under vacuum, resuspended in 50 pi TE solution 
and stored at -20#C.
Large scale isolation of bacteriophage DNA.
A suspension of phage was mixed with 0.5 ml fresh plating cells to 
give a m.o.i. of 1-10. After allowing the phage to adsorb to the cells 
for 15 min at room temperature, the suspension was inoculated into 
500 ml L. broth containing 10 mM MgSO«, 0.2% maltose and incubated 
overnight at 37°C with vigorous shaking. To the resultant phage lysate, 
chloroform (2 ml/1) and NaCl (40 g/1) were added plus RNase and DNase 
to 1 pg/ml. The lysate was incubated at room temperature for at least 
1 hour and then clarified by centrifugation at 8000 rpm in a Sorvall 
GS-3 rotor for 10 min at 4°C. Solid PEG 6000 was added to the 
supernatant to give a final concentration of 10% (w/v) and swirled to
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dissolve. The opaque solution was then left at 4®C for at least 1 hour 
to precipitate the phage. The phage was pelleted by centrifugation at 
8000 rpm for 20 min in a Sorvall GS-3 rotor at 4°C and resuspended in 9 
ml of phage buffer overnight at 4°C. The volume of phage suspension was 
made up to 10 ml with phage buffer and then 7.1 g CsCl was added. The 
phage was purified by equilibrium centrifugation in a Beckman Ty65 
rotor at 50,000 rpm for 16-18 h. The phage band was collected in a 2 ml 
syringe by side puncture and the CsCl was removed by dialysis against 
several changes of TE. The phage suspension was extracted 3 times with 
neutral phenol (equilibrated with Tris base and hydroxychinoline) and 
once with chloroform before dialysis against several changes of TE 
solution. The DNA was stored at 4°C.
Small scale preparation of lambda DNA.
This method was used to analyse clones found to be positive upon 
plaque hybridisation.
0.1 ml of the phage suspension was incubated for 20 min at 37°C with 
0.2 ml of host bacteria and 0.2 ml of a 10 mM MgCla, 10 mM MgSO« 
mixture. 2 ml of prewarmed LB (containing 0.2% maltose) was added and 
incubated overnight at 37®C with vigorous shaking. After this period 
lysis was visible and was further aided by the addition of a drop of 
chloroform and incubation for 5 min at 37®C with vigorous shaking. 
Debris and non-lysed bacteria were pelleted by centrifugation at 6000 
rpm for 15 min in a Sorvall HB4 rotor at 4®C. The supernatant was mixed 
with 0.4 ml 0.25 M EDTA (pH 8.0), 0.4 ml 0.5 M Tris-HCl (pH 9.5) and 
0.4 ml 3% (w/v) SDS and incubated at 65®C for 15 min. 0.4 ml 5 M K- 
acetate was added and incubated on ice for 10 min before being
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centrifuged for 15 sin at 6000 rpm in a Sorvall HB4 rotor at 4°C. The 
clear supernatant was then extracted twice with equilibrated phenol and 
twice with a phenol/chloroform mixture before precipitating the DNA by 
addition of two volumes of absolute ethanol and 30 min at -70°C. The 
DNA was pelleted by centrifugation at 8000 rpm for 30 min in a Sorvall 
HB4 rotor at 4°C. The washed, dried DNA was then resuspended in 200 pi 
TE and stored at 4°C.
Preparation of extrachromosomal DNA (Hirt extraction). (Hirt, 1967). 
Large scale preparation.
Cells (ca. 107-10*) were pelleted by centrifugation at 1000 rpm for 
10 min at 4°C in a Sorvall GS-3 rotor. The cells were washed once in 
cold PBS and pelleted as above before being resuspended at 3 x 10* 
cells/ml in 10 mM Tris-HCl (pH 8.0), 10 mM EDTA. SDS (10% w/v) was 
added to a final concentration of 0.6% and proteinase K (20 mg/ml in 
HzO) to 200 pg/ml. This mixture was then incubated at 60°C for 30 min.
5 N NaCl was added to give an end concentration of 1 M and incubated at 
4°C overnight. High molecular weight DNA was pelleted by centrifuging 
the lysate at 17,000 rpm for 60 min in a Sorvall SS34 rotor at 4°C. The 
resulting cleared lysate was further digested with 50 pg/ml proteinase 
K for 1 hour at 60°C before being extracted twice with equilibrated 
phenol, twice with a phenol/chlorof orm mixture and once with 
chloroform. DNA was precipitated by addition of two volumes of ethanol 
and overnight incubation at -20°C. The washed DNA pellet (70% ethanol) 
was dried under vacuum and dissolved in TE.
Before electrophoresis DNA was treated with RNase A to remove RNA
contamination.
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Small scale preparation .
(H. Veiher, pers. commun., Whitehead Institute, Boston).
1 x 10* cells were washed in PBS and then resuspended in 900 pi 10 mM 
Tris-HCl (pH 8.0), 10 mM EDTA in an Eppendorf microfuge tube. 100 pi of 
10% SDS (w/v) was added together with 200 pg/ml proteinase K (20 mg/ml 
stock solution in H2O) and incubated at 60°C for 20 min. To this was 
added 200 pi of 5 M NaCl and incubated at -20°C for 20 min. The 
precipitated high molecular weight DNA was pelleted by centrifugation 
in an Eppendorf microfuge in the cold room for 10 min. The supernatant 
was then extracted twice with a phenol/chloroform mixture and once with 
chloroform. DNA was precipitated by addition of two volumes of ethanol 
and incubation at -70°C for 20 min. Pelleted, washed, dried DNA was 
resuspended in TE solution.
Preparation of mammalian genomic DNA.
Either homogenised tissue or tissue culture cells were washed once in 
PBS and then resuspended in 10 mM Tris (pH 8.0), 10 mM EDTA. To this 
suspension was added SDS (10% w/v stock solution) to give a final 
concentration of 1% and proteinase K at 100 pg/ml. Lysed cells were 
then incubated at 37°C overnight with constant gentle agitation, before 
being gently extracted twice with equilibrated phenol, twice with a 
phenol/chloroform mixture and once with chloroform. The genomic DNA was 
precipitated by addition of two volumes of isopropanol and 0.1 volumes 
of 5 M NaCl. The precipitate was collected by spooling the DNA onto a 
closed-end Pasteur pipette. The DNA was briefly washed in 70% ethanol 
before being allowed to dry briefly at room temperature. The dried DNA 
was dissolved in TE solution and stored at 4°C.
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RNA preparation:
In all procedures involved in preparing RNA and any experiment using 
RNA, precautions against ubiquitous ribonuclease were taken. All 
glassware and OTFE Oak Ridge centrifuge tubes were heated in a dry oven 
at 160°C for at least 2 h. Polypropylene microfuge tubes and disposable 
pipette tips were used directly from the manufacturer's sealed packets. 
When possible, new containers of chemicals were used. All buffer 
solutions were autoclaved before use.
Total RNA.
The method used was that of Auffray and Rougeon (1981).
Fresh tissue, usually cultured cells, or finely ground frozen tissue 
were placed in 10 volumes or more of 6 M urea, 3 M LiCl and homogenised 
in a polytron for 1 min. The RNA was precipitated out by overnight 
incubation at 4°C and then pelleted by centrifugation at 12,000 rpm for 
30 min at 0°C in a Sorvall SS34 rotor. The RNA pellet was then 
resuspended in 8 ml 6 M urea, 3 N LiCl and again centrifuged for 30 min 
at 12,000 rpm, 0°C in a Sorvall SS34 rotor. The resulting pellet was 
then dissolved in 10 mM Tris-HCl (pH 7.5), 0.5% SDS, 50 pg/ml 
proteinase K (Merck) and incubated at 37°C for 15 min. This aqueous 
solution was then extracted 3 times with equilibrated phenol, twice 
with a phenol/chloroform mixture and once with chloroform. The RNA was 
then ethanol precipitated and dissolved in H2O and stored at -70°C.
PolvA* RNA.
This was prepared according to the method of Aviv and Leder (1972). 
The total RNA pellet was dissolved in a minimal volume of 0.5 M NaCl,
10 mM Tris-HCl (pH 7.5) and 0.5% SDS (binding buffer). This solution
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was passed three times over a small (less than 1 ml) oligo (dT) 
cellulose column (Pharmacia Type 7) preequilibrated with binding 
buffer. Unbound material, including residual DNA and proteins, was 
removed by a 30 ml wash with binding buffer. Bound material was eluted 
with 10 ml 10 mM Tris-HCl (pH 7.5) and 0.05% SDS (eluting buffer). The 
eluate was adjusted to 0.5 H NaCl and twice reapplied to the column.
The column was washed with 20 ml binding buffer, and bound material was 
again eluted with 5 ml eluting buffer and ethanol precipitated before 
being dissolved in H2O after drying. RNA to be used for any purpose was 
thawed, used immediately and refrozen as infrequently as possible.
Enzymatic reactions:
Restriction enzyme analysis.
DNA samples were digested with restriction enzymes in volumes ranging 
from 10-500 pi essentially according to the manufacturers instructions 
using the reaction buffers depicted in Table 1.
Dephosphorvlation.
The terminal 5' phosphates were removed from linearized vector DNAs 
by treatment with calf intestinal phosphatase (CIP). The DNA was 
digested to completion with a chosen restriction endonuclease, 
extracted once with a phenol/chloroform mixture prior to ethanol 
precipitation. The DNA was dissolved in a minimum volume of TE, 5 pi of 
lOx CIP buffer {Tris-HCl (pH 9.0), 10 mM MgCla, 1 mM ZnCla, 10 mM 
spermidine) were added and the volume was made up to 50 pi with 
deionised water. 0.01 units of CIP per pmole of DNA 5' ends were added. 
DNA with protruding 5' termini were incubated at 37°C for 30 min, a
[¡iiiiiiiiluiiiiiiiiiliM
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Table 1. Buffers used for digestion of DNA 
with various restriction enzymes
The conditions varied only in NaCl concentration. All 
buffers contained 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2 
and 100 pg/ml bovine serum albumin.
+++ represents 30-100% digestion activity.
++ represents 10-30% digestion activity.
+ represents < 10% digestion activity. *
* not recommended because of star activity.
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second aliquot of CIP was added and the reaction incubated for a 
further 30 Bin. Recessed 5' or blunt ends were incubated for 15 min at 
37°C and then 15 Bin at 56°C, a second aliquot of CIP was added and the 
incubations repeated. Reactions were terainated by addition of 40 pi 
HiO, 10 pi of STE and 5 pi of 10% (w/v) SDS and heated to 68°C for 15 
min. The reactions were extracted twice with phenol/chloroform and once 
with chloroform before the DNA was ethanol precipitated together with 1 
pg of glycogen carrier. CIP was obtained from Boehringer Mannheim.
Filling in.
Recessed 3' ends of double stranded DNA were filled in using the 
Klenow fragment of E.coli DNA polymerase I. Final reaction conditions 
were 0.6 mM MgCla, 6.6 mM Tris-HCl (pH 8.5), 2 mM dNTPs, 50 pg/ml DNA 
and 1 unit Klenow fragment of E. coli DNA polymerase I (Boehringer 
Mannheim). The reaction mixture was incubated at room temperature for 
30 min, extracted once with phenol/chlorof orm, and the DNA ethanol 
precipitated prior to ligation. This method was also used to label ends 
by addition of 32P dNTPs to the reaction.
Labelling of 5' ends with T4 polynucleotide kinase
This method is used to label DNA molecules with 5* protruding termini 
by catalysing the transfer of the t-phosphate of ATP to a 5' OH 
terminus in DNA (or RNA).
Digested, dephosporylated and ethanol precipitated DNA (1-50 pmoles 
of 5' ends) was resuspended in 10 pi of lOx kinase buffer (0.5 M 
Tris-HCl (pH 7.6), 0.1 M MgClj, 50 mM DTT, 1 mM spermidine, 1 mM EDTA) 
and 24 pi H*0. To this mixture 150 pCi (3000 Ci/mmol, 15 pi) (x32P)ATP 
(Amersham) was added followed by 10-20 units (1-2 pi) T4 polynucleotide
kinase (New England Nuclear). The mixture was incubated at 37®C for 30 
min, before adding 2 pi of 0.5 M EDTA and extracting once with 
phenol/chloroform and subsequently ethanol precipitated. The free 
nucleotides were separated (when needed) from the labelled DNA by spin 
column chromatography with Sephadex G-50.
Digestion of linearised DNA with Bal 31 nuclease.
DNA to be digested with Bal 31 was ethanol precipitated and then 
dissolved in 500 pg/ml (in water) of BSA. To this DNA solution was 
added an equal volume of 2x Bal 31 buffer (24 mM CaCl2 , 24 mM MgCl2 , 
400 mM NaCl, 40 mM Tris-HCl (pH 8.0), 2 mM EDTA). This mixture was 
incubated at 30°C for 3 minutes. An appropriate amount of Bal 31 was 
added and incubated at 30®C. At time intervals aliquots were removed 
from the reaction and made 20 mM EGTA on ice. The conditions used were 
that appr. 10 bp/min/end of double stranded DNA were digested.
L i g a t i o n .
For plasmid construction experiments, the DNA concentration in the 
ligation reaction was 100 pg/ml and the target to vector molar ratio 
was 3:1. The target and vector DNAs were mixed together with 5 pg 
glycogen carrier and were ethanol precipitated. The nucleic acids were 
dissolved in 8 pi TE and 1 pi of lOx ligation buffer (100 mM Tris-HCl 
(pH 7.5), 0.1 M MgCl2 , 0.15 M DTT, 10 mM spermidine). 10 mM ATP was 
added with 1 unit of T4 DNA ligase (Boehringer Mannheim). The reaction 
was incubated at 14®C overnight (room temperature for blunt ends) .
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Labelling of nucleic acids:
Nick-translation. (Rigby et al., 1977).
Final reaction conditions were 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2 ,
1 pH unlabelled dNTPs, 100 mM dithiothreitol, 50 pg/ml BSA pentax 
fraction V, 1 pg DNA, 50-100 pCi a-aaP dNTP. The reaction volume was 
made up to 44 pi with H2O. 0.5 pi of a freshly diluted DNAse solution 
(0.1 pg/ml, stock solution 1 mg/ml) together with 5 units of E.coli DNA 
polymerase I was added and mixed.
The reaction was incubated at 14°C for 1 hour and then the labelled 
DNA was separated from the unincorporated nucleotides by gel filtration 
through a Sephadex G-50 (Pharmacia) spin column (equilibrated with TE) 
in a 2 ml syringe at 1000 rpm for 5 min in a bench centrifuge. The DNA 
was denatured by boiling for 5 min, cooled on ice, then diluted as 
required into hybridisation reactions.
Routinely 50-70% of labelled dNTP was incorporated into the G-50 
excluded fraction, giving a final specific activity of greater than 
10» cpm/pg.
Oligonucleotide labelling of DNA restriction endonuclease fragments. 
(Feinberg and Vogelstein, 1984) .
This method was used to label DNA fragments excised from gels to 
high specific activity with o-32P. DNA fragments from restriction 
endonuclease digests were electrophoretically separated and isolated 
either by electroelution or NA45 paper. The labelling reaction was 
carried out at room temperature in the following way. 10-50 ng of 
fragment DNA were denatured by boiling for 10 min in 30 pi of H2O. This 
was then incubated at 37°C for 20-30 min, before adding 10 pi of OLB
100
buffer. OLB buffer is made from the following components: Solution 0: 
1.25 M Tris-HCl (pH 8.0), 0.125 M MgCla, stored at 4#C. Solution A: 1ml 
solution 0 and 18 pi 2-mercaptoethanol, 5 pi dATP, 5 pi dTTP, 5 pi 
dGTP (0.1 M in 3 mM Tris-HCl (pH 7.0), 0.2 mM EDTA), stored at -20«C. 
Solution B: 2 M HEPES, titrated to pH 6.0 with 4 M NaOH, stored at 4°C. 
Solution C: Hexadeoxyribonucleotides (Pharmacia) evenly suspended in TE 
at 90 OD260 units/ml, stored at -20°C. A:B:C was mixed at a ratio of 
10:25:15 to make OLB and was stored as 10 pi aliquots at -20°C. To 
this was then added 1 pi BSA (20 mg/ml. Sigma, pentax fraction V), 50- 
100 pCi a-33P-labelled dCTP (Amersham Buchler), 2 units of Klenow 
fragment of E. coli DNA polymerase I (Boehringer Mannheim). Incubation 
was continued at room temperature for 2-16 h, then 200 pi of the stop 
solution (20 mM Tris-HCl (pH 7.5), 2 mM EDTA, 0.25% (w/v) SDS and 1 pM 
dCTP) were added. The solution was extracted twice with a phenol/ 
chloroform mixture and once with chloroform before being denatured by 
boiling for 5 min. Specific activities of greater than 10* cpm/pg were 
routinely obtained.
Quantitation of nucleic acids:
Spectrophotometric assays.
Samples were diluted in TE and the absorbance at 260 nm was measured. 
Concentrations were calculated assuming that an ODaao of 1.0 
corresponds to 50 pg/ml of double stranded DNA or 40 pg/ml of RNA.
Radiometric assays.
DNA synthesis reactions (nick-translation etc.) were monitored by 
percentage incorporation of 32P-labelled nucleotide into acid insoluble
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material. An aliquot (0.01-0.1 reaction volumes) was diluted in 0.1-1.0 
ml TE. An aliquot of this was dried onto a Whatman GF/C filter, washed 
in acid solution followed by ethanol and dried. All filters were 
counted in toluene-based scintillation fluid. The yield of DNA 
synthesized was calculated from the percentage incorporation and from 
the known concentration of DNA the specific activity was calculated.
Electrophoretic techniques;
Neutral agarose gels.
0.4-2% (w/v) horizontal agarose gels were prepared in electrophoresis 
buffer, TAE buffer (40 mM Tris-HCl (pH 8.1), 20 mM Na-acetate, 2 mM 
EDTA) and subjected to electrophoresis in the same buffer in the 
presence of ethidium bromide (1 pg/ml) at 1.5 V/cm for 6-18 h. 0.2 
volumes of gel loading buffer (lOx: 0.25% bromophenol blue, 0.25% 
xylene cyanol, 25% Ficoll (type 400) in water) were added to samples 
prior to loading. This method was used for fine restriction mapping of 
plasmid constructs and genomic DNA. For other purposes we used an 
electrophoresis buffer consisting of 0.5x TBE (lx: 90 mM Tris, 2.5 mM 
EDTA, 90 mM boric acid (pH 8.3)) as this could be used at higher 
voltages (5-10 V/cm).
Isolation of DNA fragments after restriction enzyme digestion.
Specific DNA digestion fragments (to be used as 32P probes or for 
subcloning etc.) were isolated by either one of the following methods.
1) Electroelution.
After digestion the fragments were separated on neutral agarose gels
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(0.5-2%) in 0.5x TBE solution containing ethidium bromide, until the 
required fragment(s) was (were) well separated from other fragments. An 
agarose block (as small as possible) containing the required fragment 
was placed into dialysis tubing containing a minimal volume of 0.25x 
TBE solution (200-500 pi) and sealed without trapping any air bubbles. 
The dialysis tubing was submerged in 0.25x TBE in a mini-gel 
electrophoresis chamber and the fragment was eluted from the agarose 
block into the dialysis bag by electrophoresis at 200 V for 1 hour. 
After this period the poles were reversed and a voltage was applied 
(100-200 V) for 30 sec to remove DNA from the dialysis tubing wall.
The 0.25x TBE and DNA solution in the dialysis tubing was removed and 
extracted twice with a phenol/chloroform mixture before being ethanol 
precipitated.
2) NA45 paper. (Ken Burtis, pers. comm., Stanford, USA).
After digestion and separation of DNA fragments as described above, a 
small strip of NA45 paper (Schleicher and Schflll) corresponding to the 
length of the required band was placed in a slit directly in front of 
it. The DNA was then electrophoresed onto the NA45 paper, a process 
which was easily monitored by UV illumination. The DNA was eluted from 
the NA45 paper by incubation for 2 h at 68#C in 400 pi of 1 M NaCl, 50 
mM arginine (free base). This DNA containing solution was extracted 
twice with a phenol/chloroform mixture before being ethanol 
precipitated.
RNA glvoxal gels.
These gels contained 1-1.5% (w/v) agarose and were cast in MOPS (10 
mM MOPS, 2.5 mM Na-acetate, 0.25 mM EDTA (pH7.0)) buffer without
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ethidium bromide. Gels were subjected to electrophoresis in the same 
buffer at 1-2 V/cm for 12-18 h with constant recircularisation of the 
buffer. Samples to be analysed by electrophoresis were prepared as 
follows: 10-20 pg of total or polyA* RNA in 15.3 p i  H2O was added to 
25 p i  DNSO, 2.5 p i  0.2 M NaaHPO4/NaHaPO« (pH 7.0) and 7 p i  7 H 
deionized glyoxal. The reaction was incubated at 50° C for 60 min before 
adding 0.1 volume of loading buffer.
All glass and plexiglass ware were treated with 0.4 H NaOH for 30 min 
and then washed thoroughly with distilled water prior to use.
Size markers used for electrophoresis.
Restriction enzyme digests of plasmid or bacteriophage lambda DNA 
were used.
SDS polyacrylamide gel electrophoresis.
Polypeptides were resolved on a 10-30% gradient of polyacrylamide gel 
using the buffer system of Laemmli (1970) essentially according to Cook 
et al., (1974). Electrophoresis was at 80 V for 12-16 h until the 
bromophenol blue or the visible monomer cytochrome C band had reached 
the bottom of the gel.
Preparation of filters for DNA gel transfer hybridisation (Southern 
blotting).
DNA was transferred from neutral agarose gels to filters as described 
by Southern (1975) but incorporating some of the modifications of Wahl 
et al., (1979). Gels were treated for 15 min with five gel volumes of 
0.25 M HC1. They were then rinsed briefly with water, treated for 30 
min with five gel volumes of 0.4 M NaOH, 0.6 N NaCl and then
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neutralised with five volumes of 1.5 M NaCl, 0.5 M Tris-HCl (pH 7.4).
Gene Screen (DuPont) sheets were cut to the exact size of the gel and 
then wetted in water and allowed to soak in lOx SSC (1.5 M NaCl, 150 mM 
Na-citrate) for 15 min. DNA was transferred to these overnight using 
lOx SSC. After transfer the membrane was immersed in an excess of 0.4 N 
NaOH for 30-60 seconds to ensure complete denaturation of immobilised 
DNA. The membrane was then immersed in an excess of 0.2 M Tris-HCl (pH 
7.5), 2x SSC, before being allowed to dry at room temperature.
An alternative transfer method for nylon nitrocellulose membranes 
(Reed and Mann, 1986) was also used throughout the course of this work.
Alkaline blotting with depurination.
The gel was soaked in 2 volumes of 0.25 N HC1 with gentle agitation 
until the bromophenol blue turned yellow. The gel was rinsed briefly 
with distilled water. The normal transfer apparatus was set up during 
this procedure, except that the transfer solution was 0.4 M NaOH. 
Transfer was continued for 2-18 h, after which time the filter was 
washed in 2x SSC before being allowed to dry at room temperature.
Preparation of filters for RNA gel transfer hybridisation (Northern 
blotting).
The transfer of RNA from MOPS glyoxal gels was essentially the same 
as for DNA except that the gel was not treated after electrophoresis. 
Transfer onto Gene Screen filters was conducted with lOx SSC overnight. 
After transfer the membrane was immersed in 50 mM NaOH for 
approximately 10-20 seconds to reverse the glyoxal reaction. The 
membrane was then incubated for 30 seconds in lx SSC and 0.2 M Tris-HCl
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(pH 7.5), before allowing the membrane to dry at room temperature.
Hybridisation of DNA bound to Gene Screen Plus nylon membranes.
Dry membranes were prehybridised in a sealed plastic bag at 68° C for 
at least 15 min in 5-20 ml of the following solution: 1% SDS, 1 M NaCl 
and 10% dextran sulphate (Pharmacia Fine Chemicals).
After the prehybridisation step, 0.5-1 ml of the following solution 
was added to the bag containing the prehybridisation buffer and the 
membrane: denatured herring sperm DNA (>100 pg/ml) and denatured 
radioactive probe at a final concentration of less than 10 ng/ml (or 
1 x 10s to 10* dpm/ml). The bag was resealed and incubated for 
12-18 h at 68®C with constant agitation. After this period the membrane 
was removed and washed twice in 100 ml of 2x SSC at room temperature 
for 5 min with constant agitation, then twice in 200 ml of a solution 
containing O.lx SSC and 1.0% SDS at 65®C for 30-60 min with constant 
agitation. Finally the membrane was washed twice in 100 ml O.lx SSC at 
room temperature with constant agitation, before being blotted between 
two paper towels. Membranes were wrapped in Frappan and exposed to 
X-ray (DuPont) film at -70®C with intensifying screens.
Filters were rehybridised as above after the original probe had been 
removed by the following treatment: the membrane was incubated for 30 
min at 42®C with gentle agitation in 100-200 ml 0.4 M NaOH. After this 
the membrane was incubated in 100-200 ml O.lx SSC, 0.1% SDS, 0.2 M 
Tris-HCl (pH 7.5), at 42®C for 30 min with gentle agitation, before 
being autoradiographed to see if sufficient probe had been removed.
Hybridisation of RNA bound to Gene Screen Plus nylon membranes.
The dry membrane was prehybridised in 10-20 ml of the following
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solution: 50% deionised formamide, 1% SDS, 1 N NaCl and 10% dextran 
sulphate in a sealable plastic bag for at least 15 min at 42°C with 
constant agitation. After this preincubation denatured herring sperm 
and radioactive probe was added at the same concentration as for DNA 
hybridisation. The membrane was then hybridised at 42°C for 18-24 h 
with constant agitation.
Washing of the membrane was identical to the DNA procedure except 
that the temperature was decreased to 56°C.
To remove probe for rehybridisation, the membrane was washed twice to 
four times in 500-600 ml of boiling 0.01% SDS, O.Olx SSC. Removal of 
the probe was monitored by autoradiography.
Screening of bacterial colonies with radioactive probes. (Grunstein and 
Hogness, 1975).
In this method, 5000-10,000 colonies/plate were screened after 
transformation and plating out onto 20x20 cm (Nunc) disposable Petri 
dishes.
After 12-16 h incubation at 37°C, so that the colonies were 
approximately 0.5-1 mm in diameter, plates were removed and incubated 
at 4°C for 15 min. Colonies were lifted onto nitrocellulose membranes 
(Schleicher and SchQll) by placing the filter onto the colony covered 
dishes and marking orientation positions with India ink. Replicas of 
these lifts were produced by layering a second nitrocellulose filter 
onto colonies on the first filter and pressing firmly to equally 
distribute the bacteria to both filters. The filters were separated and 
the DNA was liberated from the bacteria by the following method.
The filters were layered colony side up onto Whatman 3 MM paper 
saturated with 10% SDS and incubated for 3 min at room temperature.
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After this the filters were transferred to 3 MM paper saturated with 
0.5 M NaOH, 1.5 M NaCl for 5 min and then to 1.5 M NaCl, 0.5 M Tris-HCl 
(pH 8.0) for a further 5 min. Finally the filters were washed in 2x 
SSPE (360 mM NaCl, 20 mM NaH2P0« (pH 7.4), 2 mM EDTA (pH 7.4)) for 5 
min before being allowed to dry at room temperature for 30-60 min. Dry 
filters were then baked between two sheets of dry 3 MM paper at 80°C 
for 2 h.
Screening of phage plagues with radioactive probes. (Benton and Davies, 
1977) .
This method was used to screen large numbers of recombinant phage 
plaques. After overnight incubation at 37°C of large (20x20 cm. Nunc) 
Petri dishes with 90% confluent plaques were incubated for 1 hour at 
4#C. Nitrocellulose filters (Schleicher and Schdll) were layered onto 
the plates and allowed to stand for 30 seconds to 1 min (replica 
filters were left longer, 1-3 min) before being carefully peeled off 
and layered onto 3 MM paper soaked with 0.5 M NaOH. After 5 min the 
filter was transferred to a second sheet of 3 MM paper soaked in 0.5 M 
Tris-HCl (pH 8.0), 1.5 M NaCl. Finally the filter was washed in 2x SSC 
and then allowed to dry at room temperature before being baked at 80° C 
for 2 h. Filters were hybridised as described for Grunstein and Hogness 
blots.
Hybridisation of DNA bound to nitrocellulose filters.
This method was used both for hybridisation of DNA bound to 
nitrocellulose filters from colony and plaque lifts.
Baked filters were prehybridised in 10-20 ml of a buffer containing 
0.2% polyvinyl-pyrrolidone (MW 60,000), 0.2% Ficoll (MW 400,000), 0.2%
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bovine serua albumin, 50 mM Tris-HCl (pH 7.5), 1 M NaCl, 0.1% 
Na-pyrophosphate, 0.5% SDS and 100 pg/ml of denatured herring sperm 
DNA for 10-16 h at 68° C with constant shaking in a sealable plastic 
bag.
After prehybridisation the buffer was removed and replaced with an 
equal volume containing 1-2 x 10* dpm/ml of denatured radioactive 
probe. The plastic bag was resealed and incubated for a further 12-14 h 
at 68°C with constant agitation. Filters were washed twice in 100 ml of 
2x SSC at room temperature for 5 min, then twice in 200 ml of O.lx SSC, 
0.1% SDS at 68°C for 30 min and finally once in 100 ml O.lx SSC, 1% SDS 
for 20 min at room temperature, before being blotted between two paper 
towels and exposed to X-ray film at -70*C.
Labelling of cells with 39S-methionine.
Log phase cells were washed once in PBS before being either 
resuspended (for non-adherent cells) or fed with GMEM containing 10%
FCS (this medium contained 1/10 the normal concentration of 
methionine). Cells were incubated for 6 h in this medium before being 
washed twice in Earle's buffered saline. Cells were labelled for 1 
hourin GMEM containing 10% FCS without methionine and 25 pCi/ml 38S 
methionine.
After this incubation period, the medium was removed and the cells 
were washed twice in ice cold PBS. Cells were either pelleted and 
resuspended in 100 pi 10 mM Tris (pH 7.2) or scraped off and 
resuspended in 100 pi of the above buffer. Samples were either stored 
at -70°C or used immediately for immune precipitation.
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I«— une precipitation. (P. Nobis, pers. c o m .. University of Hamburg) 
Preparation of extract.
Cells were lysed in 1 ml of extraction buffer (5 mM Tris (pH 9.2),
1 mM EDTA, 400 mM KC1, 1% Triton X-100, 1 mM PMSF, added just before 
use from a 100 mH stock solution in DMSO) by mixing on a vortex for 1 
min before incubating on ice for 15-30 min. The lysed cells were then 
centrifuged for 15-20 min in an Eppendorf centrifuge. The supernatant 
was removed to a fresh tube ready for precipitation.
Preparation of a Staphylococcus aureus reagent (cell adsorbed).
S.aureus were prepared as described by Kessler (1975) and was stored 
at -20°C in aliquots in PBS-azide. Before use S.aureus was pelleted in 
an Eppendorf centrifuge (1-2 min) and washed once in 20 mM Tris-HCl 
(pH 7.6), 100 mM NaCl, 1 mM EDTA. 0.5% NP40 (TEN containing 0.5% NP40) 
and then resuspended in the same buffer. Preadsorbed S.aureus were 
prepared as follows. An unlabelled cell lysate was prepared as above 
and the S.aureus were diluted 1:10 in this lysate and incubated for 1 
hour on ice. The S.aureus were then pelleted for 2 min in an Eppendorf 
centrifuge and then washed 2-3 times in TEN containing 0.5% NP40, 
before being resuspended in the start volume of TEN containing 0.5% 
NP40.
Precipitation.
0.4 - 1 ml of the labelled extract was added to calf serum-treated 
Eppendorf tubes (incubated with PBS containing 10% FCS at 37°C for 1 
hour, washed twice in PBS, aspirated dry) together with 10 pi of a 
normal serum (either goat or mouse, depending on the antiserum to be 
used) for 15-20 min on ice. After this period 60 pi of S.aureus were
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added and incubated on ice for 15-20 min. S.aureus was pelleted by 
centrifugation for 2 min in an Eppendorf centrifuge at 4°C. The 
supernatant was pipetted into a fresh tube and incubated with 10-50 pi 
of antiserum (depending on the source) and incubated for 15-30 min on 
ice. After addition of 60 pi of S,aureus and incubation on ice for 30 
min, the S.aureus antibody-antigen complex was pelleted in an Eppendorf 
centrifuge for 2 min at 4#C. The antibody specific pellet was then 
washed three times in TEN containing 0.5% NP40 and once in TEN 
containing 0.5% NP40 and 2.5 M KC1. The resulting pellet was 
resuspended in 30 pi of cracking buffer (10 mM Tris-HCl (pH 7.2), 10% 
SDS, 25% 2-mercaptoethanol, 25% glycerol, 0.1% bromophenol blue) and 
boiled for 5 min before being analysed by SDS-PAGE.
Preparation of gels for fluorography. (Bonner and Laskey, 1974).
After electrophoresis the gel was placed in DMSO and gently shaken 
for 30 min at room temperature. The DMSO was replaced with fresh DMSO 
and incubated as above. The gel was then transferred to 4 volumes of 
22.2% PPO (w/v) in DMSO and incubated with gentle shaking for 3 h at 
room temperature. The gel was soaked in running water for 15-20 min to 
swell the gel and remove DMSO, and also to precipitate the PPO. 
Afterwards the gel was dried under vacuum at 80°C in a Bio-Rad gel 
dryer for 2 h. Dried gels were exposed to preflashed Kodak X-omat H 
film at -70°C.
Electrophoretic transfer of proteins (Western blotting) to nylon 
nitrocellulose filters: Gene Screen plus.
After electrophoresis the gel was equilibrated for 30-60 min in 25 mM 
Tris-HCl (pH 8.3) and 192 mM glycine. Membrane cut to the exact size of
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the equilibrated gel was soaked in the above buffer for 15-20 min 
together with two Scotch-Brite pads and two pieces of Whatman 3 MM 
filter paper. A sandwich was prepared as follows. One piece of filter 
paper was placed onto a Scotch-Brite pad, onto which was then placed 
the equilibrated gel. The gene screen was then placed onto the gel, 
avoiding the trapping of air bubbles. The second piece of 3 MM paper 
was placed onto the filter and the sandwich was completed with the 
second Scotch-Brite pad. The sandwich was then inserted into a transfer 
apparatus so that the gene screen membrane was positioned between the 
positive electrode and the gel. Transfer was performed in 25 mM Tris 
and 192 aM glycine at 30 V (10-15 mA) overnight (16 h) at 4°C.
Immunological detection of proteins transferred to Gene Screen plus 
membranes.
After transfer, the membrane was carefully removed from the gel and 
allowed to dry for 30 min at room temperature. The membrane was then 
incubated in an excess of blocking solution (100-200 ml, 10% Instant 
Non-Fat dry milk in PBS) for 1 hour at room temperature. The blocking 
solution was removed and the filter incubated in 10 ml of incubation 
solution (10% Instant Non-Fat dry milk in PBS containing 0.03% Tween 20 
with 1 0 0 - 2 0 0 pi of antiserum) in a sealed plastic bag at room 
temperature for 1 hour with constant agitation. The membrane was then 
washed three times in an excess of washing solution (PBS containing 
0.03% Tween 20) for 5 min. After washing, the membrane was incubated in 
10 ml of incubation solution containing anti-serum IgG peroxidase 
conjugated antibody (1:1000 dilution) in a sealed plastic bag for 2 h 
at room temperature with constant agitation. The membrane was then 
washed three times 10 min each in an excess of washing solution and
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three tines 2 min each in distilled water. The gel was then stained for 
5-15 min in the following mixture of solution: 2ml chloronaphthol 
(3mg/ml) in methanol, 10 ml 200 mM MgCla, 50 mM Tris-HCl (pH 7.4),
30 pi H2O2 , and for 1-2 min in H20 to intensify the staining.
Membranes were dried between two sheets of 3 MM paper and stored at 
room temperature in the dark.
Neomycinphosphotransferase II (MPT II) assay. (C. Stewart, pers. 
comm., EMBL, Heidelberg).
In summary, the proteins of a cell extract are separated on a 
non-denaturing polyacrylamide gel. The position and amount of enzyme in 
the gel is determined by phosphorylation of the antibiotic Kanamycin 
with a radiolabelled 33P molecule. For this the substrates, Kanamycin 
and t-33P ATP, are fixed in an agarose gel which is then placed onto 
the protein gel. After the enzyme reaction the radiolabelled Kanamycin 
is transferred and fixed onto P81 ion exchange paper and monitored by 
autoradiography.
Protein extracts (20 pi, 5 x 10° cells) from either organs (spleens) 
or cells sonicated in TE (pH 8.0) were mixed with an equal volume of 2x 
sample buffer (0.2% SDS, 125 mM Tris (pH 6.8), 10% 2-mercaptoethanol, 
10% glycerol, 0.002% bromophenol blue). The samples were then separated 
on a 10% non-denaturing acrylamide gel (10% acrylamide, 0.33% 
bis-acrylamide, 0.35 M Tris-HCl (pH 8.8)) at 50 V for 12-16 h.
The gel was washed twice for 5 min in water and equilibrated for 30 
min in 67 mM Tris-maleate, 42 mM MgCls, 400 mM NH4CI (pH 7.1). The gel 
was transferred to a glass plate before being covered with a 1.5 mm 
thick 1% agarose gel containing 20 pg/ml Kanamycin sulphate, ca. 3 mM 
t-33P ATP, and incubated at room temperature for 30 min.
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The gel sandwich was covered with one sheet of Whataan P81 paper, two 
sheets of Vhataan 3 MM paper and a stack of paper towels. Transfer was 
continued for 3 h. The P81 paper was transferred to a sealable plastic 
bag containing 10 aM NasPO« (pH 7.4). 0.1% SDS, and 1 ag/al 
proteinase K, incubated at 60*C for 30 ain, and washed three tiaes in 
cold water for 5 ain, twice in hot water (80«C) for 10 ain before being 
washed again twice (5 ain) in cold water. Finally the P81 paper was 
washed in hot (80*0 50 aM NasPCU (pH 7.4) for 5 ain before drying 
briefly at rooa teaperature. The paper was then exposed with an X-ray 
fila at -70*C.
DMA sequencing:
Cloning of DNA fragaents into M13 ap series vectors was essentially 
as for subcloning into plasaids, except where otherwise specified.
M13 single stranded phage DMA.
This aethod was eaployed whenever M13 single stranded DNA was 
required for the chain teraination aethod of DNA sequencing. All M13 
strains used were of the ap series constructed by Messing (Messing, 
1979) and contained a piece of the Lac region encoding a peptide 
fragaent of 0-galactosidase capable of a-coapleaentation with the 
partial product encoded by the F Episoae present in the JM101 host 
strain (Messing and Gronneborn, 1978; Gronneborn and Messing, 1978).
The status of the M13 Lac region, functional or otherwise was indicated 
by plating out phage in H-Top agar containing the Lac inducer IPTG (200 
yg/al) and the chroaogenic substrate BCIG (x-gal) 200 pg/al onto 
ainiaal agar plates (1.05% KiHPO«. 4.5% KHzPO«, 0.1% (NH«)*S0«, 0.5% 
Na-citrate.H*0, 0.02% MgSCb 7 HiO, 0.2% glucose. 5 ag/1 Vitaain Bl,
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1.5% agar). A single plaque of the appropriate colour was picked with a 
sterile tooth-pick and grown for 8 h at 37°C in 2 ml of 2x YT medium 
(0.5% NaCl, 1% yeast extract, 1.6% tryptone), with vigorous shaking.
The host bacteria were pelleted by centrifugation for 5 min in an 
Eppendorf centrifuge. 800 pi was carefully transferred to a fresh tube. 
To this was then added 200 pi 2.5 M NaCl, 20% PEG 6000 and after 
thorough mixing was incubated at room temperature for 15 min. The 
precipitated phage was pelleted by centrifugation for 10 min in an 
Eppendorf centrifuge. All traces of the supernatant were aspirated and 
the pellet was resuspended in 100 pi TEs (TE sequencing 10 mM Tris (pH 
8.5), 0.1 mM EDTA). Protein was removed by a single equilibrated phenol 
extraction (50 pi). After centrifugation for 2 min in a microfuge the 
DNA in the aqueous phase was precipitated by addition of 10 pi 3M 
Na-acetate (pH 5.2) and 250 pi ice cold ethanol and incubation at -20#C 
for 2 h to overnight.
DNA sequencing reactions.
The procedure adopted was essentially that of Sanger et al. (1977) 
with minor modifications (Gibco/BRL, M13 cloning/dideoxy sequencing: 
Instruction Manual 1985).
For each clone sequenced, approximately 0.5-1 pg single stranded DNA 
in 3-5 pi H2O was mixed with 2 pi (4 ng) of M13 17-base sequencing 
primer, 1 pi of lOx polymerase reaction buffer (70 mM Tris-HCl 
(pH 7.5), 7.0 mM MgCl2 , 500 mM NaCl), and H2O to give a final volume of 
12.4 pi. The components were then mixed and centrifuged briefly to 
recover the contents at the bottom of the tube. DNA was denatured by 
boiling for 5 min (100°C) before being allowed to equilibrate to room 
temperature over a period of 30-45 min. This step allows annealing of
115
the primer to the template. This primer/template preparation vas either 
stored on ice or at -20°C until the sequencing reactions were ready.
During the primer annealing reaction the following was added to the 
sides of four reaction mix centrifuge tubes in separate steps:
Tube A: 1 pi A* mix, 1 pi diluted ddA (0.5 mM)
Tube C: 1 |il C* mix, 1 pi diluted ddC (0.5 mM)
Tube G: 1 pi G° mix, 1 pi diluted ddG (0.5 mM)
Tube T: 1 pi T* mix, 1 pi diluted ddT (1.0 mM).
Mixtures were prepared as follows (stored at -20° C):
A® C® G® To
0.5 mM dATP 1 Pi 20 pi 20 pi 20 pi
0.5 mM dGTP 20 Pi 20 pi 1 Pi 20 pi
0.5 mM dTTP 20 Pi 20 pi 20 pi 1 Pi
lOx polymer
neutr.buffer 20 Pi 20 pi 20 pi 20 pi
After temperature equilibration, the following was added directly to 
the tube containing the hydrolysed primer/template:
1 pi (a-3*P) dCTP (aqueous solution, 400 Ci/mM),
1 pi 0.1 M DTT,
1 pi (1 unit/pl) large fragment DNA polymerase I (Klenow fragment).
The contents were gently mixed and 3 pi aliquots were pipetted into 
the four A, C, G and T tubes. The reactants were mixed and collected by 
centrifugation to form a single drop and incubated for 20 min at 50°C. 
After this time 1 pi of 0.5 M dCTP was added to each of the reaction 
tubes and incubated for an additional 10 min at 50®C. The reactions 
were then dried under vacuum before being resuspended in 4 pi of stop 
buffer (0.1% xylene cyanol, 0.1% bromophenol blue, 10 mM Naa-EDTA, 95% 
deionized formamide). The reactions were then denatured by boiling for
116
5 «in at 90-100°C and 2 pi was loaded onto a 0.4 n  thick 6% acrylamide 
(19:1 acrylamide:bis-acrylamide) gel containing 7 M urea, run in lx TBE 
buffer. The gel was run at a constant power of approximated 50 W or at 
a voltage judged to give a running temperature of approximately 45°C, 
with the use of aluminium plates. The gel was removed and exposed to 
X-ray film without the use of intensifying screens at -70°C.
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Introduction
The Malignant stage of the Friend disease results in the formation of 
a transformed population of cells that can be established in vitro 
(Friend et al., 1966; Ostertag et al.. 1972; Ikawa et al., 1973) and 
induced to terminally differentiate along the erythroid pathway by 
addition of a variety of chemical agents to the culture medium (Friend 
et al., 1971; Reuben et al., 1980). Various studies questioning viral 
involvement in the establishment and maintenance of the transformed 
state have utilized various biological and biochemical assays to 
examine the Friend virus complex in murine erythroleukaemia cells 
(Friend leukaemia cells, FLC) that have been exposed to the 
differentiation inducing agent DNSO. One of the earliest findings was 
an increase in the number of budding virus particles on the surface of 
DNSO treated Friend cells as detected by electron microscopy (Sato et 
al., 1971). However, it could not be shown in these studies whether or 
not the increase in the number of virus particles represented an 
increased synthesis of virus or an inhibition of virus release. 
Additional work indicated that this commonly observed phenomenon that 
occurs in many separately established cell lines is a transient 
increase in virus synthesis after exposure to DNSO (Dube et al., 1975; 
Ikawa et al., 1976; Ostertag and Pragnell, 1978; Ostertag et al., 1979; 
Fagg et al., 1980). Increases in SFFV activity (from 5-200 fold) has 
been reported during the first two days of DNSO treatment, coupled 
together with a change in the tropism of the helper virus, thus 
suggesting that DNSO treatment also causes the induction of an 
endogenous virus in Friend cells (Dube et. al.. 1975; Ostertag and 
Pragnell, 1978; Ostertag et al., 1979).
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Variant cell lines also exist that show no increase in viral 
synthesis, although they may still be induced to differentiate. Thus 
from these and various other observations it has been suggested that 
the augmentation of virus gene expression and the induction of 
differentiation are independent events (Dube et al.. 1975; Ikawa et 
al., 1976; Sherton et y , . , 1976; Tsuei et y . . , 1979). Sherton et y .. 
(1976) suggested that this increase in virus synthesis may be related 
to the effects of DMSO on the cellular growth cycle of Friend cells. 
Recent experiments using a retrovirus vector containing a complete 
human fl-globin gene showed that, after infection and selection of FLCs, 
the p-globin gene was inducibly expressed after addition of DMSO 
(Cone et y ., 1987).
It has also been observed that an extrachromosomal SFFV DNA was 
present in one DMSO resistant Friend cell line (Ikawa et. y,., 1980). A 
deeper analysis of this aspect (Kern and Axelrod, 1983) revealed that 
extracbromosomal DNAs of SFFV (both circular and linear) found in the 
cytoplasm of the examined Friend cell lines were inducible with, and 
were indeed dependent upon, the continued presence of DMSO. They 
demonstrated that a greater than eight fold variation was observed in 
the amount of this DNA, with the largest amounts being found in those 
cells that were resistant to the induction of differentiation by DMSO.
Based on these observations it was decided to examine various Friend 
cell lines, made using the Mirand strain of F-SFFV (Mirand, 1967), 
which have been isolated and previously described by Ostertag and 
co-workers (Eisen et al., 1978; Ostertag et al., 1979). The studies of 
Kern and Axelrod (1983) used Friend cells (the original cell line 745A 
and siblings there of) made with an original isolate of the Friend
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virus conplex from C. Friend.
Results
The cell lines used in this study and their origin are depicted in 
Table 2. The cell lines F4N, F4-6 (F4-6 being a clone of the original 
Friend cell line F4N) and B8/3 represent cells which may be fully 
induced to terminally differentiate after the addition of DMSO, 
(Ostertag and Pragnell, 1981). B8/3 differs from the other two cell 
lines in that, due to a defect in helper virus function in which pr67 
gag is synthesized but is not aberrant and not shed, there is no 
constitutive release of F-MuLV and SFFV and very little or no 
DMSO-induced release of SFFV.
F4N+2 and F4+ may only be induced by OMSO to proceed to an early 
phase of differentiation (a precommitment phase) in which spectrin 
synthesis is induced but progression to a committed stage, in which 
haemoglobin is synthesized, is blocked. There is no constitutive virus 
release in F4N+2 although F4+ release high titres of SFFV. Both cell 
lines show no DMSO-induced virus release.
a) Optimisation of the conditions for DMSO induction of the Friend cell 
lines F4M. F4-6. B8/3. F4N+2 and F4+
Although published work from this and other laboratories have already 
defined the optimal DMSO-induction conditions, for these cells, it was 
decided to re-optimise the DMSO induction conditions as inducibility 
may vary with the medium and/or serum source. Also all cells used for 
this and further studies were from a single batch of cells, frozen and 
stored in liquid nitrogen at the start of this work in order to ensure
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Table 2. Properties of the Bouse erythroleukaeaia cells (Friend cells) 
used in the analysis of extrachroaosomal DNA species.
cell
line*
differentiation
inducibility
constituitive virus 
release
DMSO induced virus 
release
F4N full high high (SFFV)
F4-6 full high high (SFFV)
B8/3 full none none
F4N+2 early phase of 
differentiation 
(spectrin)
none none
F4+ none high (SFFV) none
*The origin of these cell lines is described in Materials and Methods.
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uniformity.
An exhaustive description of the induction protocol is shown in 
Figure 13.
Titration results for all cell lines are depicted in Figure 14. From 
these results it can be seen that using the protocol described, an 
optimal induction (as determined by benzidine staining) for all cells, 
except the non-inducible cell line F4+, is obtained at a concentration 
of 1.5% DNSO, whereas suboptimal degrees of differentiation were 
obtained when using higher or lower concentrations. These results 
obtained here correlate well with those previously published (Eisen et 
al.. 1978; Ostertag et. al., 1979).
b) Subcloning of specific hybridisation probes
A prerequisite for the planned study was to be able to identify and 
discriminate between F-MuLV and F-SFFV-specific sequences. Although 
very different in size, the two viruses are closely related and share a 
large proportion of their nucleotide sequences, (see introduction) 
including LTR, gag and pol sequences, although the latter two genes are 
altered by deletions in SFFV. However, one region which specifically 
differs between the two is the 5' env region, where the sequences in 
SFFV are highly related to MCF viruses and not to F-MuLV. This 
information was used to subclone specific nucleotide sequences which 
could be used as hybridisation probes, the strategy of which is shown 
in Figure 15.
Using available restriction enzyme and nucleotide sequence data, the 
following two env (and thus virus specific) probes were subcloned. From 
a molecularly cloned F-MuLV clone (clone 57, Oliff et. al., 1980) 
obtained from S. K. Ruscetti (NIH Bethesda, Washington) a 700 bp 5' env
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Figure 13. DMSO-induct ion protocol for Friend Cells
1) Cells grown in log phase in GMEM + 10% FCS at 37°C in 5% COa air for 
3-4 days before induction.
2) Dilute log phase cells (approximately 10*/ml) 1:100 in fresh growth 
medium, GMEM + 10% FCS. Incubate for 48 h at 37*C, 5% CO2 in air. 
(Concentration is then about 5 x 108 cells/ml.)
3) Remove 50% of the culture and replace with GMEM + 10% FCS + DMSO 
(double the end concentration needed, usually 1-1.5% end 
concentration).
This is designated day 0. Incubate at 37#C, 5% CO2 in air.
4) Incubate for 48 h, then replace 50-75% of the culture with 
GMEM ♦ 10% FCS + DMSO (day 2).
5) Incubate for a further 72 h at 37*C, 5% CO2 in air. The cell density 
is then approximately 10*/ml, and the pH of the medium is slightly 
alkaline. This is designated day 5, and the percentage of cells 
synthesizing haemoglobin is determined by benzidine staining.
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Figure 14. Titration of DMSO concentrations needed for optimal 
induction of the Friend cells used in this study.
The Friend cell lines F4N, F4-6, F4N+2, B8/3 and F4+ were incubated 
with various concentrations of DMSO (0.5%-2%) as described in 
Figure 13.
At 24 hour intervals an aliquot of cells was removed from the culture 
and stained with benzidine as described in Materials and Methods.
The results for the cell line F4+ are not shown, for at no DMSO 
concentration could the cells be induced to differentiate to give 
benzidine positive cells (above a very low background of approximately 
0.5% positive cells) .
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Figure 15^. Subcloning of env-specific sequences for use as molecular 
hybridisation probes
Shown is the strategy used to subclone, env specific probes, which 
after labelling with 32P could be used to differentiate between F-MuLV 
and F-SFFV specific sequences. The origin of the starting plasmids for 
the cloned F-MuLV and F-SFFV sequences are described in the text.
The restriction enzyme lettering code is as follows, P, PstI; S, SstI: 
K, Knnl; Pv, PvuII; E, EcoRI; X, Xbal; H, Hindlll; Sp, SpHI; B, BamHI; 
Av, Avail; Hi, Hindi; C, Clal.
The maps depicted are drawn to scale, and are based on published data 
cited in the corresponding text.
Also shown is the permutated Hindlll fragment representing the whole of 
the SFFVp genome and referred to in the text as the Hindlll probe. The 
origin of a restriction enzyme fragment used as a gag specific probe is 
also illustrated (GAG).
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specific BamHl fragment vas isolated from a preparative gel and cloned 
into the BamHl site of the pUC9 cloning vector. The resulting plasmid 
vas named pBBFNUE. Identical procedures were used to subclone a 600 bp 
BamHl-EcoRl 5' env fragment from a molecularly cloned polycythaemia 
strain of F-SFFV (pSFFVp, Linemeyer et al., 1980) to yield a plasmid 
called pBRIE.
That these plasmids, or the subcloned fragments therein, hybridised 
specifically to their respective viruses was shown in the following 
experiment. 100 ng of the plasmids pF-NuLV clone 57, pSFFVp, and the 
cloning vector pUC9, in 10 pi TE solution, were denatured by boiling 
for 5 min before being spotted onto nitrocellulose paper (BA85, 
Schleicher and SchOll). These dot blots were then hybridised under 
stringent conditions (as in Materials and Methods) with 32P 
radiolabelled env fragments isolated from the plasmids pBBFMUE and 
pBRIE, the results of which are shown in Figure 16.
From these results it can be seen that the 700 bp pBBFMUE fragment 
(Figure 16a) only hybridises to F-MuLV and the 600 bp pBRIE fragment 
only hybridises to F-SFFV under these conditions (Figure 16b).
A further probe, a 6.3 kb Hindlll fragment (present as a permutated 
linear molecule in pBR322) comprising the whole of F-SFFV genome from 
the pSFFVp plasmid hybridised to both the F-MuLV and F-SFFV sequence 
(Figure 16c) thus showing the nucleotide similarity of these viral 
genomes. No hybridisation to the cloning vector was seen.
c) Molecular analysis of extrachromosomal DNA found in Friend cells
The presence of extrachromosomal viral DNA during the course of 
DMSO-induced differentiation vas investigated using the cells, 
induction protocol and specific probes described above. Low molecular
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Figure 16. Specificity of the subcloned fragments, BRIE and BBFMUE
The specifity of the subcloned BRIE and BBFMUE fragments was tested by 
dot blot analysis.
Isolated BRIE and BBFMUE fragments (free of the pUC9 vector, after 
restriction enzyme digestion, and isolation by electroelution) were 
labelled with 32P, by the nick translation method described in 
Materials and Methods, and hybridised under stringent conditions, with 
the nitrocellulose bound plasmids, pF-MuLV, pSFFVp and pUC9.
1, 2 and 3 represent the plasmids pUC9, pSFFVp and pF-MuLV 
respectively.
The probes used were a: BRIE,
b: BBFMUE,
c: a Hindlll fragment comprising the whole of
the SFFVp genome.
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weight DNA, free froa contaminating high molecular weight DNA, was 
extracted by the method of Hirt (1967) .
In this series of experiments, the cells were induced to 
differentiate according to the protocol described in Figure 13. At 
intervals of 24 h 5 x 10* cells were removed from 20 ml cultures and 
Hirt supernatants were prepared. After a 30 min RNAse digestion to 
remove residual contaminating RNA, the DNA samples were electrophoresed 
on 0.8% agarose gels containing 0.5 |ig/ml EtBr before being transferred 
to Gene Screen by the method of Southern (1979). Blots were then 
hybridised with respective 3*P labelled DNA probes, the results of 
which are shown in Figures 17, 18, 19.
The results shown in Figure 17 represent those obtained with the cell 
line F4-6, and the Hindlll pSFFVp probe, which hybridises with both 
SFFV and F-NuLV DNA sequences. Also shown are the percentage of 
benzidine positive cells (B*) at the various sampling times post 
induction and a UV transilluminator Polaroid of the gel before it was 
blotted. This acted as an internal control to show that the Hirt 
supernatant procedure had worked to similar degrees of efficiency, for 
one always has a small percentage of contaminating high molecular 
weight DNA, which because the DNA is not digested with restriction 
enzymes stays at the top of the gel.
It can be seen that at day 0, when only 1-2% of the cells are 
benzidine positive, various bands are visible (highlighted by arrows), 
one at roughly 9 kb, a faint band at approximately 7 kL and one at 3.5 
kb. These sizes would suggest (due to the nature with which DNA 
molecules with differing conformations migrate in the presence of EtBr) 
that they correspond to a linear DNA of F-NuLV (at 9 kb), a linear DNA 
of SFFV (at 7 kb) and to a circular DNA of one of the above viruses
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Figure 17. FV extrachromosomal DNA present in the Friend cell line 
F4zi
Southern blot analysis of Hirt supernatants extracted from cells at 24 
hour intervals following DMSO induction (p.d.i.). The probe used in 
this analysis was the Hindlll fragment wich detects both F-MuLV and 
SFFV sequences.
Lane a: 0 h p.d.i., 
b: 24 h p.d.i., 
c: 48 h p.d.i., 
d: 72 h p.d.i., 
e: 96 h p.d.i., 
f: 120 h p.d.i.,
g: supercoiled 12 kb marker plasmid, 
h: supercoiled 9 kb marker plasmid, 
i: supercoiled 6 kb marker plasmid.
The numbers to the left represent molecular weight markers in kb.
Also shown (middle) are the kinetics of induction of benzidine positive 
(BM cells and (bottom) a Polaroid of the agarose gel before blotting. 
The contaminating, high molecular weight DNA acted as an internal 
control.
The samples were run for 16 h in a 0.8% agarose gel in TAE buffer in 
the presence of 0.5 pg/ml EtBr.
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although the position at which it runs would suggest that it 
corresponds to a SFFV-related molecule. After 24 h and 48 h 
respectively the bands seen on day 0 were still present although 
appreciably changed in their intensity (although this is a long 
exposure the bands are not clearly visible). However, after 72 h post 
induction when approximately 30% of the cells were benzidine positive 
two new bands appeared, which ran slower than the 3.5 kb band at 
approximately 4.0 kb and notably further at approximately 2 kb. These 
bands persisted and were detectable at 96 h, but were again not 
detectable at 120 h post induction when 60% of the cells were benzidine 
positive. The Polaroid demonstrates that the amount of contaminating 
genomic DNA is roughly equal in all samples thus suggesting that there 
was no great discrepancy in the amount of sample being loaded, which 
could have led to those results. From such results one could thus infer 
that DNA molecules corresponding to bands at 4 kb and 2 kb were being 
induced during the differentiation process of the cells, and reached a 
detectable peak at 72-96 h post induction before being again not 
detectable at 120 h post induction. This observation was seen in 
numerous experiments. A similar finding was also seen with the cell 
line F4N, but as F4-6 is indeed a subclone of this cell line and is 
biologically indistinguishable from F4N then this is not surprising.
To reveal the identity of the bands described above the blot was 
washed free of bound Hindlll pSFFVp probe and rehybridised with the 
F-SFFV env specific 3*P-labelled pBRIE probe. However due to high 
background problems no discrete bands could be detected that could be 
reproduced as a figure, although later analysis was able to identify 
unequivocaly the specificity of the bands, see large scale preparation.
Thus it appears that in this cell line there is an induction of
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Friend virus related extrachroaosoaal DNA Molecules. Fro* size and the 
behaviour of the various DNA Molecule foras in agarose gels containing 
EtBr one could suggest that these Molecules correspond to circular 
equivalents of F-SFFV (which is also suggested by the Migration of 
supercoiled plasMid controls seen on all gels) although no unequivocal 
proof can be presented at the MOMent. On exaMining the partially 
inducible cell line F4N+2 in exactly the saMe Manner (Figure 18) then 
one encounters a similar picture in which F-SFFV specific DNA Molecules 
are induced at a peak of 72 h post induction, although possibly to not 
such a great extent as F4-6. Using the Hindlll pSFFVp probe and 
coMparing with the results obtained for F4-6 one can identify the bands 
as putative linear F-NuLV, linear F-SFFV and circular F-SFFV Molecules, 
as well as the unidentified bands seen above. Analysis of the non­
inducible cell line F4+ (Figure 19) showed no induction of any viral 
extrachroMosonal DNAs throughout the whole 120 hours, although F-NuLV 
related viral DNAs are indeed present. These cells are refractory to 
the effects of DNSO, with a background level of <1% benzidine positive 
cells after 120 h post induction. Repeated analysis of the cell line 
B8/3 was unable to detect any extrachroMosonal DNAs whatsoever.
These results thus tend to suggest that there May be a correlation 
between the inducibility of the cell and the induction of SFFV viral 
extrachromosoMal DNAs. One interesting fact however, is that no 
extrachronosonal DNA of any detectable origin was detectable in the 
cell line B8/3, which has a helper virus defect (a gag gene defect) 
which May be interpreted to Mean that, a replication competent F-NuLV 
(or even More specifically a functional gag gene product) could be 
soMehow involved in this phenoMenon. These results, however, do not 
correlate with the inducibility of virus release, for as shown in
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Table 2, although F4N+2 is a partially inducible cell line, it neither 
constitutively releases virus nor is there any DNSO-induced virus 
release, although extrachromosomal ONAs were indeed induced. However, 
the cell line F4+ which is non-inducible and indeed shows no 
differentiation inducible extrachromosomal DNAs, does in fact release 
high levels of SFFV constitutively, although none is induced after DNSO 
induction. This contradicts the results of Kern and Axelrod (1983).
d) Subcellular location of extrachromosomal DNA
From the results shown it can be seen that all cells analysed apart 
from B8/3 contained extrachromosomal viral DNA, although to varying 
extents and specificities. To further analyse this and also aid in 
subsequent large scale preparation and purification of these DNAs the 
intracellular (nuclear or cytoplasmic) location of these 
extrachromosomal DNAs was determined.
The cell line used for this analysis, F4-6, was grown at log phase 
conditions in GMEM + 10% FCS without the presence of DMSO. The cells 
were then induced to differentiate as described above and after 3 days 
nuclear and cytoplasmic fractions were prepared and analysed for the 
presence of extrachromosomal DNAs by agarose gel electrophoresis (in 
the presence of EtBr) Southern blotting and subsequent nucleic acid 
hybridisation. The results of this analysis are shown in Figure 20.
From these experiments it is clear that the extrachromosomal DNAs seen 
in these cells are present within the cytoplasm of these cells as in 
the studies of Kern and Axelrod (1983) . Indeed as in these experiments 
the BRIE probe was used as a hybridisation probe, the DNA molecules 
were identified to be of SFFV related origin, i.e. a 7 kb linear 
molecule, a closed circular molecule (which ran at 4 kb) and possibly a
13 5
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Figure 20. Cellular location of the FV extrachromosomal DNA found in 
the cell line F4-6
Southern blot analysis of Hirt supernatants from subcellular fractions 
(nuclear and cytoplasmic) of DMSO-induced F4-6 cells 72 h p.d.i.
Nuclear fraction;
Lane 1: 5 x 10® cells.
Lane 2: 1 x 10‘ cells.
Lane 3: 1 x 10T cells.
Cytoplasmic fraction:
Lane 4: 5 x 10“ cells.
Lane 5: 1 x 10* cells.
Lane 6: 1 x 107 cells.
Unfractionated Hirt supernatant:
Lane 7: 5 x 10“ cells.
Lane 8: 1 x 10* cells.
Lane 9: 1 x 107 cells.
For this analysis the pBRIE fragment was used as a hybridisation probe. 
The number to the left represent molecular weight markers in kb.
Also shown is a Polaroid of the EtBr stained gel before Southern 
blotting.
The DNA samples were electrophoresed in a 0.8% agarose gel in TAE 
buffer for 12 h in the presence of 0.5 pg/ml EtBr.
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supercoiled molecule or related variant that ran at approximately 2.5 
kb. No extrachromosomal viral DNA was detectable in the nucleus.
e) Absence of extrachroaosomal DNAs in non-producer cells
The presence of retroviral extrachromosomal ONAs in cells is not 
unique to the observations described above, or those published by Kern 
and Axelrod (1983). For example unintegrated MMTV DNA is persistently 
present in non-murine cells infected with the virus. Unintegrated MMTV 
DNA in infected hepatoma cells is present as linear or open circular 
duplexes containing two LTRs and also as covalently closed circular 
viral DNA with either, one or two LTRs (Ringold et al., 1977; Shank et 
al.. 1978).
To analyse the distribution of SFFVp specific extrachromosomal DNAs 
further it was decided to look in non-erythroid cells (fibroblasts) of 
both murine and non-murine origin to see if our observations were 
indeed confined to the system described earlier. For these experiments 
the SFFVp non-producer and producer fibroblast cell lines depicted in 
Table 3 were analysed.
Extrachromosomal DNA (Hirt supernatants) from 1 x 107 cells was 
prepared from both stably infected non-producer and producer cell lines 
either in the presence (1.5%) or absence of DMSO (to simulate 
conditions subjected to the Friend cells) in the culture medium and the 
DNA was analysed by agarose gel electrophoresis and Southern blotting. 
As can be seen from Figure 21, in none of the conditions examined could 
extrachromosomal DNA of SFFVp or F-MuLV origin (or related origin) be 
detected, when using a whole SFFV Hindlll fragment probe. The figure 
presented here represents a long exposure. Such results would suggest 
that the presence of extrachromosomal Friend virus DNA in murine
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Table 3. Won-ervthroid producer and non-producer fibroblast cell 
lines,used for the analysis of FV extrachromoaoaal DNA
Cell Line Host Cell Virus* Reference
SC204+H SCI (mouse) SFFV-P*, F-MuLV* Bilello et al., 1980
6S21 SCI (mouse) SFFV-P* Bilello et al., 1980
S2D409 SCI (mouse) SFFV-P* Bilello et al., 1980
NRK643/22N NRK (rat) F-MuLV* Bilello et al., 1980
All SFFV-P were of the Mirand strain.
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Figure 21. Southern blot analysis of Hirt supernatants fro« producer 
and non-producer fibroblast cell lines
The origin of the cell lines has been described in Table 3.
0 represents cells that were cultured in the absence of DNSO.
2, 3 and 4 represent cells that were incubated in the presence of 1.5% 
DNSO, for 48 h, 72 h and 96 h respectively.
The pSFFVp Hindlll was used as a hybridisation probe.
The numbers to the left represent molecular weight markers in kb.
The DNA samples were electrophoresed in a 0.8% agarose gel in TAE 
buffer for 12 h in the presence of 0.5 pg/ml EtBr.
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erytbroleukaemia cells is possibly restricted to these cells, although 
examinating a larger selection of cell types would be needed to 
substantiate this statement.
f) Large scale production of extrachromosomal FV DNA from F4-6
The experiments described so far were all designed to accumulate data 
as to which erythroleukaemia cell line would be best suited for the 
isolation and molecular cloning of the extrachromosomal DNA molecules 
corresponding to the Friend virus complex, F-NuLV and F-SFFVp. Thus 
from the accumulated data it was decided to use the cell line F4-6, for 
not only could considerable amounts of these extrachromosomal DNAs be 
detected in the cytoplasm, but also upon induction, these amounts could 
be amplified with respect to F-SFFV.
One other interesting observation seen in earlier studies was that 
not only is an endogenous N-tropic virus induced upon differentiation 
of the cell line F4N, as compared to the normal NB-tropic virus being 
released from these cells (Dube e£ al.. 1975), but also that there is a 
change in genome composition of the Friend virus complex during 
differentiation of the cell line F4-6 (an observation that could well 
explain the phenomena seen earlier: Ostertag and Pragnell, 1975).
Indeed this induced SFFVp has somewhat different biological properties, 
as compared to the non-induced virus in that it has a more profound 
effect on CFU-E formation in the bone marrow of susceptible mice (Fagg 
et al., 1980) .
As a prerequisite for large scale extrachromosomal DNA preparation, 
F4-6 cells were adapted to growth in roller bottles (in culture volumes 
of .’100ml) over a period of two weeks until the cells could 
reproducibly be induced to differentiate to give 50-60% benzidine
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positive cells after 96 h post induction (as seen in earlier 
experiments). Such roller bottle adapted cells (5 x 107) were analysed 
at time intervals post induction with DMSO, as in the previous 
experiments, for the presence of extrachromosomal viral DNAs. The 
results of these experiments are shown in Figure 22. The Southern blot 
depicted in this figure was hybridised with the SFFVp specific BRIE 
fragment. During the induction and differentiation phase of these cells 
the amounts of both linear and circular SFFVp DNA increased, thus 
demonstrating that the roller bottle adapted cells were comparable in 
this respect to the pre-adapted F4-6 cells used in the previous 
experiments.
The presence of two circular DNAs which probably represent closed 
circular molecules with one and two LTRs was also demonstrated in this 
analysis. It can also be seen that there was no gross detectable 
alteration in the genome size of SFFVp during the induction, as was 
reported by Ostertag and Pragnell (1975), although these studies were 
done at the RNA level.
These results represent somewhat of a paradox as the DNA previously 
seen to migrate at approximately 2.5 kb (assumed to be supercoiled) was 
not present. This may be explained by the culture adaptation in roller 
bottles or equally by the conversion of the supercoiled DNA to a closed 
circular conformation during the sample preparation.
In order to obtain enough material for restriction enzyme analysis 
and subsequent molecular cloning, thirty roller bottle cultures were 
seeded at day 0 with 1 x 10° log phase F4-6 cells/ml (in 100ml) at 
37®C, rolled at 2 rpm. After 24 h 100 ml GMEM + 10% FCS + 3% DMSO was 
added to the culture to give a final DMSO concentration of 1.5%. The 
cells were then cultured for a further 48 h at 37°C before being fed
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Figure 22. Southern blot analysis of Hirt supernatants from roller 
bottle adapted F4-6 cells
DNA samples were electrophoresed in a 0.8% agarose gel in the presence 
of 0.5 pg/ml EtBr for 12 h before being Southern blotted to a 
nitrocellulose filter and hybridised with a 32P labelled BRIE probe 
under stringent conditions. The bands are labelled linear and circular 
on hand of their migration behaviour in agarose gels in the presence of 
EtBr.
Lane a: Hirt supernatant from 1 x 107 cells at O h  p.d.i..
Lane b: Hirt supernatant from 1 x 107 cells at 24 h p.d.i..
Lane c: Hirt supernatant from 1 x 107 cells at 48 h p.d.i..
Lane d: Hirt supernatant from 1 x 107 cells at 72 h p.d.i..
The numbers to the left represent molecular weight markers in kb.
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with 100 ml GMEM + 10% FCS +1.5% DMSO. After a further 48 h the cells 
were harvested (at this time, 120 h post induction 60-70% of the cells 
were benzidine positive) and extrachromosomal DNA was prepared from the 
cytoplasm of these cells as in Materials and Methods: From a total of 
3.5 x 10* cells, 5.25 mg of extrachromosomal DNA was obtained after 
RNAse digestion and ethanol precipitation. This preparation was then 
further fractionated on a CsCl gradient (0.94 g/ml) in a 6 ml Beckman 
quick seal tube in a VT165 rotor for 18 h at 50,000 rpm. After 
centrifugation 0.5 ml fractions were dialysed over night against 100 
fold excess of TE solution. Aliquots of these fractions were then 
analysed by EtBr agarose gel electrophoresis and Southern blotting. The 
autoradiograms resulting from these experiments are shown in Figure 23. 
When the pSFFVp Hindlll fragment was used as a hybridisation probe then 
no detectable signals were seen (Figure 23 A) in the fractions 1, 2 and 
3. In fraction 4 there were a number of signals which have been given 
the nomenclature a-f. These are all extrachromosomal DNAs which have 
been described previously and can now, in most cases, in conjunction 
with the BRIE env probe (Figure 23 B), be conclusively identified as, 
a: contaminating cellular genomic DNA, b: linear F-MuLV, c: linear 
F-SFFVp, d: circular F-MuLV with one and two LTRs, e: circular F-SFFVp 
with one and two LTRs and f: which although appears to be F-MuLV 
related in that it does not hybridise to pBRIE, cannot as yet be 
identified. Thus it was possible to separate the linear from the 
circular DNAs (with the exception of band f), although there was still 
a mixture of F-MuLV and F-SFFVp DNAs.
g) Restriction enzyme mapping of linear F-MuLV and F-SFFVp DNAs
To further analyse the isolated DNAs and thus establish a simple
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Figure 23. Southern blot analysis of CsCl fractionated F4-6 
extrachromoBomal DNA
Aliquots of the fractionated DNA were electrophoresed in 1% agarose gel 
at 50 V over night in TAE buffer (0.15 pg/ml EtBr) before being 
subjected to Southern blot analysis. The blot was hybridised either 
with the Hindlll fragment or with the env specific pBRIE fragment.
Lane a: Fraction 1.
Lane b: Fraction 2.
Lane c: Fraction 3.
Lane d:: Fraction 4.
Lane e:: Fraction 5.
Lane f: Fraction 6.
Lane g:: Fraction 7.
Lane h:: Fraction 8.
Lane i:: supercoiled 12 kb marker plasmid.
Lane j: supercoiled 9 kb marker plasmid.
Lane k:: supercoiled 6 kb marker plasmid.
The numbers to the left represent molecular weight markers in kb.
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restriction enzyme map of F-MuLV and F-SFFVp, the linear DNAs of F-MuLV 
and F-SFFVp were further purified by preparative agarose gel 
electrophoresis. For this purpose the fractions 5, 6 and 7 were pooled 
and run on a 1% preparative agarose gel. Using NA45 paper (described in 
Materials and Methods) DNA was isolated from regions of the gel, 
corresponding to the linear F-MuLV (approximately 9.5 kb) and F-SFFVp 
(approximately 7.0 kb). After dissociation from the NA45 paper and 
subsequent ethanol precipitation, these isolates were then analysed for 
the presence of linear DNAs by agarose gel electrophoresis and Southern 
blotting. The autoradiograph shown in Figure 24 (A and B) shows that 
both the F-MuLV and the F-SFFVp linear DNAs had been isolated 
relatively free of contamination (although on longer autoradiograph 
exposures minor hybridising contaminants could be seen). These DNAs 
also hybridised to their respective specific env probes.
i) F-MuLV linear DNA.
Aliquots of the isolated linear DNA were digested with the 
restriction enzymes EcoRI. Xbal, Xhol, Bindlll, Sail. SstI and SpHI. 
the DNA was electrophoresed on a 0.9% agarose gel before being Southern 
blotted and hybridised with a 32P labelled F-MuLV probe, (a molecularly 
cloned complete F-MuLV genome in pBR322, pF-MuLV, Oliff et al., 1980) 
and pBBFMUE. Figure 25, shows the restriction pattern obtained from 
such an analysis. From this it was thus possible to construct a 
physical restriction enzyme map, with the help of a previously cloned 
F-MuLV (Oliff et al,. 1980) and also from work from this laboratory 
(Frisby and Ostertag, unpublished). This restriction enzyme map is 
depicted in Figure 26. The orientation of the respective fragments, and 
the subsequent genomic location was determined by removing the pF-MuLV
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Figure 24. Isolation of linear F-MuLV and F-SFFVpM extrachromosomal 
DNA
DNA samples were electrophoresed in a 0.8% agarose gel in the presence 
of 0.5 pg/ml EtBr for 12 h before being Southern blotted to a 
nitrocellulose filter and hybridised with the respective probe.
A. Lane a: appr. 7 kb DNA.
Lane b: appr. 9 kb DNA.
Hybridised with the pBBFMUE probe.
B. Lane a: appr. 7 kb DNA.
Lane b: appr. 9 kb DNA.
Hybridised with the pBRIE probe.
The numbers to the left represent molecular weight M a rk e r s  in kb.
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Figure 25. Restriction enzyme analysis of the isolated F-MuLV linear 
DNA
Aliquots of the isolated F-MuLV linear DNA were digested with 
restriction enzymes, before being analysed by agarose gel 
electrophoresis and Southern blotting.
Lane a: uncut.
Lane b: SpHI.
Lane c: Hindlll.
Lane d: EcoRI■
Lane e: Xbal.
Lane f: Sstl.
Lane g: Sail.
Lane h: Xhol.
A, was hybridised with the F-MuLV probe (pF-NuLV 57).
B, was hybridised with the pBBFMUE probe.
The numbers to the left represent molecular weight markers in kb.
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Figure 26. Restriction map of isolated F-MuLV linear DNA
The restriction enzyne lettering code is as follows.
S, SstI; H, Hindlll: R, EcoRI; Sp, SpHI; X, Xbal.
This restriction enzyme map was constructed from the data presented in 
Figure 25 and also from unpublished data from this laboratory (Frisby 
and Ostertag unpublished data). The SstI sites were allocated to the 
LTRs from analysis of an integrated F-MuLV genome in NRK cells which 
gave fragments of approximately 6.0 kb and 2.8 kb, thus indicating SstI 
sites in both of the LTRs as well as one SstI site within the genome. 
This is also in agreement with data for most ecotropic LTR sequences 
where a SstI site is highly conserved.
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57 probe (Figure 25A) and rehybridising with the env specific pBBFMUE 
probe (Figure 25B). From this one can see that the smaller 3.75 kb SpHI 
fragment corresponds to the 3' (env) part of the F-MuLV genome along 
with the 3.9 kb Hindlll. 5.9 kb Sstl and 6.6 kb EcoRI fragments. In 
this experiment the enzymes Sail and Xhol were shown to be non-cutters.
ii) F-SFFVp linear DNA.
A similar approach as shown above was used to map restriction enzyme 
sites to the isolated F-SFFVp linear DNA using the enzymes EcoRI. 
Hindlll, Xhol. Clal, Sstl. Sail, SpHI. and Xbal. The results of this 
analysis are shown in Figure 27 (A and B). Results from this analysis 
show that the enzymes Sail. Xhol and Xbal are non-cutters (as in the 
F-MuLV genome except for Xbal which cuts at the start of the env gp70 
gene). Again two different probes, notably pBRIE, and a Hindlll total 
SFFVp probe, were used to locate various fragments to env locations 
(B), or to the rest of the genome.
Hybridising with the Hindlll probe (Figure 27 A), demonstrated that 
the uncleaved SFFVp linear DNA is approximately 7.0 kb, as already seen 
earlier. Digestion with the restriction enzyme EcoRI, gives rise to 
three fragments of 3.1 kb, 1.8 kb and 1.75 kb, (a double band) of which 
the 1.8 kb band is the only one hybridising to the env specific probe 
pBRIE. This 1.8 kb fragment corresponds to an internal env fragment, 
for, previous restriction enzyme analysis of integrated SFFVp in Friend 
cells (notably F4-6), this 1.8 kb EcoRI fragment was a characteristic 
for the Nirand strain of SFFVp, (Frisby and Ostertag, unpublished 
results). The results of this analysis are depicted as a restriction 
map in Figure 28.
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Figure 27. Restriction enzyme analysis of the F-SFFVpM linear DNA
Aliquots of the isolated linear DNA were digested to completion with 
various restriction enzymes before being subjected to agarose gel 
electrophoresis and Southern blotting.
Lane a 
Lane b 
Lane c 
Lane d 
Lane e 
Lane f 
Lane g 
Lane h 
Lane i 
Lane j
A. Hybridised with the Hindlll SFFVp probe.
B. Hybridised with the pBRIE probe.
: uncut.
: EcoRI.
: Hindlll.
: SpHI.
: Clal.
: Xbal.
: Xhol.
: Sail.
: Sstl.
: molecular weight numbers in kb.
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Figure 28. Restriction enzve map of the linear F-SFFVpM DNA 
The nap is drawn to scale.
The restriction enzyme lettering code is as follows:
S, SstI; H, HindlII; R, EcoRI; Sp, SpHI; C, Clal.
Xbal. Xhol and Sail are non-cutters.
This restriction enzyme map was constructed from the data presented in 
Figure 27 and also from unpublished data from this laboratory (Frisby 
and Ostertag unpublished data). The SstI sites seen within the LTRs 
were deduced in a similar way as in Figure 26 after restriction enzyme 
analysis of an integrated SFFVpM genome in NRK cells (Frisby and 
Ostertag, unpublished data).
15:
Discussion
Data have been presented that extrachromosomal DNA of the FV complex 
are present in FLC and that these DNAs (notably a SFFVp component) 
increase upon treatment of these cells vith DMSO. This increase in both 
the linear and covalently closed circular extrachromosomal DNA 
molecules, however is only observed in those cells that are able to 
differentiate into a haemoglobin producing cell (as determined by 
benzidine staining). In those cells that are refractory to the effects 
of DMSO (i.e. non-inducible) no change was seen in the amounts of SFFVp 
extrachromosomal DNA. Although extrachromosomal DNAs of F-MuLV were 
also identified, they appeared not to be amplified by DMSO treatment in 
any of the cells analysed.
The presence of SFFVp specific extrachromosomal DNA (notably the 
linear DNA only) in FLC was first shown by Ikawa et al.., (1980), 
although they did not compare amounts found in undifferentiated and 
differentiated cells. They also did not observe the presence of 
extrachromosomal F-MuLV DNA, although these FLCs release high virus 
titres of SFFVp as well as F-MuLV.
More recent experiments by Kern and Axelrod (1983) looked in more 
depth at this observation. In their studies they used derivatives of 
the 745A line which had been derived by sib-selection in vitro for 
resistance, or sensitivity to the inducing effects of DMSO (Axelrod 
et al., 1979). Upon analysing these cells, they found that there was a 
greater than eight fold variation in the amount of SFFV 
extrachromosomal DNA present, with the largest amounts being found in 
cells that were resistant to the induction of differentiation by DMSO. 
These results conflict with those presented in this study where the
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reciprocal is the case. However the cells used by Kern and Axelrod all 
stem from the same parent, 745A. In the study presented here, the cell 
lines analysed in detail, notably F4-6, F4N+2, F4+ and B8/3 are all 
individually isolated clones that have not been selected for their 
resistance to DMSO, (although B8/3 is a BUdR selected clone of F4 from 
which F4-6 is derived). These cells thus represent mutants that are 
blocked in their differentiation capacity (either precommitted or 
committed) per se, and not cells that are selected in vitro by their 
resistance to the inducing effects of DMSO. This could possibly 
contribute to the explanation of these conflicting results.
Results, only mentioned, and not further discussed in the study of 
Kern and Axelrod, also state that they had also isolated cell lines, 
that did not show the correlation which they presented as their main 
argument. Further queries can also be posed about the 745A cell line 
used, which according to the literature is transformed by the FV-A 
strain of Friend virus and also releases this virus, (Friend et al.. 
1971; Golde et al., 1979), although the authors claimed that the 
extrachromosomal DNA seen was of a polycythaemia strain.
A further observation, i.e. there is an immediate decrease in the 
amount of extrachromosomal SFFV DNA, related to the transient delay in 
the G1 phase of the cell cycle (that is observed in FLCs after the 
addition of DMSO to the growth medium, Friedman and Schildkraut, 1978; 
Terada et al.. 1977), is also seen in the cell lines F4-6 and F4N+2. 
That no (or very little) extrachromosomal DNA is seen in F4-6 and F4N+2 
after 96 h p.d.i. could be explained by the fact that the growth arrest 
in these terminally differentiated cells (Gusella et al., 1976) leads 
to the cessation in synthesis of the extrachromosomal DNA.
The cytoplasmic location of these extrachromosomal DNAs, in the cell
154
line F4-6, corresponds to that found by Kern and Axelrod. What is 
unknown is the stimulus for synthesis of this extrachromosomal DNA. It 
is possible that the elevated extrachromosomal SFFV DNA reflects 
increased viral transcription and secondary reverse transcription 
similar to a system observed in dexamethasone-treated rat hepatoma 
cells infected with MMTV (Ringold et ai., 1978). The possibility was 
considered by Kern and Axelrod that the effects of prolonged DNSO 
treatment on the cell membrane result in an increased rate of 
superinfection. However, if this were the case one would expect to see 
new integration sites in these superinfected cells. In both the studies 
presented here (data not shown) and those conducted by Kern and 
Axelrod, no new integration sites could be detected, suggesting that 
this was indeed not the case. Such events, i.e. reintegration, have 
been seen in HTLV-1 infected human HL60 cells, after passage in vitro. 
(Hiramatsu et al., 1988).
To further explain their results, Kern and Axelrod suggested two 
possibilities.
i) Continual selection for pre-existing subpopulations of cells that 
contain increased amounts of extrachromosomal SFFV DNA. 
ii) Increased synthesis or maintenance of this DNA associated with the 
prolonged exposure of DMSO required for the transition from 
DNSO-sensitivity to DNSO-resistance.
In the study of Kern and Axelrod both of these possibilities could 
hold true for the cells used were selected for either resistance or 
sensitivity to the stimulating effects of DMSO. However in the 
experiments presented here extrachromosomal DNAs were seen in cells 
that could be induced by DMSO, thus suggesting that the hypothesis 
presented above is not generally applicable.
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One intriguing observation is that they detected no helper related 
sequences, as found here, but they did not mention whether the 745A 
derivative used actually produced virus or not. Also is the study 
described here no extrachromosomal DNA whatsoever in the cell line 
B8/3, which has a defect helper virus function, suggesting that 
possible helper virus functions could assist in the synthesis of this 
extrachromosomal DNA, although at the moment no mechanism can be 
suggested.
The finding of extrachromosomal DNAs (FV specific) only within FLC 
and not in non-producer or producer fibroblast cell lines of either 
murine or non-murine origin suggests that they may be restricted to FLC 
or cells of erythroid nature. Examination of chemically induced rat 
erythroleukaemia cell lines (Kluge et al., 1976) infected with FV-P 
could further clarify this point.
These experiments were designed as a pre-requisite to obtain 
information as to which cell line would be most suitable as a source 
of the extrachromosomal DNA (in particular circular) for molecular 
cloning. The cell line F4-6 was selected as it reproducibly synthesized 
detectable amounts of both F-MuLV and F-SFFVp extrachromosomal DNA.
It was also interesting to see whether it was possible to molecularly 
clone an "induced-DNA" of the F4-6 SFFVp. Large scale preparation of 
extrachromosomal DNA from (72 h p.d.i.) F4-6 cells followed by CsCl 
gradient fractionation and finally preparative agarose gel 
electrophoresis led to the isolation of both the F-MuLV and F-SFFVp 
linear DNAs. The restriction enzyme digestion and Southern blot 
analysis using specifically cloned probes enabled the construction of 
primary restriction enzyme maps.
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Introduction
Although many SFFV strains have been cloned, including F-SFFVa, 
(Kaminchik et al., 1982) various strains of F-SFFVp (Linemeyer et al., 
1980; Yamamoto et al., 1981; Amanuma et al., 1983), as veil as the 
R-SFFV (Bestvick et al., 1984; Bess et al., 1984), it was still very 
interesting to molecularly clone the Nirand strain of F-SFFVp (Nirand, 
1968), for two reasons. The approach which was to be adopted, as 
outlined in the previous chapter, meant that both the F-NuLV and 
F-SFFVp, would be molecularly cloned from the same cell in which it has 
been previously shown that the helper virus and SFFVp had indeed 
co-evolved very closely (Mol et al., 1981). All other cloning 
experiments have cloned either the helper virus or the SFFV, from 
producer or productively infected cells, in which the two viruses had 
thus been separated, and in some cases for long periods (up to several 
years), thus allowing for the two viral components to molecularly 
diverge. The genetic heterogeneity of F-SFFVp is most likely a 
consequence of two processes. New recombinations of the SFFVp genome 
with replication competent mink cell focus forming virus (MCFV) or MuLV 
and accumulation of mutations in those parts of the genome which are 
not required for biological activity. Recombination between SFFV and 
helper virus sequences can be inferred from the data of Mol et al.. 
(1981) and Obata et al., (1984).
Whether the genetic heterogeneity of F-SFFVp is also of biological 
importance is at present uncertain. An interesting indication of 
biological divergence of F-SFFVp variants is still unexplained. Most 
F-SFFVp variants induce a large increase in CFU-E density in the spleen
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and only a very small increase, if at all in the bone marrow (Liao and 
Axelrad, 1975; Peschle et al., 1980). This is different for a F-SFFVp 
complex (notably the Nirand strain) released by some Friend cells and 
cloned in fibroblasts (Fagg et al., 1980; Ostertag and Pragnell, 1981; 
Fagg and Ostertag, 1982).
Results
a) Molecular cloning strategy
The results obtained in the previous chapter enabled the construction 
of primary restriction enzyme maps, which could thus be used to select 
for an enzyme for the molecular cloning of the F-MuLV and F-SFFVp 
extrachromosomal DNAs, and also to identify such positive clones on 
hand from specific restriction enzyme fragments. Thus as it was 
proposed to molecularly clone the circular DNAs of these two viruses 
using a restriction enzyme which cuts only once within the genome of 
the two viruses. The restriction enzyme SpHI was chosen for this 
purpose, for it cuts only once (as far as could be determined from the 
restriction maps obtained and also from published sequence data, where 
it appears that a single SpHI site is conserved in both F-MuLV and 
SFFV, Amanuma et al., 1983; Clark and Mak, 1983; Wolff et. al.., 1983; 
Adachi et al., 1984; Koch et al., 1984; Koch et al., 1984; Wolff et 
al.. 1985). According to this analysis it was decided to molecularly 
clone the SpHI digested viral DNAs into the plasmid cloning vectors 
p(JC19 and pBR322, before transforming the recombinant plasmids into 
competent bacteria, prepared by the Hanahan procedure (Hanahan, 1983, 
1985) a method which has been successfully applied to the molecular 
cloning of various other SFFVs (Linemeyer et al., 1980; Kaminchik et.
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al., 1982; Aaanuma et al., 1983; Bestwick et al.. 1984).
One requisite for this approach vas to have highly coapetent bacteria 
so that a representative number of recoabinant clones could be 
obtained. Thus as a starting point batches of coapetent cells (DH1 and 
DH5a) were prepared, frozen and then tested in their transforaation 
efficiency. These bacterial strains were chosen for they are known to 
give highly coapetent cells, after preparation according to Hanahan.
The results of this analysis are shown in Table 4.
From these experiments it can be seen that the two batches of cells 
froa experiment 3 (0H1, 1 x 107) and experiment 10 (DH5a, 4 x 107) gave 
the highest transforaation frequencies, at an order of efficiency 
required for such a cloning experiment. DH5a had an additional 
advantage over DH1 in that one is able to determine the percentage of 
recoabinant plasmids in the presence of X-gal and IPTG when used in 
conjunction with pUC19. A second plasaid cloning vector pBR322 was used 
in parallel.
b) Construction of the library
CsCl fractionated circular, F-HuLV and F-SFFVp DNA (i.e. those found 
in fraction 4 in Figure 23, 100 ug/al) was digested to completion with 
the restriction enzymes SpHI. Xhol and Sail. and after 
phenol/chlorofora extraction was ethanol precipitated before being 
resuspended at a concentration of 1 jig/ml in TE solution. The Xhol and 
Sail digestion step vas performed so as to digest non-specific DNA 
containing these restriction enzyme sites giving non-compatible ends, 
which would then not be able to fora viable recoabinant plasmids.
The ligation of SpHI digested and calf-intestinal phosphatase treated 
pUC19 and pBR322 (in a total volume of 10 pi) was performed at various
160
Table 4. Preparation of competent cells for Molecular cloning
Experiment Cells used Transformation efficiency
colonies/pg pBR322
1 DH1 1 X 10*
2 DH1 5 X 10*
3 DH1 1 X 107
4 DH1 1 X 10*
5 DH1 5 X 107
6 DH5o 1 X 107
7 DH5a 5 X 10*
8 DH5a 1 X 10*
9 DH5a 3 X 107
10 DH5a 4 X 107
Cells were prepared as in Materials and Metbods (Hanaban, 1985) and 
then frozen and stored at -70*C.
All preparations were tested at tbe same time on the same batch of agar 
plates, so as to avoid variables.
Transformations were as described in Materials and Metbods.
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vector to insert ratios, as described in Materials and Methods, before 
being transformed into either competent DH1 or DH5a. The results are 
shown in Table 5.
c) Screening of the library
i) Identification of positive clones
The colonies obtained (which had been plated out on Nunc 20x20 cm 
LB ampicillin plates, either with or without X-gal and IPTG depending 
on the cloning vector and bacteria used) were then screened for 
positive recombinants by the method of Grunstein and Hogness (1975).
Replica nitrocellulose filters were hybridised with the F-SFFVp 
Hindlll 33P-probe which hybridises to both F-MuLV and F-SFFVp related 
sequences. An autoradiogram from one pair of replica filters is shown 
in Figure 29. A total of 10 positive clones were detected by this 
procedure, which were designated pcl-1 to pcl-10. Rehybridisation of 
the washed filters with the F-MuLV specific probe, (the BBFMUE 700 bp 
insert) revealed that two clones, pcl-5 and pcl-10, hybridised with 
this fragment. However, after removal of the pBBFMUE probe and 
rehybridisation for a third time with a 3*P labelled BRIE fragment, no 
positive colonies were detected.
Thus from the primary screening of the plasmid library obtained, it 
appeared that there were two F-MuLV related clones, and eight clones 
which hybridised only with the F-SFFVp genomic probe, and not with 
either of the two env specific probes. Of the ten positive clones 
obtained, only one (pcl-8) was obtained with the pBR322, DH1 
combination. All others were in pUC19 and DH5o.
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Table 5. Construction of plasnid libraries to clone the circular 
F-MuLV and F-SFFVpM
Liaation conditions Transformation results
Vector (pUC19) Insert Total number of white DH5a
(pg) (pg) colonies (%)
0.1 0.5 382 90
0.1 1 867 88
0.1 2 1727 95
0.1 5 1238 92
Vector (pBR322) Insert Total number of Tet* DH1
(pg) (pg) colonies (%)
0.1 0.5 90 5
0.1 1 93 3
0.1 2 273 6
0.1 5 159 5
Controls
Vector (100 ng) DH5a DH1
pUC19.SdHI.CIP 50
pUC19.uncut 3xl07
pBR322.SdHI.CIP - 20
pBR322.uncut 2.5xl0T
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Figure 29. Screening of bacterial colonies for recombinant plasmids 
by in situ hybridisation (Grunstein and Hogness blots)
Depicted are the autoradiographs of replicate filters, lifted from a 
20 x 20 cm LB ampicillin plate onto which plIC19 recombinants in DH5a 
had been plated. The filters were hybridised as in Materials and 
Methods with a 3*P labelled SFFVp, Hindlll probe.
The numbered signals represent recombinant clones, which were visible 
on both films. Other signals represent orientation markers.
Exposure was at -70°C for 24 h.
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d) Molecular analysis of F-MuLV clones
Small scale plasmid DNA preparations, from the clones pcl-5 and 
pcl-10, revealed that both contained approximately 9 kb inserts after 
digestion with the restriction enzyme SpHI followed by agarose gel 
electrophoresis. These clones contained a 9 kb fragment, which 
hybridised to the F-MuLV specific BBFMUE probe as seen above. Further 
digestion of these plasmids with the restriction enzymes Hindlll and 
BamHI revealed that both of these clones contained an identical cloned 
insert in the same orientation. Further analysis was carried out on the 
pcl-5 clone.
i) Restriction enzyme mapping of pcl-5
To further identify the nature of the clone pcl-5, the bacteria were 
expanded and CsCl gradient purified plasmid DNA was prepared. The 
plasmid DNA was then analysed by restriction enzyme mapping, agarose 
gel electrophoresis and Southern blotting. The results of this primary 
analysis are depicted in Figure 30. This analysis demonstrated that the 
insert cloned in pcl-5 was a permutated circular copy of the F-MuLV 
linear DNA described in Chapter 1 (Figure 26). This conclusion can be 
drawn, from the size of the restriction enzyme fragments, which 
hybridised to the F-MuLV env specific probe (BFFMUE) i.e. cloning of 
the circular molecule, by SpHI digestion into the corresponding site 
into pUC19, and then digestion of this permutated copy with SstI would 
give rise to either 2.85 or 5.9 kb env specific fragment depending on 
the orientation.
This primary analysis thus positively identified the nature of the 
DNA molecule cloned in pcl-5 (identical results were obtained for 
pcl-10, thus substantiating the conclusion presented earlier) and also
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Figure 30. Restriction enzyme analysis of the F-MuLV recombinant 
clone pcl-5
The plasmid pcl-5 was analysed by a combination of restriction enzyme 
digestion and Southern blotting. Plasmid DNA (1 pg) was digested to 
completion before being subjected to agarose gel electrophoresis (1% 
gel in 0.5x TBE buffer at 150 V for 3 h in the presence of ethidium 
bromide). After photographing the ethidium bromide stained gel, the DNA 
fragments were transferred to a nitrocellulose filter by the method of 
Southern. The filter was then hybridised with a 3*P labelled F-MuLV env 
specific probe BBMFUE.
Lane M; lambda DNA diaested with Hindlll in
Lane a; SpHI.
Lane b; EcoRI.
Lane c; Hindlll.
Lane d; Pstl.
Lane e; SstI.
Lane f ; KpnI.
Lane g; BamHI.
Lane h; Sail.
Lane i; Smal.
Lane j; PvuII.
Lane k; EcoRI.
Lane 1; Bglll.
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gave further information for the further analysis of this clone. From 
the analysis here (and previously. Chapter 1) it can be seen that Sail 
does not cut within the pcl-5 insert, but cuts once within the 
polylinker cloning region of pUC19. Similarly Clal cuts only once 
within the pcl-5 insert and not at all within the pUC19 plasmid vector. 
This information was important for the restriction enzyme mapping which 
was performed according to a method developed by Smith and Birnstiel 
(1976). In this method the DNA molecule to be analysed, is labelled at 
one end with 32P and then partially digested with the desired 
restriction enzymes. DNA fragments are obtained which form an 
overlapping series of molecules, all with a common labelled terminus. A 
restriction map can then be constructed from the analysis of the size 
distribution of these molecules.
Thus pcl-5 was digested to completion with Sail and the free ends 
were then labelled with 32P x-ATP using polynucleotide kinase (as 
described in Materials and Methods). The 32P labelled linear DNA was 
then digested to completion with the enzyme Clal giving rise to two DNA 
fragments of 4.55 kb and 5.15 kb, which were separated and isolated by 
preparative agarose gel electrophoresis and electroelution. These 
labelled fragments were then used for the detailed restriction enzyme 
mapping procedure described above. This analysis enabled the 
construction of a detailed restriction enzyme map (Figure 31).
e) Molecular analysis of F-SFFVp
From the molecular screening procedure it was seen that, excluding 
pcl-5 and pcl-10 (which were demonstrated to be molecularly related to 
F-MuLV), there were eight further clones which, although they did not 
hybridise to env specific probes, did hybridise to the F-SFFVp Hindlll
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Figure 31. Detailed restriction enzyme map of pcl-5
From the analysis of the clone pcl-5 (and also for pcl-10 which is 
identical) as detailed in the text, a detailed restriction enzyme map 
was constructed. The map of the permutated copy, cloned at the SpHI 
site is shown in A.
A linear map delineating the genome is shown in B.
Restriction enzyme lettering code:
B, BamHI; Bg, Bglll; C, Clal; H, HindiII; K, Kpnl; P, PstI; Pv, PvuII; 
R, EcoRI; Rv, EcoRV; S, SstI; Sm, Smal; Sp, SpHI; X, Xbal.
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probe. Restriction enzyme analysis of small scale plasmid preparations 
from these clones (pcl-1 to pcl-4 and pcl-6 to pcl-9) as well as 
detailed restriction enzyme analysis of CsCl gradient purified plasmid 
DNA, showed that all of these clones represented rearranged (deleted) 
versions of DNA molecules that were similar to the F-SFFVpN linear DNA 
described in Chapter 1 (Figure 28).
Restriction enzyme maps of these clones (Figure 32) demonstrated that 
all of these clones appeared to be deleted versions of F-SFFVpM, and 
that all deletions were located within or encompassed the presumptive 
env (gp55) region. Indeed in some cases even part of the polylinker, 
including the SpHI site had been deleted (as shown by linearisation of
the plasmids, after digestion with SpHI).
Why or how these deletions occured is somewhat unclear, although 
cloning within pUC19, which is a prokaryotic expression vector, when in 
the correct reading frame can give rise to a fi-galactosidase fusion 
protein, which may prove toxic for the bacteria. Indeed similar 
problems have been encountered, when subcloning SFFV env specific 
sequences into the related pUC9 vector (N. Hess, pers. commun.) and 
also when cloning a novel ras containing F-MuLV recombinant virus (J. 
Friel, pers. commun.). It may also be that sequences within this region 
are poisonous per se or prone to recombination in the bacteria used in 
this study.
f) Molecular cloning of F-SFFVpM in a bacteriophage lambda
Due to the unforseen difficulties encountered with the plasmid 
cloning strategy of F-SFFVpM (although successful for F-MuLV, pcl-5, 
and indeed other SFFVs) it was decided to develop a new strategy for 
the cloning of the circular extrachromosomal DNA which had been
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Figure 32. Restriction enzyme maps of recombinant F-SFFVpM plasmid 
clones
All plasmid DNA from clones, pcl-1 - pcl-4 and pcl-6 - pcl-9 were 
purified by two rounds of CsCl equilibrium centrifugation, before being 
subjected to restriction enzyme digestion and agarose gel 
electrophoresis. The clones were analysed by digestion with the 
restriction enzymes;
C, Clal; H, HindlII; R, EcoRI: S, SstI and Sp, SpHI.
All maps are drawn to scale.
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previously isolated. To this aia a new strategy was planned, vbicb 
involved molecular cloning in a bacteriophage lambda cloning vector: 
Molecular cloning of the virus in two fragments. Fro* the restriction 
nap of the F-SFFVpM linear DNA, it was shown that there are two Hindlll 
restriction enzyme sites within the F-SFFVpM genome. Thus digestion of 
a circular F-SFFVpM DNA molecule would give rise to two fragments of 
approximately 2.5 kb and 4.0 kb.
The isolated circular F-SFFVpM extrachromosomal DNA (which also 
contained F-MuLV circular forms) was digested to completion with 
Bindlll and ligated to Hindlll digested and dephosphorylated Charon 21A 
DNA (arms), the details of which are in the Methods. The ligation 
reactions were then packaged in vitro resulting in an infectious 
recombinant phage library. This library was then screened (at a density 
of 10B plaques/ 20x20 cm dish) by the method of Benton and Davies 
(1977). Replica filters were hybridised with the Hindlll F-SFFVp probe 
as described in Materials and Methods. From the primary screening of 
4 x 10° plaques, twenty four gave positive hybridising signals on 
replica filters. These positive plaques were picked and purified by a 
second round of low density plaque screening. Single, positive plaques 
were picked, and small scale DNA preparations of these clones, were 
analysed by agarose gel electrophoresis and Southern blotting after 
digestion of tbe recombinant lambda DNA with Hindlll. Hybridisation 
with the Hindlll F-SFFVp probe revealed that twenty two of these 
lambda clones did contain SFFV related sequences either 4 - 4.5 kb in 
size (9 clones designated L 411 - L 419) or 2.5 kb fragments (13 clones 
L 211 - L 2113). To further analyse these clones, the recombinant 
lambda DNA was analysed as above except that the Southern blots were 
hybridised with SFFV env and ais. specific probes. These probes were
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chosen for according to the linear map constructed of F-SFFVpN from the 
data in Chapter 1 then the approxiaately 4.5 kb F-SFFVpM Hindlll 
fragment should hybridise to the BRIE probe, whereas both the 
approximately 4.5 kb and 2.5 kb fragments should hybridise to a gag 
specific probe. This analysis showed that clones L 214, L 4#5, L 416 
and L 417 hybridised to the BRIE probe whereas L 2fl, L 213, L 214, L 
218, L 219, L 2112, L 419, L 416, L 4«5 and L 4*4 hybridised to the ga£ 
specific probe.
The remaining DNA from the small scale lambda DNA preparations was 
digested with Hindlll and after separation of the DNA fragments by 
agarose gel electrophoresis, the recombinant DNA inserts were isolated 
by electroelution and subcloned into Hindlll digested pUC9 cloning 
vector. After transformation into competent NM522 bacteria, small scale 
plasmid preparations were performed on the recombinant clones.
These bacteria were chosen for they overproduce the lac repressor, 
which binds to the promoter region in the pUC plasmids thus repressing 
expression of genes cloned in the polylinker region. However, this 
repression is not absolute. Clones containing the correct inserts were 
then analysed by a combination of restriction enzyme mapping and 
Southern blotting after purifying the plasmids by two rounds of CsCl 
gradient centrifugation. The restriction maps assembled from this 
analysis are depicted in Figure 33.
The clones p2*l, p2*3, and p2#8 all have the same structure as 
determined by digestion with the enzymes EcoRI and Bamfll and that this 
preliminary restriction enzyme map agrees with that described by the 
analysis in Chapter 1. All three of these clones hybridised with the 
gag fragment and not with the BRIE specific probe, thus confirming the 
internal origin of this Hindlll fragment. However, three further
hybridisation with clone
env gag
H H BgB BR Bg H ♦ p 2 * 1
H H 6,6 BR 6 , »
p 2 # 3
H HR X H
p 2 # 4
HP SP R H p 2 # 1 2
H HP Sp R H
p 2 # 9
H H 6^6 BR 6 , H
p 2 # 8
H H R S B
1 p
HSp B R C S P PH p L # 6
H H S ,B R
i  ?
P PH
p L # 5
H
1__________
H X
__________ 1____1----- i
X H 
— 1--------1 p  U t L
1Kb
172
Figure 33. Restriction enzyme maps of subcloned F-SFFVpM Hindlll 
fragments
Depicted in this diagram are scale maps of the Hindlll subgenomic 
fragments cloned in pUC19. Also shown are the hybridisation data 
with the env specific (pBRIE) and gaa specific probes.
Restriction enzyme lettering code:
B, BamHI; Bg, BglII; C, Clal; H, Hindlll; P, PstI; R, EcoRI; S, SstI; 
Sp, SpHI; X, Xbal.
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clones, notably p2|4, p2f9 and p2fl2, which hybridised to either the 
gag (p2#9 and p2|12) or BRIE probe (p2|4) had sonevhat different 
restriction enzyme maps as compared to the others. The nature and 
origin of these fragments is unclear for they could not be assigned to 
either the F-SFFVpM or the F-MuLV genome.
Analysis of the clones p4|9, p4|6, p4|5 and p4t4, also showed that 
there was a heterogeneity in the fragments that had been cloned. Of the 
clones that hybridised with the gag specific probes, two, p4#6 and p4#5 
corresponded to the second Hindlll fragment produced after digestion of 
the F-SFFVpM circular form as confirmed by their hybridisation to the 
BRIE probe. Two further clones p4|9 and p4|4 had different restriction 
enzyme patterns. On further analysis p4|9 could be identified as the 
internal F-MuLV Hindlll fragment when compared with the restriction map 
of pcl-5. Clone p4i4 which hybridised to the gag probe, had a 
restriction enzyme pattern which was non-identical to either that of 
pcl-5 (F-MuLV) or F-SFFVpM.
g) Molecular analysis of the molecularly cloned Mirand strain 
F-SFFVpM.
i) Construction of a restriction enzyme map for F-SFFVpM
Using the different cloning procedure described above, the two 
Hindlll fragments specific for F-SFFVpM had been successfully cloned. 
These two fragments (using the clones p2ffl and p4!6) were then 
subjected to a detailed restriction enzyme analysis using the 
methodology of Smith and Birnstiel (1976). This analysis thus enabled 
the construction of a detailed restriction enzyme map representing the 
F-SFFVpM proviral DNA linear molecule.
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ii) Comparative analysis of F-SFFVpM with other molecularly 
cloned SFFVs
Having a detailed restriction enzyme map of F-SFFVpM thus enabled the 
comparative analysis of the DNA proviral genome with other molecularly 
cloned SFFVs as depicted in Figure 34. In this figure F-SFFVpM is 
compared with three strains of F-SFFVp as well as F-SFFVa and R-SFFV. 
The first point to note from this analysis is that the Hirand strain of 
F-SFFVp although having similar biological properties as the other 
SFFVps and although similar at the genome level (as determined by 
hybridisation with specific probes) is also unique (as seen by the 
restriction enzyme map) thus showing divergence of this strain as 
compared to the others. F-SFFVpM is approximately the same size as the 
Axelrod (Ax) and the Lilly and Steeves (LS) SFFVp's with a linear DNA 
proviral genome of 6.5 kb. Although various restriction enzyme sites 
are shared between the different SFFV strains, including F-SFFVpM, it 
is only when one examines the env gene that a similarity becomes 
apparent. In nearly all of the SFFVs depicted above there is an area of 
approximately 1 kb which appears to be conserved to a high degree in 
most of the gp55 env genes (determined by sequence analysis of the 
other SFFVs depicted here), centered around the Smal. EcoRI and PvuII 
restriction enzyme sites. This is based on sequence analysis of 
previously cloned SFFVs. This part of the gp55 gene corresponds to the 
region which is of non-ecotropic origin i.e. from MCF or endogenous 
mouse sequences and are indeed sequences which are used to diagnose 
SFFV specificity both at the nucleotide and protein levels. Comparison 
of the rest of the genome, using the restriction enzyme sites shows 
that at this level there is very little homology which is not 
surprising when one considers that SFFVs are recombination products
1Kb
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Figure 34. Coiparison of the restriction enzyme map of F-SFFVpM with 
other molecularlv cloned SFFVs
All maps are drawn to scale. The restriction as were adapted from 
Kaminchik et al., 1982;
Wolff et al., 1984: F-SFFVa;
Amanuma et al., 1983: F-SFFVpIK;
Yamamoto et al.., 1981;
Clark and Mak, 1983: F-SFFVpAx;
Linemeyer et al., 1980;
Wolff et al.. 1985: F-SFFVpLS;
Bestwick et al.. 1984;
Hess et al., 1984: R-SFFV.
Restriction enzyme lettering code:
B, BamHI; Bg, Balli; C, Clal: H, HindlII: K, Kpnl; P, PstI; Pv, PvuII; 
R, EcoRI: Rv, EcoRV; S, Seti; Sm, Smal; Sp, SpHI; X, Xbal.
176
between ecotropic viral sequences and MCF like env sequences.
h) Biological activity of molecularlv cloned F-MuLV and F-SFFVpM
i) F-MuLV: Construction of a linear form of F-MuLV
The results presented previously have shown that two permutated 
copies (both with one LTR) of F-MuLV (pcl-5 and pcl-10) had been 
molecularly cloned. Comparison of their (only pcl-5 is presented) 
genome continuity with F-MuLV 57 showed a certain degree of 
relatedness. However to further test this it was necessary to determine 
whether these clones (pcl-5) did indeed have the characteristic 
biological properties of F-MuLV. To this aim it was then essential to 
construct a linear form of the pcl-5 clone which could be transfected 
into recipient cells. The strategy employed in the construction of a 
linear form of pcl-5 (pcl-5 1L) is depicted in Figure 35. Restriction 
enzyme analysis of 24 clones with the enzyme SstI revealed that two 
clones pcl-5 1L#3 and pcl-5 1L#9 gave the correct restriction fragment 
pattern. These two clones were then expanded and CsCl plasmid ONA was 
isolated. Further restriction enzyme analysis (Sst, EcoRV and 
EcoRI.Xbal) substantiated that these clones contained the construct 
depicted in Figure 35.
ii) Transfection of RATI cells
Having constructed a linear F-MuLV it was necessary to construct cell 
lines which express this construct and thus release replication 
competent F-MuLV. To this end the following strategy was employed: RATI 
cells were transfected with either pcl-5 1LI3 or pcl-5 1LI9 (as in 
Materials and Methods) and these transfected cells were then further 
propagated so that the cells were continually in log phase. After ten
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Figure 35. Construction of a linear clone (pcl-5 1L) of the permutated 
F-MuLV clone pcl-5
pcl-5 1L (19) was constructed as follows.
A 4.5 kb Hindlll.SpHI fragment, encompassing the 3' end of pol. the 
complete env and 3' LTR as well as 5' portion of gag, was isolated by 
preparative gel electrophoresis and electroelution.
A second fragment (Xbal to SpHI, 8.2 kb) was isolated by a similar 
procedure. The two fragments were ligated in equimolar amounts with 
Xbal, Hindlll digested pUC19. After transformation into competent 
NM522, ampicillin resistant colonies were screened by restriction 
enzyme analysis of small scale plasmid DNA preparations.
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days of culture the supernatant was tested in the reverse transcriptase 
assay to see whether replication competent virus was being released.
In all cultures, a high reverse transcriptase activity was detected, 
thus showing that the pcl-5 1L constructs could give rise to 
replication competent virus. The transfected cells were then further 
cultured and the supernatants were used to infect RATI cells. This step 
was undertaken to obtain cell lines that only had correctly integrated 
viral copies, for after transfection of plasmid DNA into cells, there 
always appears to be a certain amount of recombination, thus leading to 
aberrant copies. The infected RATI cells were then analysed after ten 
days in culture for the production of replication competent virus 
(reverse transcriptase assay). All cell cultures analysed released high 
titres of virus. From one of these cultures cell clones were isolated 
by plating out the cells at low density and then picking isolated 
colonies after an incubation period of seven days. Two clones 
RATI pcl-5 1LI6 and RATI pcl-5 1LI10, both of which originated from the 
molecular clone pcl-5 1LI9, and had high RT levels were then used for 
further analysis. The production of these cell lines is depicted in 
Figure 36.
iii) Molecular analysis of the producer cell lines RATI pcl-5 1L|6
To substantiate that the virus being produced from the cell line 
RATI pcl-5 1L|6 was indeed identical to that, that had been constructed 
and transfected, the following analysis was performed. Genomic DNA from 
the cell line RATI pcl-5 1LI6 was digested to completion with the 
enzymes Sst. Kpnl, BamHI and EcoRV. The plasmid DNA pcl-5 1L#9 was 
digested with the same enzymes and both DNAs were then analysed in 
parallel by Southern blotting. The results of this analysis are shown
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Figure 36. The construction of the F-MuLV producing cell lines 
RATI pci-5 1L<6 and RATI pcl-5 1LI10
Plasmid DNA: pcl-5 1L#3 and pcl-5 1L#9
1
transfect into RATI cells
\
culture for 10 days
/
Assayed for reverse transcriptase (RT) activity
\
RT positive supernatants used to 
infect RATI cells
s
Assayed for RT activity
N.
RT positive cultures.
Two cell lines were cloned out.
/ \
RATI pcl-5 1L|6 RATI pcl-51L|10
High RT High RT
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in Figure 37. Using the pcl-5 SpHI insert fragment as a 3*P labelled 
probe it can be seen that the internal fragments (highlighted by bars) 
produced after digestion with these enzymes are identical for both the 
plasmid and the integrated viral DNA. The other bands not marked with 
arrows represent either, viral plus flanking sequences (integration 
sites), or non linear sequences of the pcl-5 1LI9 construct (i.e. 
plasmid sequences etc.).
Thus it appeared that not only does RATI pcl-5 1LI6 (similar data not 
shown was also seen for RATI pcl-5 1LI10.) release a replication 
competent virus, but also that this is of the correct molecular 
composition.
iv) Biological assay of F-MuLV being released from producer cells
To further substantiate the claim that what had indeed been 
molecularly cloned and transfected, was indeed F-MuLV, the virus being 
released from the cell line RATI pcl-5 1LI6 was assayed for biological 
activity both in vitro and iii vivo.
To test the biological activity of the virus being released in vitro 
the XC assay was employed. This method exploits the observation that 
NuLVs are able to cause the formation of syncitia after infection of 
RAT XC cells. This method, in combination with the fibroblast cell 
lines (A31, Balb/c or NIH3T3, NIHSwiss) is also able to define the 
tropism of the virus being assayed. Thus virus being released from the 
cell line RATI pcl-5 1L|6 was titrated on the A31 and NIH3T3 cells in 
the XC assay. As a positive control virus being released from the cell 
line F4-6 was also titrated in parallel. The results are shown in 
Table 6.
This experiment demonstrated that the virus being released from
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Figure 37. Restriction enzyme mapping of the F-MuLV producer
Genomic DNA (10 pg) in parallel with plasmid DNA (pcl-5 1L#9, 80 pg) 
was digested with various restriction enzymes followed by agarose gel 
electrophoresis and Southern blotting. The resulting filter was then 
hybridised, with the SpHI fragment isolated from pcl-5 after labelling 
with **P.
Lane a 
Lane b 
Lane c 
Lane d 
Lane e 
Lane f 
Lane g 
Lane h 
Lane i
: RATl.Sstl.
: RATI pcl-5 !L#6.SstI.
: pcl-5 1LÌ9.SstI.
: RATI pcl-5 !LI6.KpnI.
: pcl-5 !Ll9.KpnI.
: RATI pcl-5 !Ll6.BamHI. 
: pcl-5 ILI9.BamHI.
: RATI pcl-5 !Ll6.EcoRV. 
: pcl-5 1LI9.ECORV.
The numbers to the left represent molecular weight markers in kb.
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Table 6. Biological activity of the molecularly cloned F-MuLV (pcl-5)
in vitJQ
______ XC Dlagues/ml_____
Virus A31 3T3
F4-6 5 x 10» 6 x 10®
RATI pcl-5 1LI6 3 x 10® 3 X 10®
643/22N 4 x 10® 4 x 10®
183
RATI pcl-5 1LI6 was a replication competent HuLV of NB tropism, as was 
also the virus being released from the uninduced cell line F4-6 (from 
which pcl-5 was cloned), and RATI 643/22N (biologically cloned F-MuLV 
from F4-6). Thus in vitro the molecularly cloned F-MuLV (pcl-5) had 
identical biological properties as compared to its biologically 
uncloned and cloned counterparts.
Previous work using either the replication competent virus of the 
Nirand FV-P strain being released from non-induced (and indeed induced) 
F4-6 cells as well as the biologically cloned virus 643/22N, has shown 
that in vivo this virus is only able to cause a lymphatic leukaemia in 
newborn mice (Pragnell et al., 1978) and has thus been referred to as 
lymphoid leukaemia virus (also earlier by other workers, Steeves et 
al., 1971). This virus, unlike other helper virus variants in Friend 
virus complexes which are able to induce splenomegaly and 
erythroleukaemia in susceptible newborn mice (i.e. F-MuLV 57), shows no 
erythroid involvement in it's pathology. To test this, virus being 
released from the cell line RATI pcl-5 1L#6 was used to inoculate 
newborn DBA/2J mice by the intraperitoneal route. XC assay of the 
supernatants used revealed that 10® XC p.f.u. were being injected in 
the 100 pi inoculum. Virus being released from the cell line 643/22N 
was used to infect parallel groups of newborn mice as a positive 
control. The mice were observed for 3-4 months after which time no 
spleen enlargement could be detected. Animals sacrificed after this 
time showed no spleen or liver involvement. However greatly enlarged 
lymph nodes were apparent combined with an increased white blood cell 
count indicating that the lymphoid system had been affected in these 
animals, thus suggesting an abnormality in lymphoid function as 
predicted by previously reported data using the biologically cloned
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virus and also by the identical manifestations indicated by 643/22N 
infected mice. Further observation of the animals up to six months 
revealed that the mice became sick at this time but without fatal 
consequences. Again no spleen involvement was observed.
v) Construction of a linear F-SFFVpM DNA molecule 
As with the F-MuLV (pcl-5) described above, in order to test the 
biological activity of the molecularly cloned F-SFFVpM from F4-6 cells 
it was essential to construct a representative functional DNA genome 
from the fragments which had been molecularly cloned. The scheme 
employed is shown in Figure 38. The Hindlll fragment from the plasmid 
p2#l was isolated by electroelution after preparative gel 
electrophoresis. This fragment corresponded to the internal Hindlll 
fragment from F-SFFVpM. Two further fragments were isolated in a 
similar manner from the plasmid p4!6 and corresponded to a 2.5 kb 
Hindlll.EcoRI fragment (3' env» the LTR and all of the gaa sequences to 
the Hindlll site) and a 2.8 kb Hindlll.PstI fragment (encompassing the 
3' end of env the LTR and part of the gaa region until the first PstI 
site). These three fragments were ligated together with Hindlll.PstI 
digested pUC9. After transformation of competent NM522 bacterial cells 
and ampicillin selection small scale plasmid preparations were used to 
analyse forty eight clones. From these clones which were analysed by 
restriction enzyme digestion and gel electrophoresis only two proved 
positive in giving the correct restriction fragments expected. From one 
of these clones (pSM-lL) plasmid DNA was prepared by CsCl density 
centrifugation. Detailed restriction enzyme analysis of the clone 
further substantiated its identity. Thus the construction of pSM-lL 
meant that a colinear DNA molecule had been constructed which could be
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Figure 38. Construction of a linear F-SFFVpM DNA molecule (pSM-lL) 
froa Hindlll subgenomic fragments
A linear SFFVpM DNA aolecule was constructed as follows:
A Hindlll.EcoRI fragment from p4#6 encompassing the 5' LTR and gag 
sequences was ligated with the p2fl Hindlll insert (the internal 
fragment) and a Hindlll.PstI (env and 3' LTR) fragment from p4|6 and 
EcoRI.PstI digested pUC19. Ligation reactions were transformed into 
competent NM522 cells. Ampicillin resistant clones were analysed by 
restriction enzyme digestiotf fof the correct construct 
pSM-lL.
Restriction enzyme lettering code:
B, BamHI; Bg, BulII; C, Clal: H, Hindlll; K, Kpnl; P, PstI; Pv, PvuII; 
R, EcoRI; Rv, EcoRV; S, SstI; Sm, Smal; Sp, SpHI; X, Xbal.
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used as a substrate with which to transfect fibroblast cells.
vi) Co-transfection of RATI fibroblast cell with pSM-lL and a 
dominant selectable marker
Due to the replication defectiveness of SFFV a strategy had to be 
devised to detect cells that had been transfected with pSN-lL. To this 
end pSM-lL was co-transfected with pAG60 which is a plasmid containing 
the Herpes Simplex thymidine kinase promoter linked to the neomycin 
phosphotransferase gene. Transfection of this plasmid into eukaryotic 
cells confers resistance to the aainosidase analogue G418 (neomycin). 
Thus RATI fibroblasts were transfected with pSM-lL and pAG60 (at a 
ratio of 10:1) as in Materials and Methods. After the first medium 
change the medium was supplemented with G418 at a concentration of 400 
pg/ml. Growth medium was changed every three days until single isolated 
clones could be seen (14-21 days). Ten clones were picked using cloning 
cylinders, expanded and genomic DNA was isolated. Southern blot 
analysis of SstI digested genomic DNA demonstrated that all G418 
resistant clones contained several copies of pSM-lL after hybridisation 
with the env specific BRIE probe. In some cases recombination events 
had resulted in rearranged copies which did not migrate the same 
distance in the gel as the SstI digested pSM-lL control plasmid.
Western blot analysis of three of these clones revealed that gp55 was 
also being synthesized in detectable amounts demonstrating that at 
least some of the transfected, integrated copies were capable of being 
transcribed into functional mRNA. One of these non-producer cell lines 
RATI pSM-ILf3 which contained no detectable rearranged copies and also 
synthesized detectable amounts of gp55 was then infected with F-MuLV 
being released from the cell line RATI pcl-5 1L#6, so that the
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replication defective F-SFFVpN could be rescued. Supernatants fro* this 
cell line (where H stands for helper virus) were checked ten days after 
infection for the release of virus. In two parallel cultures of RATI 
PSN-1LI3 +H the supernatants had high reverse transcriptase titres 
which stayed at a high level over a period of weeks.
vii) Biological activity of SFFVpM in vivo
Using the cell lines constructed above it was intended to test 
whether the biological activity in vivo of the Friend virus complex 
reconstructed after molecular cloning and transfection (and super 
infection) of RATI cells was the same as the Friend virus complex being 
released from the parental cell line F4-6. To this aim groups of six 
DBA/2J mice were infected with five fold serial dilutions of virus 
being released from RATI pSM-lL|3 +H, F4-6 and as controls RATI 
pcl-5 IL#6 and mock infected mice (three mice per control). After 
eleven days the mice were sacrificed and the spleens were removed, 
weighed and stored in 70% ethanol.
In the positive control (F4-6) all of the mice displayed an acute 
splenomegaly (for undiluted and 1:5 dilutions) with numerous foci which 
were only quantifiable at the higher dilutions (Figure 39, Table 7). 
Mice infected with the FV-P complex being released from the cell line 
RATI pSM-lL|3 +H showed an identical acute splenomegaly again with 
numerous foci, whose number again were proportional to the dilution 
being inoculated. Mock infected mice (GMEM *■ 10% FCS) as well as F-MuLV 
infected mice (RATI pcl-5 1LI6) displayed no visible spleen 
enlargement.
Thus the molecularly cloned and reconstituted FV-P complex was able 
to induce an acute splenomegaly in susceptible mice in an identical
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Figure 39. Splenomegaly caused by infection of DBA/2J mice with 
F-SFFVpM
Adult female DBA/2J mice were infected with 0.5 ml of five fold
serially diluted tissue culture supernatants from F-SFFVpM producing
cell lines. After 11 days the mice were sacrificed and the spleens were
removed and stored in 70% ethanol after weighing.
a: control uninfected spleen.
b: F4-6 (undiluted).
c: F4-6 (1:125 dilution).
d: (undiluted).
e: (1:125 diluted).
The dilutions are shown to demonstrate confluent (b and d) and isolated
foci (c and e).
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manner as the F4-6 FV-P complex from which the two viral components had 
been molecularly cloned. It was apparent from these and also the 
previous series of experiments using F-NuLV from RATI pcl-5 1LI6 that 
this acute splenomegaly was caused by the F-SFFVpM component of the 
viral complex.
The infection of susceptible mice with the FV-P complex not only 
leads to an acute splenomegaly after a very short incubation period, 
but also to a dramatic proliferation of late erythroid precursor cells 
(CFU-E) which are, unlike their counterparts in non-infected mice, able 
to proliferate in the absence of the hormone erythropoietin. This 
capacity is assayable in that either spleen or bone marrow cells may be 
plated out in methylcellulose supplemented with growth medium and CFU-E 
can be scored after 48 h. The presence or absence of erythropoietin in 
the culture medium can be used to determine whether these CFU-Es are 
erythropoietin independent or not.
To test this aspect and thus verify the identity of the molecularly 
cloned virus (F-SFFVpM), adult DBA/2J mice were infected i.v. with 
either FV-P being released by F4-6 or RATI pSM-12L|3 +H. After eleven 
days the mice were sacrificed, spleens were removed, weighed and single 
cell suspensions were plated out at various cell densities in 
methylcellulose growth medium supplemented with or without 
erythropoietin. After 48 h CFU-E were scored. Bone marrow cell 
suspensions were plated out similarly. The results of these experiments 
are shown in Table 7a.
Spleen cells from mock infected mice when plated out in the absence of 
erythropoietin were only (a background level is usually detectable due 
to low levels of epo in serum) able to give rise to very few mature 
CFU-E, thus demonstrating that these cells are normally dependent upon
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this hormone. This also shows that the components used in this assay 
(notably the calf serum) contained no substantial erythropoietin like 
activity. However in the presence of erythropoietin CFU-Es were readily 
detected in the spleen.
In F4-6 infected spleens there were two dramatic observations to be 
seen in that there was an enormous expansion in the number of CFU-E 
present which at the same time were erythropoietin independent, a 
characteristic expected for SFFVp. Infection of mice with the FV-P 
complex being released from the RATI pSM-lL|3 +H cell line resulted in 
an identical picture as seen for F4-6 in that the spleens demonstrated 
an enormous proliferation of CFU-Es which were erythropoietin 
independent. Thus in the spleen at least the SFFVp being released from 
the cell lines F4-6 and RATI pSM-lL#3 +H were identical.
As mentioned in the introduction, most SFFVp variants induce a large 
increase of erythropoietin independent CFU-Es in the spleen, but have 
very little effect upon CFU-E formation in the bone marrow. However it 
has been reported that the FV complex released by some Friend cells 
(notably the Mirand strain of SFFV used in this laboratory) is able to 
cause a profound erythropoietic proliferation in the bone marrow 
(CFU-E) in susceptible mice (Fagg et. al., 1980; Fagg and Ostertag,
1982) . Thus bone marrow cells of the above infected mice were plated 
out at various cell densities in methylcellulose as for the spleen 
cells and CFU-E were scored after 48 h (Table 7a).
In non-infected control mice, in the absence of erythropoietin a 
background level of CFU-E comparable to that seen in the spleen 
could be detected. In the presence of erythropoietin CFU-E could be 
detected although not at the level seen in the spleen. Mice infected 
with the FV colmplex being released from F4-6 surprisingly showed very
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few erythropoietin independent CFU-E although with erythropoietin 
comparable numbers as seen in the control could be scored. A similar 
picture was seen with RATI pSN-lLl3 +H infected mice although the 
number of erythropoietin independent CFU-E was approximately two-fold 
higher, this was still not within the range which has been reported by 
Fagg and Ostertag (1982). This result is somewhat puzzling although 
similar observations to those reported here have been repeatedly found 
by other members of this laboratory (T. Franz, pers. commun.). Why 
these results of Fagg and Ostertag (1982) are not reproducible remains 
unclear although one possibility may be that the culture conditions 
(such as serum batches etc.) are somehow inhibitory to the formation of 
CFU-E in bone marrow cultures, as difficulties in the bone marrow CFU-E 
assay have been encountered in general (C.Laker, G.GrAnning, pers. 
commun.).
Discussion
The molecular cloning of both components of a Friend virus complex has 
been described. In the procedure adopted the extrachromosomal DNAs 
corresponding to circular proviral intermediate molecules found within 
the Friend cell line F4-6 after DMSO induction were molecularly cloned 
either in a plasmid or a bacteriophage cloning vector. Although the 
F-MuLV was readily cloned in the plasmid vector pUC19 no intact SFFVp 
molecules could be obtained by this method. From the library screened 
all of the SFFVp related molecules examined had undergone deletions. 
What was further surprising was that all of the deletions, without 
exception, encompassed the env region of SFFVp. From these observations 
it may be proposed that the combination of cloning site (SphI) and
194
cloning vector (together with the recipient bacteria) somehow led to 
the alterations. The SphI site is positioned 5' to the splice acceptor 
site for the env gene (as determined from sequence analysis of other 
cloned SFFVs) thus digestion with this enzyme would leave the env gene 
intact. Cloning within an expression vector such as pUC19 could thus 
result in transcription and translation of the env gene product which 
could be envisaged to have deleterious effects on the bacterial life 
cycle, for not all eukaryotic proteins are expressable in certain 
strains of bacteria. However even the one clone which was obtained with 
the pBR322, DH1 combination had a rearranged env gene. In this cloning 
vector the SphI site is within the tetracycline resistance gene 
approximately 600 bp downstream from the promoter. Thus for the env 
product (assuming to be in the correct orientation) to be synthesized, 
either it must be a fusion protein or initiated from internal 
sequences. Both of these are unlikely so one could propose that the env 
sequences per se were poisonous and thus led to the recombinants 
observed.
These problems for SFFVp were overcome by cloning the virus in two 
fragments in a bacteriophage cloning vector in which digestion with the 
restriction enzyme Hindlll disrupted the continuity of the env gene. 
This approach proved more successful allowing the molecular cloning of 
the Mirand strain of SFFVp and subsequent construction of a detailed 
restriction enzyme map.
When one compares the biological activity of pcl-5 with F-MuLV 57 
then pcl-5 causes a lymphatic leukaemia whereas F-MuLV 57 is able to 
induce an erythroleukaemia in newborn mice. It has been shown that the 
disease specificity of the helper virus appears to be determined by the 
viral LTR (BOsze et al., 1986). Recombinants between F-MuLV and Mo-MuLV
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as well as between F-NuLV and amphotrophic NuLV constructed by 
exchanging fragments containing the 3' end of the genomes demonstrated 
that the LTR was responsible for the tropism of the viruses (Chatis et_ 
al., 1983, 1984; Des Groseiller and Jolicoeur, 1984; Des Groseiller et. 
al., 1983; Oliff et al., 1984; Holland et al., 1985, 1987). One 
interesting point is that it has also been shown that leukaemia induced 
by F-MuLV is also dependent upon gag sequences (Oliff et all., 1985).
The genome size of both the anaemia and polcythaemia inducing SFFVs is 
remarkably variable. This probably reflects their long evolutionary 
history in different laboratories and also indicates that large parts 
of the genome are not essential for the rapid induction of 
erythroleukaemia in adult animals. Thus when the F-SFFVpM is compared 
with the other molecularly cloned SFFVs (Figure 34) one can see that 
although some restriction enzyme sites are common to most of the SFFVs 
(notably in the env region) there is no extensive homology at this 
level. The size heterogeneity of the different SFFVs is mainly due to 
deletions within the gag-pol region as shown by immune precipitation of 
viral proteins, oligonucleotide fingerprints and hybridisation 
experiments (Bilello et al., 1980; Mol et ad., 1982; Langdon et al., 
1983; Ruscetti et al., 1984).
As previously mentioned it has been demonstrated with the Mirand 
strain of SFFVp that upon induction of various Friend cell lines 
(transformed by the Mirand strain, including F4-6) that a novel SFFV is 
synthesized (as shown at the RNA level) and indeed released presenting 
a biological activity, erythroid proliferation, extending to the bone 
marrow (Ostertag and Pragnell, 1981). In these studies it was suggested 
that the OMSO induced differentiation of F4-6 led to the synthesis and 
release of an "original” SFFV as well as an N-tropic helper virus. Thus
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it was hoped that in the analysis presented here and earlier more light 
could be shed onto this phenomenon in that this new SFFVp could be 
further characterised at the molecular level and also possibly 
molecularly cloned. However in the primary analysis no detectable 
heterogeneity in the size of SFFVp related extrachromosomal DNA 
molecules was seen during the course of induction and indeed upon bulk 
preparation and purification thus suggesting the presence of a single 
DNA species (so far as could be determined by this analysis for no 
aberrant bands were detected after restriction enzyme mapping). That 
after the molecular cloning of this SFFV DNA and subsequent biological 
testing proved that the cloned F-SFFVpM had a biological activity 
restricted to the spleen with very little effect on the bone marrow, 
suggested that either the novel SFFV was not present as an 
extrachromosomal DNA form within these cells or was not molecularly 
clonable using the strategy presented.
Construction of a biologically active F-SFFVp retroviral vector
containing a dominant selectable marker gene
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Introduction
It has been generally realised for some time that retroviral genomes 
are good candidates for vehicles to introduce desirable genes into 
eukaryotic cells (Shimotohno and Temin, 1981; Tabin et al.. 1982; 
Williams et. al., 1985). This has been greatly aided by an intimate 
understanding of the functional organisation of retroviral genomes and 
a full appreciation of the large variety of ways in which retroviruses 
have acquired one genes as part of their genetic make up. There are a 
number of characteristics of the retrovirus life cycle that in 
combination render these agents uniquely suited for certain types of 
experimental manipulations involving expression of foreign genes in 
cells and in whole animals. Their ability to efficiently integrate into 
the host chromosomal DNA and be stably transmitted as well as the broad 
spectrum of cells which they are able to infect makes retroviruses a 
more attractive and superior gene transfer system than calcium 
phosphate transfection (Wigler et al.. 1977; Wigler et^  al., 1978).
It has been shown that virally transduced genes are expressed at 
10-50 fold higher levels than those introduced by DNA mediated gene 
transfer (Hwang and Gilboa, 1984). Thus much effort has been put into 
developing retrovirus vectors. The introduction of genetic markers into 
the retrovirus genome has greatly extended the utility of these vectors 
for selecting and identifying infected cells (Coffin, 1985). The 
introduced marker gene may either be under control of an independent 
promoter, which may be their own, or of those promoter/enhancer 
elements found within the LTRs of the retrovirus.
Attempts to construct a biologically active SFFV containing a 
dominant selectable marker gene have until now met with limited success
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(Joyner and Bernstein, 1983; Hess, 1985). In both cases deletions after 
transfection of the viral genomes gave rise to recombinant viruses in 
which the selectable marker and transforming functions had segregated. 
However other selectable, biologically active retroviruses have been 
successfully constructed (Wei et al., 1981; Ostertag et al., 1986;
Friel et al., 1987).
Little is known about the target cell interactions that lead to 
erythropoietin independent differentiation of SFFVp infected erythroid 
precursor cells. In order to study these it is necessary to define the 
target cells. A study of target cell/SFFV interaction has proven to be 
difficult, even though the efforts of Hankins group on in vitro 
infection in mass cultures have confirmed many of the assumed 
properties of the SFFV target cells (Hankins and Troxler, 1980). The 
exact target cell of SFFV however remained elusive. Differentiation 
induction and/or malignant transformation mediated by SFFV has also not 
been achieved with sorted and enriched erythroid precursor cells 
(Johnson and Ostertag, pers. commun.).
The main problem to define the target cell(s) has been on the one 
hand the in. vitro cell system and on the other hand the problems 
involved in tracing infections of SFFV to single cell progeny. Better 
cell systems are now available with stem cell lines that can be induced 
to differentiate along any of the myeloid lineages including the 
erythroid pathway (Boettiger et al., 1984; Spooncer et al., 1986).
A selectable marker gene within the frame work of a biologically 
active SFFV would also be of advantage in analysing the causes which 
may lead to malignancy of Friend cells, i.e. aiding analysis of the 
integration site(s) of SFFV. Finally the intriguing correlation between 
induction of viral functions and erythroid differentiation (Ostertag et
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al., 1987) of Friend cells could be studied more easily if SFFV genomes 
could be assayed not only by in vivo assays but also by in vitro assays 
utilising a selectable marker gene.
In this chapter the following questions were posed.
1) Is it possible to avoid the difficulties in constructing a hybrid 
selectable SFFVp?
2) Is it possible to elicit an erythroid hyperprofilerative disease 
with such a recombinant neoR SFFVp?
3) Can malignant Friend type cells be generated with such a recombinant 
vector virus?
A brief overview of the MPSV biology and molecular biology will be 
presented here as a prior knowledge for the construction of neoR SFFV.
The myeloproliferative sarcoma virus (MPSV) is a member of the 
Moloney murine sarcoma virus (Mo-MuSV) family. MPSV is unique for not 
only does it efficiently transform fibroblasts in vitro and cause 
sarcomas upon intramuscular inoculation of adult mice, a property also 
of Mo-MuSV, but it also gives rise to extensive haemopoietic changes in 
vivo characterised by proliferation of late erythroid precursor cells, 
haemopoietic stem cells and granulocyte-macrophage precursor cells 
(Ostertag et. al., 1980; Klein et. al., 1981). Molecular analysis of the 
MPSV genome has revealed that it is composed entirely of Mo-MuLV and 
cellular mos proto-oncogene derived sequences (c-mos), as is the 
Mo-MuSV (Kollek et al., 1984). It has been shown that the unique 
leukaemia inducing capacity of MPSV is due to a cooperative interaction 
between the U3 region of the 5' LTR, which differs slightly from those 
of the related Mo-MuLV and MuSV, and the mos oncogene (Stacey et al.. 
1984; Stocking et al., 1985; Stocking et al., 1986; Ostertag et. al., 
1987). MPSV is like most other oncogenic viruses replication defective.
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Results
a) Construction of the neo* SFFVp retroviral vector
It was intended to construct a neo* SFFVp vector using the SFFVp 
cloned in the previous chapter, however due to the problems encountered 
with the aolecular cloning of this viral genome, it was decided to 
utilise a subgenoaic fragment from the Lilly and Steeves strain of 
SFFVpLS (Linemeyer et_ al., 1980), in the construction of this vector. 
Further arguments which substantiated this decision, were that 
construction of such a retroviral vector requires, nucleotide sequence 
data, so that various important sequences (i.e. splice acceptor sites 
and restriction enzyme sites) can be recognised and thus utilised in 
the construction process, and various derivatives thereof. It was thus 
decided to use the SFFVpLS clone, which is indistinguishable in its 
biological activity, from F-SFFVpH.
The efforts of Joyner and Bernstein (1983) and Hess (1985) to 
construct a selectable SFFV, utilised the genome of SFFVp as a 
backbone, and attempted to insert the marker within the non-functional 
qag-pol region. In the construction of neo* SFFVp a different approach 
was used, in that a hybrid virus consisting of the 5' LTR, gag. 3' pol. 
and the neomycin resistance gene sequences, originating from the neo* 
MPSV (neo* mos-2), together with the env gene and 3' LTR from SFFVpLS, 
was constructed (Figure 40).
A 2.5 kb Hindlll-Pstl fragment encoding the env gp55 gene with its 
3* splice acceptor sequences, a complete 3' LTR and part of the gag 
sequence, was isolated from the pSFFVpLS plasmid, by preparative 
agarose gel electrophoresis and electroelution. A similar procedure was 
used to isolate a 6 kb EcoRI-Hindlll fragment from the neo* mos- 2
SFFVpL
S
5*LT R 
3 LTR
2o:
Figure 40. Construction of neo* SFFVp
neo* SFFVp was constructed as described in the text.
Transformation of competent CMK603 followed by small scale plasmid DNA 
analysis, led to the isolation of a clone pMF16, the structure of which 
is shown (cloned into the EcoRI and PstI sites of pUC19). See A.
The restrictipn enzyme code is as follows
B, BamHI; Bg.jljB q l H : H, Hindlll; K, Kpnl: P, PstI; R, EcoRI; Rv, EcoRV; 
S, SstI; Sa, Sail; X, Xbal; Xh, Xholl.
♦  s.d. splice donor sequence.
• s.a. splice acceptor sequence.
B) This diagram illustrates that after one round of viral replication 
i.e. reverse transcription, the U3 region of the SFFV 3' LTR will also 
be present in the 5' LTR.
The shaded areas represent genomic DNA sequences either cloned with 
and flanking the integrated MPSV provirus, or genomic flanking 
sequences after integration of neo“ SFFVp.
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plasmid. This fragment contains cellular genomic DNA sequences 5' to 
the LTR (as a consequence of cloning the integrated proviral MPSV DNA), 
gag and pol sequences, as well as the Tn5 neomycin resistance gene.
Neo* SFFVp was constructed by ligating these two fragments (in 
equimolar concentrations of approximately 2 0 0 ng) together with 
EcoRI-PstI digested pUC19 (100 ng) as described in Materials and 
Methods. Recombinant plasmids were screened by ampicillin resistance 
selection after transformation of competent CMK603 bacterial cells. 
Analyses of twenty four clones, revealed that four had the predicted 
restriction enzyme pattern after digestion with PstI. One clone (pMF16) 
was then grown up for large scale plasmid preparation and further 
analysed by restriction enzyme analysis combined with Southern 
blotting. The results of this analysis are shown in Figure 41.
From this analysis it can be seen that the predicted restriction 
enzyme map is correct giving the correct restriction enzyme fragments 
after digestion with Sstl. Pstl. EcoRl. Hindlll. BamHI. Sail, and Xhol. 
That these fragments also correspond to the appropriate genes was shown 
in that hybridisation with both neo and env (BRIE) specific probes gave 
rise to the expected hybridisation pattern (Figure 41).
b) Construction of neo* SFFVp non-producer and producer cell lines
The neo* SFFVp vector described above has a 5' LTR originating from 
MPSV and a 3’ LTR from SFFVp. However, due to the replication strategy, 
after one round of infection and replication, both the 5' and 3' LTRs 
will have U3 regions of SFFVp origin (Figure 40). Since these regions 
contain the transcription control elements for the retrovirus, the 
ensuing virus will be regulated by SFFVp specific U3 control sequences.
Thus in order to obtain neo* SFFVp non-producer and producer cell
M  a  b  c  d  e  f  g a  b  c
Xh
NEORSFFV P P
V7ZÌ
n eo  p r o b e e n v  p r o b e
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Figure 41. Restriction enzyme analysis of PMF16 (neo“ SFFV).
Plasmid DNA (0.5 jig) of pMF16 (neo“ SFFVp in pUC19) was digested to 
completion with the enzymes SstI (lane a), PstI (lane b), EcoRI 
(lane c), Hindlll (lane d), BamHI (lane e), Sail (lane f) and 
Xhol (lane g). After separation of the fragments by agarose gel 
electrophoresis and subsequent Southern blotting the filter was 
hybridised with either the neo (B) or gp55 env specific probe BRIE (A).
A photograph of the ethidium bromide stained gel is depicted to the 
left (P).
Also shown under the figure are the origin of the probes used in this 
and further analysis using neo“ SFFV and related vectors.
The numbers to the left of A represent molecular weight markers in kb.
lane M.
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lines a strategy was used, to ensure that one round of replication had 
been completed before isolating the relevant cells. This was performed 
as follows. NeoB SFFVp DNA (pMF16, 5 pg/T75 flask, i.e. 1 x 10* cells) 
was transfected into both PA317 and psi-2 cells by the calcium 
phosphate precipitation method. These two fibroblast cell lines have 
the capacity to encapsidate defective retroviral RNA genomes, and thus 
release, helper free infectious virus. Viruses released from PA317 have 
an amphotropic host range, whereas viruses released from psi- 2  virus 
have an ecotropic host range.
The cells were cultured for 48 h in GMEM + 10% FCS at 37®C and 5%
CO2 . After this period of time, the supernatants from these cell 
cultures, were filtered (0.45 urn) before being used to infect either 
PA317 cells (psi-2 supernatant), psi-2 cells (PA317 supernatant) or 
RATI fibroblasts (both psi-2 and PA317 supernatants). These infected 
cells were then selected for successful viral transfer (G418 
resistance) by incubation in medium supplemented with G418 at a 
concentration of 400 pg/ml. G418 resistant clones appeared after 14-20 
days and were picked and expanded for further analysis.
Supernatants of the resulting psi-2 and PA317 clones were assayed for 
reverse transcriptase, to detect quantitatively virus being released 
from these cells. Only those cells releasing appreciable amounts of 
virus (i.e. >50% of the positive control) were kept for further 
analysis.
i) Southern blot analysis of neoB SFFVp infected cell lines
High molecular weight cellular genomic DNA was isolated from G418 
resistant, psi-2, PA317 and RATI clones, and was analysed by Southern 
blot hybridisation following digestion with restriction enzymes to
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confirm integrity, stability and copy number of the viral genomes (Only 
the data for the RATI clones are shown. Figure 42).
Digestion with the restriction enzyae SstI which cuts once within the 
LTR of the viral genoae gave rise to a fragaent of 8 kb which 
hybridised both to neo and SFFVp env (BRIE) specific probes.
Most of the integrated copies were of the correct size (as coapared 
to the SstI digested plasaid pMF16, which was run as a control). 
However, there were also cell lines which contained altered integrated 
viral DNA copies, aostly with deletions, which had probably arisen as a 
product of the transfection and recombination events leading to 
aberrant proviruses (Figure 42). Froa this analysis, five cell lines 
froa each group (i.e. RATI, psi-2 or PA317), containing the correct 
sized genome were catalogued frozen and stored in liquid nitrogen. The 
remaining cell lines were discarded.
ii) Expression of neo* SFFVp functions in fibroblasts
RNA isolated froa neo* SFFVp fibroblasts (PA317, psi-2 and RATI) was 
analysed to confira the correct transcription and processing of the 
neo* SFFVp construct.
PA317 and psi-2 cell lines having high reverse transcription titres 
were analysed (clones PA317 neo* SFFV #5, psi-2 neo* SFFVp 111 and 
psi-2 neo* SFFVp 16). Froa this analysis it can be seen that both full 
genoaic viral RNA (appr. 8 kb, seen upon hybridisation with env) as 
well as spliced env specific subgenomic RJ)A were detected in the 
northern blots shown in Figure 43 (Bilello et al., 1980). It can be 
seen however that one of the RATI non-producer clones, (RATI neo* SFFVp 
18a) synthesized considerable amounts of genoaic and subgenoaic RNA.
Due to this observation and also to the nature of the experiaents
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Figure 42. Southern blot analysis of neo» SFFVp infected RATI clones
Genomic DNA (10 pg) was digested to completion with SstI before being 
subjected to agarose gel electrophoresis and Southern blotting.
The filter was hybridised with either a neo (A) or an env specific 
(BRIE) 32P labelled probe (B).
Lane a: 
Lane b: 
Lane c: 
Lane d: 
Lane e: 
Lane f: 
Lane g: 
Lane h:
neo« SFFVp plasmid DNA (pMF16, 80 pg). 
RATI.
RATI neo« SFFVp Ila.
RATI neo« SFFVp 12.
RATI neo« SFFVp 14.
RATI neo« SFFVp 15.
RATI neo« SFFVp |6 .
RATI neo» SFFVp |8a.
The numbers to the left represent molecular weight markers in kb.
lane N.
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Figure 43. Nothern blot analysis of neo» SFFVp infected producer and 
non-producer cell lines
In this analysis 1 pg of polyA* RNA from each of the cell lines was 
electrophoresed on a 1.0% MOPS gel as described in Materials and 
Methods. After blotting onto Gene Screen Plus the RNA was hybridised 
with an env (BRIE) specific probe, which detects both genomic mRNA as 
well as the spliced env mRNA.
Lane a: F4-6.
Lane b: RATI.
Lane c: PA317 neo“ SFFVp *5.
Lane d: psi-2 neo“ SFFVp 111.
Lane e: psi-2 neo“ SFFVp 16.
Lane f: RATI neo“ SFFVp |8a.
After removing the env probe, and hybridising with a neo specific probe 
only the genomic band was detected (data not shown).
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planned, (see later) most of the effort vas concentrated on the RATI 
non-producer cell line RATI neo* SFFVp I8a, however, where parallel 
experiments were performed with PA317 or psi-2 clones, the data will be 
presented.
iii) Co-expression of the selectable marker and of the env related 
qp55 gene in fibroblasts
Co-expression of both genes, the selectable aarker gene and the env 
gp55 gene was examined in order to exclude cross-interference of 
virally coded functions as has been reported for other vectors 
(Bandyopadhyay and Temin, 1984; Eaeraan and Teain, 1984).
In addition it was desirable to generate a neo* SFFVp producer cell 
line which could be utilised as a source of virus for infection of Bice 
in order to establish the pathogenicity of the neo* SFFVp construct.
The non-producer RATI cell clone 18a (which contains a single intact 
vector genome, which is transcribed) was infected with aolecularly 
cloned F-NuLV virus (RATI, pcl-5 1L#6), as a helper virus. At time 
intervals of three days, supernatants were removed from the 
RATI neo* SFFVp |8a+H (where H stands for helper virus) cell culture 
and assayed for reverse transcriptase activity. After ten days, this 
cell line was then tested for the titre of neo* SFFVp virus being 
released, in the Geneticin transfer assay. The results of these 
experiments are depicted in Table 8 , together with the titres being 
released from psi-2 and PA317 clones, having the highest reverse 
transcriptase titres.
From this analysis it can be seen that, the RATI neo* SFFVp |8a+H 
cell line releases high titres of neo* SFFVp (1.5 x 10* GTU/ml) whereas 
the psi-2 and PA317 cell lines released only moderate titres (1 x 10* -
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Table 8 . GTU titres released by neo* SFFVp infected cell lines
Cell Line GTU/ml being released into
tissue culture supernatant*
RATI neo* SFFVp #8a+H 1.5 X 1 0*
psi- 2 neo* SFFVp « 1 1 X 1 0*
psi- 2 neo* SFFVp 16 5 X 1 0*
psi- 2 neo* SFFVp 17 2 X 1 0»
psi- 2 neo* SFFVp » 1 1 3 X 1 0®
psi- 2 neo* SFFVp 117 1 X 1 0»
PA317 neo* SFFVp »5 2 X 1 0 3
PA317 neo* SFFVp 19 2 X 1 0*
* The GTU assay was performed on RATI fibroblasts as described in 
Materials and Methods.
Results represent the mean of dilutions performed in triplicate.
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5 x 10« GTU/ml) .
These G418 resistant cell lines were then tested for expression of 
the env glycoprotein gp55. 3 8 S-*ethionine labelled cell lysates were 
immune precipitated with a goat anti-Friend virus antiserum. The Friend 
cell line F4-6 which releases high titres of F-SFFVpM was used as a 
positive control, along with RATI pcl-5 1LI6, which is a F-MuLV 
producer cell line (Figure 44). In this analysis it can be seen that 
the positive control, F4-6 (lane c) synthesized high levels of gp55 (as 
well as gp70 and Pr85). This is not unexpected, for SFFV infected 
Friend cells are known to synthesize gp55 at much higher levels than 
SFFV infected fibroblasts (Bilello et al., 1980). Considerable amounts 
of gp55 are also present in the RATI neo“ SFFVp cell lines (|8a, lane b 
and |8a+H, lane j). Also seen in the RATI neo“ SFFVp |8a+H cell line 
are the F-MuLV specific gp70 and Pr85 env gene products, which are also 
seen in the RATI pcl-5 1LI6 (F-MuLV infected) cell line (lane d).
The psi-2 cell lines analysed here, synthesize barely detectable 
amounts of gp55, with psi-2 neo“ SFFVp 16 producing the largest amounts 
(lane f). The gp70 molecules seen in the psi-2 cell lines originate 
from the defective Mo-MuLV genome integrated in the cell lines.
iv) neo“ SFFVp is stabilv transferred in vitro
Although the cell line RATI neo“ SFFVp #8a+H contains a single stably 
integrated proviral genome, which is transcribed to give the correct 
gene products (i.e. G418 resistance and gp55 synthesis) and also 
releases virus which is able to confer G418 resistance to infected 
cells (as seen from the GTU titres), it was important to see whether 
the virus being transferred was stable. To test this, virus released by 
the cell line RATI neo“ SFFVp |8a+H was used to reinfect RATI cells to
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Figure 44. Immune precipitation analysis of neo“ SFFVp infected cell 
lines. Dual expression of G418 resistance and qp55.
Cell lysates from 38S labelled cells (3 h labelling), were immune 
precipitated with a goat anti-Friend virus antiserum (provided by 
P. Nobis, University of Hamburg). The precipitated proteins were then 
resolved on a 10-30% SDS gradient gel, which after completion of 
electrophoresis, was prepared for fluorography as in Materials and 
Methods. After drying the gel was exposed to Kodak X-omat A film at 
-70°C, after pre-flashing.
Lane a: 
Lane b: 
Lane c: 
Lane d: 
Lane e: 
Lane f: 
Lane g: 
Lane h: 
Lane i: 
Lane j:
psi- 2
RATI neo“ SFFVp |8a 
F4-6
RATI pcl-5 1LI6 
psi-2 neo“ SFFVp |1 
psi-2 neo“ SFFVp 16 
psi-2 neo“ SFFVp |7 
psi-2 neo“ SFFVp 111 
psi-2 neo“ SFFVp 117 
RATI neo“ SFFVp |8a+H
The numbers to the left represent protein molecular weight markers in
kd, lane M.
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obtain a series of secondarily infected (and G418 selected, 400 119/ml) 
neoB SFFVp cell lines at end point dilution. The neoB SFFVp virus 
integrated proviral DNA genome was then analysed in 25 of these clones 
by Southern blotting to test the stability of the neoB SFFVp on viral 
transfer. Digestion of these DNAs with SstI and hybridisation with the 
neo probe, showed that all viruses were of the correct size (data for 
14 of these clones are shown in Figure 45). All of these clones also 
showed expression of gp55 as determined by western blot analysis, (data 
not shown).
c) NeoB SFFVp induces an acute ervthroid hyperplasia identical to that 
caused by wild type SFFVp
All previously tested selectable SFFV vectors had grossly altered 
biological properties when tested in vivo (Joyner and Bernstein, 1983; 
Hess, 1985). The genome of virus rescued after such infections was 
rearranged and as a consequence of that the virus no longer dually 
expressed the selectable marker gene and transforming functions. Thus 
to analyse this aspect and also to see whether the neoB SFFVp could 
induce a disease which was indistinguishable from the wild type SFFV, 
susceptible mice were infected with virus (neoB SFFVp+ F-MuLV) being 
released from the cell line RATI neoB SFFVp |8a+H. Filtered 
supernatants (0.45 pm) containing virus were injected intravenously in 
serial 5 fold dilutions into groups of six DBA/2J female mice. These 
virus dilutions were also titrated in vitro in the GTU assay to 
determine the number of viable (i.e. conferring G418 resistance to 
infected cells) neoB SFFVp virions being transferred.
The prototype SFFV of the Friend cell line F4-6 was injected as a 
positive control. Eleven days p.i., the mice were sacrificed, spleens
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Figure 45. Southern blot analysis of G418 resistant RATI clones
infected with virus released from RATI neo« SFFVp I8a-H. 
neo« SFFVp is stabilv transferred.
High molecular weight genomic DNA (10 jig) from individual G418 
resistant RATI clones was digested with Sstl. After electrophoretic 
separation of the digested DNA fragments and subsequent Southern 
blotting the filter bound DNA was hybridised with a 32P radiolabelled 
neo specific probe.
The analysis of 14 of the 25 clones are shown below although the 
remaining 1 1 clones displayed identical results.
Lane a: RATI neo« SFFVp #8a-H.
Lane b: to lane o: neo« SFFVp infected RATI clones.
The numbers to the left represent the molecular weight markers in kb
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were removed, weighed and fixed in 70% ethanol, prior to the counting 
of foci. All mice infected with neoB SFFVp showed grossly enlarged 
spleens with numerous foci (Figure 46; Table 9). Comparison, with the 
unmodified SFFV being released from F4-6, show that neo* SFFVp induces 
pathological symptômes indistinguishable from those of the wild type 
SFFV. Indeed histological examination of both neoB SFFVp and wild type 
SFFV infected spleens displayed identical features, mainly massive 
infiltration of erythroblasts into the red pulp of diseased spleens 
(Figure 47) as is typical for mice infected with SFFVp.
d) neoB SFFVp infected ervthroid precursor cells are increased, do not 
require erythropoietin for colony formation and are resistant to 
qeneticin (G418)
It has already been shown, that in neo1 SFFVp infected fibroblasts 
there was co-expression of G418 resistance and synthesis of SFFV coded 
gp55. It was thus important to obtain evidence for co-expression of 
SFFV env transforming properties and geneticin resistance in erythroid 
target cells, in vivo. Two transformation properties can easily be 
tested in neoB SFFVp infected mice. Expansion of erythroid precursor 
cells and erythroid proliferation in the absence of the normally 
required hormone erythropoietin. Erythroid colony formation in vitro of 
in vivo infected spleen cells can be utilised to test for these 
properties.
Adult DBA/2J female mice were inoculated either with 5 x 103 SFFU/ml 
prototype SFFV supernatant (F4-6) as a positive control or 2 x 109 GTU 
equivalent of neoB SFFVp. After eleven days p.i. mice were sacrificed, 
spleens removed and cell homogenates were plated out at various 
densities in methylcellulose in the presence or absence of
I
4
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Figure 46. neo* SFFVp is able to cause an acute splenomegaly with 
discrete spleen foci in susceptible mice
Eight week old DBA/2J female «ice were inoculated (i.v.) with either 
FV-P being released from F4-6 (5000 SFFU) or neo* SFFVp being released 
from RATI neo« SFFVp f8a+H (1 x 10# GTU).
Eleven days post infection mice were sacrificed and the spleens were 
removed, and stored in 70% ethanol.
a) Uninfected spleen.
b) F4-6 wild type SFFVp (1:125 diluted).
c) F4-6 wild type SFFVp (undiluted) .
d) neo« SFFVp (1:125 diluted).
e) neo* SFFVp (undiluted).
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Figure 47. Histopathological analysis of spleens from neo* SFFVp 
infected mice
All sections were prepared as outlined in Materials and Methods and 
after staining were photographed at either 25x or 40x magnification.
A. Uninfected spleen (25x). A section showing the red pulp of the 
spleen in which very few large blast cells can be seen. Areas of active 
erythropoiesis can be seen (E) which give rise to fully differentiated 
blood cells (erythrocytes, ery).
B. F4-6 infected spleen eleven days post infection (25x). The section 
demonstrates the presence of large numbers of erythroid blasts (Eb) and 
normocytes (N). Very little fully differentiated erythropoiesis is 
seen.
C. F4-6 infected spleen eleven days post infection (40x). The heavily 
staining cells represent normocytes (N) and the larger cells represent 
erythroid blasts (EB).
D. neoB SFFVp infected spleen eleven days post infection (25x). This 
picture shows a similar pattern as shown in B.
E. neo* SFFVp infected spleen eleven days post infection (40x).
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erythropoietin and G418 and erythroid colonies (CFU-E) were counted 
after 48 h (Table 10).
CFU-E in the spleens of mock infected «ice required, as expected, the 
presence of exogenously added erythropoietin. Addition of G418 (1.5 
mg/ml) to the culture nedim inhibited the formation of these CFU-E 
colonies. Those few colonies that survived were smaller than regular 
CFU-E with only a small fraction of these colonies being benzidine 
positive (B*) (Figure 48). 1.5 mg/ml G418 thus inhibited, within two 
days the development of late erythroid colonies. This is an observation 
that is not entirely unexpected if toxicity of geneticin is related to 
active metabolism and/or cell division. Late erythroid progenitors are 
known to be fast replicating cells, passing through an average of 7 
cell divisions within two days to generate colonies of more than 10 0 
cells.
Infection of mice with wild type SFFVp (F4-6) yielded an enormous 
increase in the number of CFU-Es which proliferated in the absence of 
exogenously added erythropoietin as expected. The number of CFU-Es 
scored either in the presence or absence of erythropoietin was always 
significantly lower when cultured in the presence of G418. Almost all 
of the CFU-Es were benzidine positive (B*) if no G418 was added, 
however in the presence of 1.5 mg/ml G418, colonies were much smaller 
than those of uninfected controls. They did not differentiate to 
synthesize haemoglobin and were thus benzidine negative (B~), again 
like G418 treated control CFU-E.
Infection of mice with neo* SFFVp resulted in an enormous increase of 
late erythroid precursor cells in the spleens of infected mice. These 
CFU-E did not require erythropoietin. CFU-Es of these infected animals, 
in contrast to controls were resistant to G418 and gave rise to large
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Figure 48. CFU-E induced by neo* SFFVp are erythropoietin independent 
and G418 resistant.
CFU-E colonies from the experiments depicted in Table 10 were 
photographed under 16x magnification, in cultures containing G418 and 
after benzidine staining.
A: Uninfected spleen CFU-E stained with benzidine in the presence of 
G418.
B: F4-6 infected spleen CFU-E stained with benzidine in the presence of 
G418.
C: neoR SFFVp infected spleen CFU-E stained with benzidine in the 
presence of G418.
In these photographs the benzidine positive (B* ) colonies appear darker 
than the benzidine negative (B-) cells although under the microscope 
the staining (i.e. blue for B*) is more obvious.
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Figure 48. CFU-E induced by neoB SFFVp are erythropoietin independent 
and G418 resistant.
CFU-E colonies from the experiments depicted in Table 10 were 
photographed under 16x magnification, in cultures containing G418 and 
after benzidine staining.
A: Uninfected spleen CFU-E stained with benzidine in the presence of 
G418.
B: F4-6 infected spleen CFU-E stained with benzidine in the presence of 
G418.
C: neo* SFFVp infected spleen CFU-E stained with benzidine in the 
presence of G418.
In these photographs the benzidine positive (B*) colonies appear darker 
than the benzidine negative (B-) cells although under the microscope 
the staining (i.e. blue for B* ) is more obvious.
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colonies, with up to several hundred cells. Almost all of the CFU-E 
synthesized haemoglobin in the presence of G418 and were thus B* in 
contrast to uninfected CFU-E or CFU-E infected with the prototype SFFV 
(Table 10; Figure 48). All CFU-E must have been infected with 
functional neoB SFFVp conferring both erythropoietin independence and 
G418 resistance to the CFU-E cells.
e) Stability of neoB SFFVp after serial in vivo passage
Co-expression of the neomycin resistance gene (neoB) and the gp55 
gene of SFFV, the latter of which is required for erythroid precursor 
cell transformation, was detected in all fibroblasts infected with neoB 
SFFVp virus, even after viral passage. The data with CFU-E colonies in 
neoB SFFVp infected mice, indicated that the majority, if not all, of 
the CFU-Es expressed coordinately growth factor independence and G418 
resistance in contrast to previous SFFV vectors. To further confirm 
co-expression of the neoB marker and the transforming gene (gp55) in 
virus infected transformed cells, mice were infected with neoB SFFVp, 
and the virus was retested, after serial in vivo passage by the 
criteria outlined below.
Mice infected with neoB SFFVp were sacrificed eleven days p.i. and 
the spleens were removed and homogenised to give a single cell 
suspension. The cells were then pelleted and the resulting supernatant 
was titrated for virus activity both in vivo (spleen focus formation) 
and in vitro (GTU assay). From the cell fraction, DNA and protein was 
prepared for detailed analysis. The results of these experiments are 
shown in Table 11 and Figure 49.
Spleen passaged neoB SFFVp always conferred G418 resistance to 
infected fibroblasts and induced the erythroid hyperplasia as expected.
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Figure 49. Serial passage of neo* SFFVp in vivo
a) Southern blot analysis of spleen genomic DNA after serial passage of 
neo* SFFV in DBA/2J mice. Genomic DNA (10 pg) was digested with SstI 
and then analysed by Southern blotting and hybridisation to a neo 
specific probe.
Lane a: neo* SFFVp plasmid DNA (pMF16, 80 pg) .
Lane b: DBA/2J spleen DNA.
Lane c: neo* SFFVp passage 1 spleen.
Lane d: neo* SFFVp passage 2 spleen.
Lane e: neo* SFFVp passage 3 spleen.
The numbers to the left represent molecular weight markers in kb, 
lane N.
b) Western blot analysis of serially passaged spleen and control cell 
lines. Protein extracts were separated by SDS-PAGE before being 
transferred to Gene Screen Plus and probed with a goat anti-Friend 
virus antiserum.
Lane a: F4-6 infected spleen.
Lane b: F4-6.
Lane c: RATI neo* SFFVp |8a+H.
Lane d: neo* SFFVp passage 1 spleen.
Lane e: neo* SFFVp passage 2 spleen.
Lane f: neo* SFFVp passage 3 spleen.
Lane g: DBA/2J spleen.
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c) Neoaycin phosphotransferase assay.
Lane a: DBA/2J spleen.
Lane b: neo* SFFVp spleen passage 1.
Lane c: neo* SFFVp spleen passage 2.
Lane d: neo* SFFVp spleen passage 3.
Lane e: F4-6 infected spleen.
Lane f: RATI neo* SFFVp #8a+H.
For this analysis 100 pg aliquots of protein were assayed for 
functional neoaycin phosphotransferase as described in Materials and 
Methods.
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However, surprisingly an altered ratio of GTU transfer to fibroblasts 
and of spleen focus formation in the animal after one passage was seen 
in all experiments. The relative spleen focus forming capacity 
(SFFU/GTU) of the neo" SFFVp was thus increased (Table 11).
The reasons for the biological alterations induced in neo* SFFVp 
after passage in vivo are unclear, although no gross alterations at the 
DNA proviral genome level could be detected. Southern blot analysis of 
infected spleen cells showed predominantly an 8 kb band which 
hybridised to a neo specific probe after digestion with the restriction 
enzyme SstI (Figure 49a). No aberrant hybridising bands were detected, 
thus the majority if not all of the integrated neo* SFFVp copies were 
of the correct size.
Levels of gp55 expression were comparable to those found in F4-6 
virus infected spleens as shown by western blot analysis depicted in 
Figure 49b. Neomycin phosphotransferase enzyme analysis of infected 
spleens showed that the neo gene was also being transcribed and 
translated in vivo (Figure 49c) . This analysis suggested that no 
segregation had occured between the neo and the env gene although it 
could not be ruled out that such infected spleens did indeed contain 
subsets of virus expressing only the neo gene or alternatively the 
env (gp55) gene.
To analyse this point in further detail, end point dilution of 
neo* SFFVp virus was made on fibroblasts utilising G418 as a selectable 
marker for detecting neo* SFFVp infected cells. G418 resistant 
fibroblast non-producer clones obtained from these end point dilutions 
of in vivo passaged virus were grown up and analysed for gp55 
expression and integrity of the integrated proviral DNA genome. All of 
the 30 clones, which had one full sized copy of the neo* SFFVp virus as
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seen by Southern blot analysis also expressed gp55 (Figure 50).
Virus rescued from these clones and used to infect DBA/2J mice 
generated leukaemia and displayed the same altered SFFU/GTU ratio 
(Table 12).
These data reinforced the interpretation that co-expression of the 
neoR and gp55 genes were stable functions of the neoR SFFVp virus, 
although mutations leading to alterations of gene expression 
(presumably) occured and were selected during mouse passage to confer 
maximal transformation potential.
f) NeoR SFFVp can be used to generate permanent Friend leukaemia cell 
lines which are resistant to G418
Although it is possible to establish transplantable cell lines from 
tissues infected with SFFV in the later stages of the disease, most of 
the proliferating cells early in the disease have a limited self 
renewal capacity and fail to grow in syngeneic donor mice or as cell 
lines in vitro. Tambourin and Wendling (1971) therefore proposed that 
the disease induced by SFFVp consists of multiple stages:
i) an early stage in which the accumulating erythroid precursor cells 
have a limited life span and the size of this proliferating compartment 
is controlled by removal of excessively proliferating cells,
ii) a late stage (more than three weeks) in which truly malignant cells 
proliferate and are capable of autonomous and tumourigenic growth in 
vivo.
The reasons for the emergence of the malignant cells are still 
obscure, even though a requirement for SFFV expression has been shown 
(Wolff et al.. 1986; Ostertag et al., 1987).
It was thus decided to examine the potential of neoR SFFVp in
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Figure 50. Southern blot analysis of G418 resistant RATI clones after 
end point dilution of in vivo passaged neo“ SFFVp
Genomic DNA (10 pg) from end point dilution RATI clones was digested 
with Sstl prior to agarose gel electrophoresis and Southern blotting. 
The filter bound DNA was then hybridised with a 3aP radiolabelled neo 
specific probe.
The analysis of 16 (from a total of 30) clones is depicted below.
Lane a: to lane p: neo“ SFFVp infected RATI clones (pi to pl6 ).
Lane q: RATI neo“ SFFVp |8a+H.
2 2 9
Table 12. Biological properties of in vivo passaged neo® SFFVp 
released by clones after end point dilution
_____ neo* SFFVp virus release gp55
Clone GTU/ml SFFU/ml SFFU/GTU expression
pl 1 X 10® 9 X 10® 0.09 ♦
P2 3 X 10® 3.3 X 10® 0.11 +
p3 1 X 10® 1.2 X 10® 0.12 *
P4 8 X 10® 1.3 X 10® 0.16 *
p5 7 X 10® 5.6 X 10® 0.08 <■
p6 1 X 10® 1 X 10® 0.1 +
P7 8 X 10® 7.2 X 10® 0.09 *
p8 9 X 10® 1 X 10® 0.11 +
p9 3 X 10® 3.9 X 10® 0.13
plO 2 X 10® 2.8 X 10® 0.14
•30
transforming erythroid precursors to malignancy in order to test 
questions related to malignancy and co-expression of SFFV function and 
differentiation.
DBA/2J mice were infected with 1 x 10* GTU neo“ SFFVp (from the cell 
line RATI neo“ SFFVp |8a+H) i.v.. After 3-4 weeks, surviving mice were 
sacrificed, the spleens were removed, and cellular homogenates were 
prepared. Cells were plated at a density of 5 x 10°/ml in GMEM +
10% FCS, and were fed at 3 day intervals by removing part of the cell 
culture medium and replacing with new medium. After 2-4 weeks clones 
appeared and expanded at a fast rate. From six mice eight uncloned 
Friend cell lines (NF1 to NF8) were obtained. All of these cell lines, 
when cultured in medium supplemented with 2 mg/ml G418 (a concentration 
which is toxic for Friend cells, i.e. F4-6, B8/3), were resistant to 
the drug.
Further analysis of these Friend cells (Table 13) demonstrated that 
they all had a high cloning efficiency in agar, (in the presence of 
2 mg/ml G418) a property of normal FLC.
Southern blot analysis of genomic DNA isolated from these cell lines, 
digested with SstI yielded fragments consistent with the presence of 
only full length virus in most cell lines, after hybridisation with neo 
(Figure 51). Western blot analysis also revealed that gp55 was being 
synthesized in large amounts in these cell lines.
Titration of tissue culture supernatants, from the cell lines 
NF1 to NF8 , in the GTU assay showed that between 1 x 103 and 1 x 10‘ 
GTU/ml of neo“ SFFVp virus was being released (Table 13), whose 
biological activity was identical to that of the neo“ SFFVp virus 
passaged in mice, and differed in the SFFU/GTU ratio from the original 
vector virus (RATI neo“ SFFVp |8a+H, Table 11).
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Figure 51. Southern blot analysis of G418 resistant Friend cells
Genomic DNA (10 |ig) from all Friend cell lines was digested with SstI 
before being analysed by agarose gel electrophoresis and Southern 
blotting. The filter was then hybridised with a neo specific 32P 
labelled DNA probe.
Lane a: RATI neo* SFFVp |8a+H.
Lane b: neo* SFFVp plasmid DNA (pMF16,
Lane c: DBA/2J spleen.
Lane d: F4-6.
Lane e: NF-1.
Lane f : NF-2.
Lane g: NF-3.
Lane h: NF-4.
Lane i : NF-5.
Lane j: NF-6 .
Lane k: NF-7.
Lane 1 : NF-8 .
The numbers to the left represent molecular weight markers in kb.
lane N.
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All of these cells could also be stimulated (to varying degrees) to 
differentiate and synthesize haemoglobin in the presence of DNSO 
(1.5%, Table 13).
Discussion
The study of the specific cellular interaction of the SFFV coded 
glycoprotein requires experiments with defined erythroid target cells. 
These are only possible if selectable SFFV vectors can be utilised. 
Construction of selectable SFFV vectors have encountered unexpected 
difficulties utilising the SFFV genome alone (Joyner and Bernstein, 
1983; Ostertag et al., 1987). Some of the constructs were unstable, 
some others showed lack of co-expression of the selectable marker gene 
and of gp55. In this study a selectable retrovirus vector, neo* MPSV 
was used as a base to construct a hybrid viral vector with the SFFV env 
gene and the SFFV U3 region (neo* SFFVp) of the LTR. This vector 
induced erytbroleukaemia in animals, co-expressed the marker gene and 
the gp55 gene in fibroblasts and the marker gene and transforming 
functions in progeny of in vivo infected single erythroid precursor 
cells.
The only features of SFFV which are essential for retaining specific 
transformation potential, are the SFFV env region, including the env 
splice acceptor sequence of SFFV, together with the U3 region of the 
LTR. All other sequences within this virus originate from a NPSV 
vector, which has been shown to have no leukaemogenic effects both in 
vitro and in vivo, and is only able to transfer neo* to fibroblasts 
(Stocking et al., 1985). This is an agreement with the data of others, 
who utilised an alternative approach. They retained as a base SFFV but
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selected for env gene autants, which could not induce erythroid 
transformation (Rabat et al., 1980; Ruta et al., 1983; Machida et al., 
1984, 1985a,b). These studies, however did not define SFFV sequences 
which aay contribute to the high expression of gp55 in erythroid cells 
leading to transformation and the lower expression found in fibroblasts 
(Bilello et. al.., 1980; Ostertag et. al., 1987). The elevated expression 
of gp55 in erythroid cells appears to be due to the large amounts of 
spliced env mRNA which is found in erythroid cells but not in 
fibroblasts (Bilello et al., 1980). It may also be that the elevated 
expression of SFFV in erythroid cells is due to the U3 region 
(containing the enhancers), which may have an erythroid tissue 
specificity, as has been shown for F-MuLV (Bosze et al., 1986).
However, data (Wolff and Ruscetti, 1986) have shown that the 
pathogenicity of SFFVa is not dependent upon the LTR. However in these 
experiments, no expression studies per se were performed.
It may be interpreted that high expression and biological activity 
are determined by the env region, for the 3' region of the virus, 
including the env splice donor is derived from MPSV in this construct. 
Presence of the neo* gene in the intron region which is also MPSV 
derived appears not to be responsible for high expression of gp55 in 
erythroid cells, although in the study of Joyner and Bernstein (1983b) 
deletion of sequences 3* to the env gene disrupted expression of gp55.
It would thus appear that either the env splice acceptor of SFFV or 
the gp55 gene itself is crucial for high erythroid expression of the 
SFFV genome. Replacement of the gp55 coding region and insertion of a 
reporter gene could distinguish between these alternatives.
The studies reported here, however, do not only contribute to the 
question which regions of SFFV are essential and which are contributory
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to the specific inclusion of proliferation of erythroid precursor 
cells, they also open for the first time a way to define the target 
cell interactions required to elicit the SFFV specific erythroid 
response.
The biological activity of the neo* SFFVp as compared to the wild 
type SFFVp is indistinguishable in every respect, including time course 
of the disease and organ involvement.
The dysfunction of CFU-E colonies (with respect to cell metabolism, 
i.e. haemoglobin production) in the short term CFU-E assay also 
potentiates the usefulness of this construct in defining the target 
cell for SFFVp.
This problem can now be approached utilising the selectable neo*
SFFVp described, in single haemopoietic precursor cell infections. For 
these experiments the helper free psi-2 and PA317 cell lines could be 
used. However, these cell lines do not produce very high titres (Table
8) although extended cell culture and selection could probably better 
the situation.
Although serial passage of neo* SFFVp in adult DBA/2J mice results in 
no segregation of neo and gp55 expression or gross rearrangements of 
the viral genome, the fact that the SFFU/GTU ratio increases after one 
passage in vivo and that this ratio remained stable for the next two 
passages suggests that some form of selection had occured in the mouse, 
for a neo* SFFVp that is able to confer G418 resistance and cause 
spleen foci more efficiently.
The second type of erythroid cell which is altered as a consequence 
of SFFVp infection is the transplantable tumour cell, which can also be 
passaged in vitro. These cells are arrested in differentiation in 
contrast to the undefined CFU-E precursor cells which differentiate
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regardless of the presence of erythropoietin if infected by SFFVp in 
vitro.
Transformation of these cells requires the interaction of at least 
two mutations in the FLC. One is the requirement for SFFV expression 
and a second event which may be related to integration of SFFV or the 
helper virus close to sequences that result in a block in 
differentiation and/or immortalisation (Ostertag and Pragnell, 1982; 
Ostertag et al., 1987).
Reports by several groups have shown in a variety of Friend cell 
alterations in expression and structure of the p53 locus (Ruscetti and 
Scolnick, 1983; Shen et al., 1983; Rovinski et al., 1987). This could 
possibly be due to integration of SFFV near to one of the alleles, thus 
leading to dysfunction of p53, which is thought to be important in the 
control of the cell cycle (Rovinski et al.. 1987). However, a second 
fraction of FLC are not altered in the expression of p53. The question 
then remains whether p53 activation is the primary event in causing 
malignancy or just a consequence of later mutations in the course of 
malignant progression. Recently, study of the integration sites of SFFV 
using an oligonucleotide probe (Moreau-Gachelin et al., 1986) has led 
to the finding that SFFVp integrates near to a putative oncogene Spi-1 
in 95% of the tumours caused by this virus. Due to the prokaryotic 
nature of the neomycin gene, the neo* SFFVp described provides a useful 
opportunity to analyse further the integration of SFFV in transformed 
FCLs which were obtained in this study.
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Introduction
The studies described in the previous chapter described the 
construction of a biologically active selectable F-SFFVp retroviral 
vector. Apparently from these studies only the env gene (gp55) in 
combination with the U3 region of F-SFFVp alone was required to cause 
pathological symptoms indistinguishable from the wild type F-SFFVp. 
Earlier studies which came to the same conclusion (Linemeyer et_ al., 
1982) did however not exclude a role of the LTR in generating or 
reinforcing disease specificity. It has been shown that the U3 region 
of the MPSV LTR is crucial for expansion of the host range of this 
acutely oncogenic virus to some embryonal carcinoma cell lines (Hilberg 
et al., 1987) and for generating the MPSV specific myeloproliferative 
disease (Stocking et al., 1985, 1986). The MPSV U3 region moreover 
confers a higher transcription rate than the corresponding sequences of 
Mo-MuLV in dually permissive cells (W. Ostertag, pers. commun.).
Friend MuLV U3 sequences are required for the erythroid specificity 
of the Friend helper virus induced erythroproliferative disease (Chatis 
et al.. 1984). The LTR of SFFV has retained features of both MCFV and 
F-MuLV (Ostertag et. al., 1987). It was thus interesting to determine 
whether the U3 region of MPSV, which was utilised to generate a hybrid 
selectable neo* SFFVp vector would alter the host range of SFFVp, or in 
view of the increased transcription rates accelerate the erythroid 
disease as compared to that elicited by the standard SFFVp. To this aim 
a new vector was constructed containing the U3 region from MPSV. This 
vector was designated neo* SFFV-M. Similar studies, using the F-SFFVa 
strain (Wolff and Ruscetti, 1986) have shown that replacement of the
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SFFVa LTR with that fro* Mo-MuLV did not alter the pathological outcome 
of the disease per se although no detailed analysis was carried out in 
this study.
Results
a) Construction of neo* SFFV-M
A detailed description of how neo* SFFV-M was constructed is shown in 
Figure 52. In this construct (pMFM#21) the 3* LTR, which was formerly 
of F-SFFVp origin (pMF16, neo* SFFVp) was replaced by the 3' LTR of 
MPSV.
The Bal31 digestion step which was used to remove the F-SFFVp LTR 
sequences, was controlled by sequencing of the digested fragment after 
subcloning into a M13 vector (Figure 52). It can be seen from the 
sequence that all of the F-SFFVp LTR sequences had been removed without 
disturbing the gp55 coding sequence. The MPSV 3* LTR (subcloned as a 
Hindlll fragment in pUC9, see Figure 53) from molecularly cloned MPSV 
has a partial pl5E sequence 5' to it. However this sequence is 
separated from the stop codon in gp55 by a short sequence, 
corresponding to the polylinker cloning sequence from p(JC19. From 
sequence data these sequences would not be translated even if the gp55 
stop codon was overread. Thus neo* SFFV-M is exactly the same as neo* 
SFFVp except that the 3' LTR along with a small coding region 5’ to it 
are of MPSV origin. In this vector the only sequences which are of F- 
SFFVp origin are the splice acceptor sequence and the gp55 coding 
sequence itself.
( pMF 16 ) neo0 SFF V
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Figure 52. Construction of the retroviral vector, neo* SFFV-M
The retroviral vector neo* SFFV-M (pMFM21), which differs from the 
original neo* SFFVp vector, in that the 3' LTR is of MPSV origin, was 
constructed as follows.
Due to the absence of usable restriction enzyme sites within the 
non-coding region between the COOH terminus and the start of the SFFVp 
LTR, the LTR sequences were deleted by using the endonuclease Bal31.
For this purpose, an EcoRI-PstI fragment encompassing the COOH terminus 
of env (gp55), the entire LTR and gag sequences of SFFVp origin, (from 
neo* SFFVp, pMF16) was subcloned into pUC19 to give the plasmid pRPEL. 
This plasmid was then digested with SstI (which cuts within the LTR), 
and the resulting free ends were digested with Bal31. under the 
appropriate conditions. After preparation of blunt ends with Klenov, 
and EcoRI digestion of the Bal31 treated plasmid, fragments of the 
correct size (according to sequence data appr. 500 - 600 bp) were 
collected after electrophoretic separation.
These fragments were then cloned into EcoRI.Smal digested pUC19. The 
resulting recombinants were then screened, after digestion with EcoRV 
and BamHI for inserts of appr. 220 bp. One such clone pEL-, had an 
EcoRV.BamHI insert of appr. 220 bp and was used for further analysis. 
The EcoRV.BamHI insert was subcloned into M13mpl8, and subsequently 
sequenced as outlined in Materials and Methods.
This sequence analysis revealed that all of the LTR sequences had been 
removed, without disturbing the env coding region (see Figure 53). pEL- 
was then digested with Hindlll and a Hindlll fragment, encompassing a 
portion of the pl5E sequence, the MPSV 3' LTR as well as genomic
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flanking sequences (3' to the LTR), was ligated into pEL- to give rise 
to a new recombinant plasmid pNFN'.
pMFM' was digested with EcoRI and an EcoRI fragment from pMF16, 
delineating the 5' LTR (from MPSV), neo gene and the 5' env sequences 
was ligated into pMFM' to give rise to pMFM21 (neoR SFFV-M).
The restriction enzyme single lettering code is
B, BamHI; Bg, Bglll; C, Clal; H. Hindlll; K, Kpnl; P, PstI; R, EcoRI; 
S, SstI; Sa, Sail; Sp, SpHI; X, Xbal; Xh, Xhol.
^  Splide donor.
• Splice acceptor.
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Figure 53. Nucleotide sequence analysis of pEL- 
Shown are the nucleotide sequences of:
1) env: This sequence represents the COOH terainus (the last two aaino 
acids) of the env gene used for the construction of pEL-.
3' to the COOH terainus is the untranslated sequence which is 5' to the 
3' LTR.
2) pEL-: This sequence represents the Bal31 digestion analysis and thus 
shows that all of the LTR has been reaoved without altering the env 
(gp55) gene sequence.
3) N13mpl8: This sequence deaonstrates the transition from the M 3  
polylinker (BamHI) to the cloned pEL- sequence.
Hoaologous sequences are joined by
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b) Construction of neo» SFFV-M non-producer and producer cell lines
i) Southern blot analysis
To further test the biological activity of this new construct, 
non-producer and helper independent producer cell lines were 
constructed in a similar manner as described for neo* SFFVp. Transient 
harvests (48 h) of supernatants from transfected psi-2 and PA317 cells 
were used to infect either psi-2 cells or F-MuLV producing NIH3T3 cells 
(3T3+H) . Clones were selected for three weeks in GMEM + 10% FCS 
supplemented with 400 pg/ml G418. Southern blot analysis of SstI 
digested genomic DNA from individually picked clones (both psi-2 and 
3T3+H) revealed that about 50% of the neo* SFFV-M infected clones 
contained stably integrated viruses of the correct size (Figure 54) . 
Further analysis of these clones revealed that virus titres (expressed 
as GTU/ml) of up to 10* GTU/ml were being released (Table 14).
ii) Coexpression of neo* SFFV-M functions in fibroblasts
The cell lines neo« SFFV-M 3T3+HI1, neo« SFFV-M 3T3+HI7 and
neo* SFFV-M 3T3+HI9 (cells of which release a complex of both F-MuLV 
and SFFV-M) which released titres of 10«- 10‘ GTU/ml, were then further 
analysed by western blotting to determine whether gp55 was being 
produced in these cells. The result depicted in Figure 55 indeed shows 
that neo« SFFV-M infected clones synthesize gp55 in comparable amounts 
to that of neo“ SFFVp, although the amounts in neo« SFFV-M 3T3+HI1 were 
barely detectable. The neo* SFFV-M construct is, like the related neo“ 
SFFVp construct, able to confer G418 resistance to infected cells and 
synthesizes detectable amounts of gp55. That these cell lines contained 
a stable single integrated copy of neo* SFFV-M, again shows that there 
has been no segregation between neo* and gp55 expression.
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Figure 54. Southern blot analysis of neo* SFFV-M infected NIH 3T3+H 
and psi-2 clones
Genomic DNA (10 ug) from the individual clones was digested with SstI, 
before being analysed by agarose gel electrophoresis and Southern 
blotting. The filter was hybridised with a 32P labelled neo fragment. 
Lane a: pMFM 121 (80 pg).
Lane b: psi-2.
Lane c: NIH 3T3+H.
Lane d: neo* SFFV-M 3T3+HI1.
Lane e: neo* SFFV-M 3T3+HI3.
Lane f : neo* SFFV-M 3T3+HI5.
Lane g: neo* SFFV-M 3T3+HI6.
Lane h: neo* SFFV-M 3T3+HI7.
Lane i : neo* SFFV-M 3T3+HI8.
Lane i : neo* SFFV-M 3T3+H|8a
Lane k: neo* SFFV-M 3T3+HI9.
Lane 1: neo* SFFV-M psi-211.
Lane m: neo* SFFV-M psi-212.
Lane n: neo* SFFV-M psi-213.
Lane o: neo* SFFV-M psi-214.
Lane p: neo* SFFV-M psi-217.
Lane q: neo* SFFV-M psi-218.
Lane r: neo* SFFV-M psi-215.
Lane s: neo* SFFV-M psi-219.
The numbers to the left represent molecular weight markers in kb,
lane N.
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Table 14. GTU titres being released froa neo* SFFV-M infected cells
Cell Line GTU/ml*
neo* SFFV-M 3T3+HI1 1 X 10s
neo* SFFV-M 3T3+HI5 5 X 10®
neo* SFFV-M 3T3+HI7 1 X 10®
neo* SFFV-M 3T3+HI9 7 X 10®
neo* SFFV-M psi-2#l 1 X 10®
neo* SFFV-M psi-217 1 X 10*
neo* SFFV-M psi-218 3 X 10®
neo* SFFV-M psi-2#9 1 X 10*
* All supernatants titrated on RATI cells as described in Materials and 
Methods. Titres represent the aean of triplicate dilutions.
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Figure 55. Western blot analysis of neo« SFFV-M infected fibroblasts
100 pg samples of protein lysates prepared from the various clones 
were analysed by SDS PAGE in a 10-30% gel system as described in 
Materials and Methods. The separated protein were then electro- 
transferred to a nitrocellulose filter. The filter bound proteins were 
then hybridised with an anti-Friend virus goat anti-serum. Specific 
bands were visualised by incubating with a peroxidase conjugated anti­
goat antiserum.
Lane a: RATI 
Lane b: F4-6
Lane c: neo* SFFV-M 3T3+H 11 
Lane d: RATI pcl-5 1LI6 
Lane e: neo« SFFV-M 3T3+H »7 
Lane f: neo« SFFV-M 3T3+H 19 
Lane g: RATI neo« SFFVp |8a-*-H
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The virus released froa these cell lines was also able to confer G418 
resistance, and underwent no detectable genetic alterations after 
transfer to RATI cells as seen by Southern blot analysis, as described 
for neo* SFFVp (data not shown) .
c) Neo* SFFV-M causes an acute ervthroid hyperplasia in susceptible 
■ice, similar to neo* SFFVp. but with a different kinetics
Fro« the data presented above it appeared that like the neo* SFFVp 
vector neo* SFFV-N was capable of dual expression of G418 
resistance and gp55 synthesis, after stable transfer in fibroblast 
cells. It was thus interesting to see whether the LTR change fro* SFFVp 
to MPSV U3 specific control sequences had any diverse effect upon the 
biology/patbology of this acutely transforming virus. To this end the 
following in vivo experiments were performed.
Serial dilutions of virus being released from the cell lines F4-6 
(which served as an internal positive control) RATI neo* SFFVp |8a-H 
and neo* SFFV-H 3T3I9, were inoculated i.v. into groups of six female 
DBA/2J mice. Eleven days post infection the mice were sacrificed, 
spleens were removed, weighed, fixed in alcohol and the foci were 
counted. The results from this preliminary experiment indicated that 
both neo* SFFVp (as shown previously) as well as neo* SFFV-M induced 
splenomegaly (although to varying extents) and spleen foci (SFFV) if 
the same titre of biologically active virus particles as determined by 
fibroblast GTU (Table 15) was injected. The ratio GTU/SFFU was similar 
for both constructs if mice were sacrificed at 11-16 days post 
infection. However, in a parallel set of experiments, in which the same 
virus inoculums were used, but in which the mice were sacrificed at day 
8-11, the spleen foci, induced by neo* SFFV-H were difficult to score.
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and also the spleen weights were significantly lower as compared to 
neoB SFFVp (or even F4-6), when equivalent virus titres (GTU) were 
inoculated.
To distinguish whether neoB SFFV-M caused a qualitatively identical 
or even a different disease as compared to wild type SFFVp and neoB 
SFFVp, a separate series of mice were infected with the two viral 
constructs as well as the standard SFFVp (F4-6).
At different times post injection (day 4, 9 and 16) mice were 
sacrificed and the spleens were removed for histological study as well 
as for in vitro colony assays. The results of this analysis are shown 
in Table 16 and Figure 56. The erythroproliferative disease, typical of 
SFFVp was observed in all of the animals infected with SFFVp (F4-6, 
neoB SFFVp and neoB SFFV-M). However, the erythroproliferative disease 
caused by neoB SFFV-M (expansion of epo independent and G418 resistance 
CFU-E), was somewhat delayed in the spleens of these infected animals, 
although an equivalent titre was inoculated as compared to neoB SFFVp.
Histological examination of the spleen, showed that all three viruses 
caused an erythroproliferation in the red pulp at early phases post 
infection. At day 16, SFFVp and neoB SFFVp in contrast to neo* SFFV-M 
infected spleens showed already signs of necrosis and a large 
proportion of immature erythroblasts with very little active 
erythropoiesis. Spleens infected by neo* SFFV-M thus had retained a 
similar histological picture at a later phase as compared to the 
pathological picture seen in an earlier phase of the disease, for SFFVp 
and neoB SFFVp thus suggesting also at this level that although the 
same viral titres were being inoculated the disease kinetics were 
indeed notably different. One very interesting observation seen in the 
white pulp of neoB SFFVp and neoB SFFV-M but not SFFVp (F4-6) was the
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Figure 56. The kinetics of the histopatholoqical effects of neo* 
SFFTp and neo* SFFV-« in the spleen of DBA/2J »ice
56.1. Section of an uninfected DBA/2J mouse spleen demonstrating the 
cell content of both the white (VP) and the red pulp (RP) (A. 
photographed at 25x magnification) and a more detailed look at the 
subcapsular region of the red pulp (B, 40x magnification).
Active erytfcropoiemis can be seen (E) in the red pulp as well as 
various differentiation stages in erythropoiesis.
S represents normocytes and !C is the marginal zone.
Sections were stained with Giensa.
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56.2. Day fomrjjnrt infection, (all 25x after staining with 
haemolysin and eosin)
A. SFFVp. A section of the red pulp in which a cluster of erythroblasts 
(Eb) can be seen just below the connective tissue (CT) of the spleen. 
Again areas of active erythropoiesis can be seen (E) .
B. neoB SFFVp. Sect!«» mi 'ttfc* red pulp to demonstrate two foci of 
erythroblast like cells, one focus of which is in the subcapsular space 
of the red pulp. Compared to SFFVp the foci are somewhat larger and 
more numerous.
C. neo* SFFV-M. Foci of erythroblasts are very hard to find and are not 
numerous in the red pulp.
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56.3. Day nine post infection (40x, HE)
A. SFFVp. The pulp is full of erytbroblasts. the foci being 
confluent. IslaMs at normal «rytliropoiesis (£, erythrocytes and 
normocytes) can still ie seen.
B. neo* SFFVp. This section of the red pulp demonstrates that the 
predominant cell types are erythroblasts, with very few normocytes and 
mature erythrocytes, thus demonstrating radical proliferation of 
immature erythroid cells. There is less differentiation as compared to 
the SFFVp and neo* SFFV-M infected mice.
C. neo* SFFV-M. The picture seen here represents an intermediate of the 
above sections. Areas of erythropoiesis can be seen. There is overall 
more differentiation to be seen. Numerous erythroblasts can also be
seen.
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56.4. Day sixteen post infection (25x,, HE)
A. SFFVp. Numerous blasts can be seen although there is more normal 
erythropoiesis (mare 'differentiation) as compared to neoR SFFVp.
B. neoR SFFVp. Larger blasts with fewer normocytes and less 
differentiated erythropoiesis.
C. neoR SFFV-M. The picture seen here resembles that seen for neoR 
SFFVp at day nine.
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56.5. Histopathology in the white pulp of neo» SFFVp infected 
spleens (day 16)
A. This section (40x, Giemsa) demonstrates the presence of 
erythroblasts and areas of active erythropoiesis in the white pulp. 
Various granulocytes (G), histiocytes (H) and monocytes can also be 
seen.
The picture seen demonstrates a general stimulation of myelopoiesis.
R. This section of the white pulp (16x, acid phosphatase) demonstrates 
the extensive proliferation of histiocytes.
C. A section of a normal uninfected spleen (16x) after alkaline 
phosphatase staining demonstrating the distribution of mononuclear 
monocytes in the WP and RP.
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infiltration of erythroid blasts and to some extent mature erythroid 
cells. This effect was more pronounced in day 16 neoR SFFVp infected 
spleens than in neo* SFFV-M infected animals (Figure 56.5, A and B).
A parallel observation which also seemed to be specific for the neoR 
SFFVp vectors (also neoR SFFV-M) was a dramatic proliferation of 
histiocytes in the white pulp which was not seen for SFFVp (Figure 
56.6).
d) Construction of a neoR SFFVp based retroviral vector
From the data presented in this and the previous chapter it can be 
seen that the neoR SFFVp and the neoR SFFV-M constructs are both 
biologically active and stable after both in vitro and in vivo 
infections. It has also been seen that the env gene in these vectors 
(notably neoR SFFVp, gp55) is expressed at high levels both in vitro 
and in vivo in cells of the erythroid pathway (i.e. CFU-E and Friend 
cells). From the constructs presented here, it appears that the high 
level of expression of the gp55 gene, is either a consequence of more 
efficient splicing of this subgenomic mRNA, or is indeed a property of 
the env gene per se. Thus to further analyse this question it was 
decided to construct a neoR SFFVp based vector in which the gp55 env 
gene is deleted and replaced by restriction enzyme recognition sites 
which could be used for the insertion of respective genes. The 
construction of this vector is shown in Figure 57. This construct 
differs somewhat from the original neoR SFFVp vector in that the neoR 
MPSV coding sequences, including part of the neo gene have been 
deleted. This was undertaken, to: 1) Remove restriction enzyme sites 
which were be used for the cloning of genes into the vector (notably 
EcoRI and BamHI). 2) To reduce the size of the vector so that larger
(pMF16) neoR SFFV
B /B qR x?S j< p XhB/egP P So B RySK h
*  ÏH1 'RPRRv1
EB neoR SFF1
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Figure 57. Construction of a neo* SFFVp based retroviral vector, E3 
The E3 vector was constructed as follows:
1) pRPEL (fro« the construction of neo* SFFV-M) was digested with 
Hindlll and then partially digested with EcoRV. The resulting fragment 
(COOH terainus of gp55, and the 3’ LTR) was cloned into "Bluescript” 
(pE-1).
2) The Hindlll.Baafll 600 bp fragment which contained the splice 
acceptor sequence and none of the env coding sequence, was cloned into 
the sa«e sites in the "Bluescript" cloning vector (pFs.a.).
The splice acceptor sequence was then isolated after digestion with 
Baafll and Sail (see polylinker site of Bluescript) and ligated together 
with Baafll digested (and "cipped") pE-1 and a Bglll.Sail fragment 
isolated from pMF16.
The single letter restriction enzy«e code is as follows:
B, Baafll; Bg, Bglll; C. Clal; H, Hindlll; K, Kpnl; P, PstI; R, EcoRI; 
Rv, EcoRV: S, SstI; Sa, Sail; Sa, Saal; X, Xbal; Xh, Xhol.
^  Splice donor.
• Splice acceptor.
* represent cloning sites in the E3 vector.
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sequences could be introduced into the vector, without leading to 
problems when packaging the subsequent viral RNA into virions. The 
scheme used involved several subcloning experiments in the bacterial 
cloning vector "Bluescript", whose polylinker sequence enabled the 
introduction of the EcoRI site into the E3 vector. Further subcloning 
of the splice acceptor region of neo* SFFVp, encompassed within the 
Hindlll BamHI fragment, into "Bluescript" enabled the excision of this 
sequence with Sail and Bamfll terminal sequences, which were compatible 
to the other ends of the fragments used in this construction.
This vector thus offers a unique opportunity to examine whether the 
high expression of the gp55 env protein in erythroid cells is a 
property of the protein per se or whether the elevated splicing of this 
subgenomic message is a property of the SFFVp splice acceptor 
sequences. Insertion of indicator genes within the polylinker cloning 
site may well aid to analyse this question.
Discussion
It has been demonstrated in the previous chapter that a retroviral 
vector containing a dominant selectable marker gene, the env gp55 gene 
(including its splice acceptor sequence) and the SFFVp U3 region is 
able to cause a disease indistinguishable from the wild type SFFVp.
This virus neo* SFFVp was also able to confer G418 resistance to 
infected cells. From this study it could be concluded that only the env 
gene (gp55) from SFFVp along with the U3 are needed to give an 
erythroproliferative disease, for the rest of the retroviral genome, 
was derived from neo* MPSV which has been shown to cause no detectable 
pathological symptoms in vivo as well as in vitro. It was thus
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interesting to ask whether the U3 region is responsible for the tissue 
specificity/pathogenicity of the retrovirus as has been shown in other 
systems (Chatis et al., 1984; Stocking et al., 1985, 1986).
A similar study performed by Wolff and Ruscetti (1986), using a SFFVa 
construct, demonstrated that the LTR did not determine the disease 
specificity of SFFVa per se. The results presented here substantiate 
this finding, in that neoB SFFV-M was able to cause an 
erythroproliferative disease, whose target cells (CFU-E) were also 
erythropoietin independent and G418 resistant. However in all of the 
experiments performed where both neoB SFFVp and neoB SFFV-M were 
inoculated in parallel and in equivalent titres, there was always a 
"lag" in the disease caused by neoB SFFV-M, as determined by spleen 
weight, colony assays or at the histopathological level. Although the 
neoB SFFV-M vector was apparently less efficient than the neoB SFFVp 
construct it was also able to stimulate the infiltration of immature 
erythroid cells into the white pulp of the spleen and also cause a 
massive proliferation of macrophages again in the white pulp. This was 
not seen for the wild type SFFVp and may thus reflect that part of the 
genome which is not of SFFVp origin is able to cause this effect 
although further explanations for this are at the moment possible.
Analysis of the stability of neoB SFFV-M in vitro showed that the 
construct, was stably integrated in the cell lines used in this study, 
and that the virus was stably transferred to RATI fibroblasts. This 
analysis (Southern blotting) was unable to detect any changes in the 
genome structure of neoB SFFV-M. Thus it may be concluded that the lag 
in the disease, was caused by the LTR change. A possible reason for 
this may be a decreased transcription rate within the target cells 
(i.e. those of the early erythroid pathway), although MPSV itself is
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able to cause an increase of CFU-E (and also BFU-E) within the spleen, 
thus demonstrating that the LTR is functional within these cells. 
However, the MPSV disease, is caused by the mos oncogene (in 
conjunction with the U3 region. Stocking et al., 1985, 1986), which 
apparently needs only be expressed at very low levels in order to cause 
transformation either in vitro or in vivo. High expression of mos 
appears to be toxic for the cell. These observations may thus help to 
explain the phenomenon seen with the neo* SFFV-M vector. It may well be 
that the SFFVp in order to cause its rapid erythroproliferative disease 
is dependent upon high levels of gp55 expression within the infected 
target cells. This reduced expression, within the early erythroid 
compartment from the MPSV LTR may well lead to a lag in the disease 
kinetics, in that more time is needed to, a) reach the level of gp55 
needed to cause the erythroproliferative, or b) be expressed in enough 
target cells. The basis for this expression is not obvious. The MPSV 
LTR sequence is very similar to that of Mo-MuLV (Stacey et al.. 1984; 
Ostertag et al., 1987; M. Grez, pers. commun.), which was used in the 
study of Wolff and Ruscetti (1986). However, one obvious difference, 
apart from several point mutations, between the MPSV and the SFFVp LTR 
is a deletion of one of the direct repeats from the U3 region of SFFVp. 
This deleted "enhancer" containing region, could thus possibly be 
responsible for the elevated expression of gp55 in the spleen of 
infected animals. A variant of MPSV, PCMV has also undergone deletion 
of one of the direct repeats, has an extended host range due to this 
deletion (as well as a further deletion in the gag region). Thus 
although the neo* SFFV-M is able to cause the same erythroproliferative 
disease as neo* SFFVp there is a difference in the kinetics, which may 
be assigned to the LTR. One interesting observation, however, is that
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no transformed Friend cell lines could be isolated using this virus, 
even after repeated inoculation of susceptible mice with high virus 
titres and prolonged incubation periods (up to six weeks). The reason 
for this is unclear, for parallel experiments using neoB SFFVp, 
consistently gave rise to transformed cells, after culture in vitro. 
Possible explanations could be that either not enough target cells were 
expanded, which could thus lead to the rare event of transformation, or 
that the proposed specific integration even of SFFVp (adjacent to the 
putative oncogene Spl) is LTR sequence specific, a consideration that 
is unlikely. It may well be a combination of both high expression of 
gp55 which leads to an erythroproliferative expansion and then 
subsequent selection for a transformed phenotype (i.e. Friend cells).
In this respect the high levels of gp55 may well be critical, and a 
determining step for the expansion of the erythroid target cells. 
Although neo* SFFV-N is able to cause the erythroproliferation, 
(although be it with a different kinetics), it may well be insufficient 
to allow for a selection and thus subsequent proliferation of the 
transformed cells. Indeed in some of the infected mice, there was a 
regression in the spleen weight after prolonged incubation periods with 
neo* SFFV-N due to the host immune system. In this case it appears that 
the immune system is able to control the tumourogenic action of the 
neo* SFFV-N virus.
From the data presented in this and also the previous chapter it 
appeared that the neo* SFFVp, could well be an interesting vector for 
analysing gene expression within the erythroid pathway, although it is 
not clear whether the high expression of gp55 within erythroid cells is 
property of the gene itself, or of the splice acceptor sequences, 
together with the U3 of SFFVp. Thus to attempt to elucidate both of
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these questions a neo* SFFVp E3 retroviral vector was constructed, in 
which genes may be inserted behind the splice acceptor site in place of 
the gp55 gene (which has been in most part deleted).
This vector is being employed to look at the effects of epo, the 
SFFVa env gene, SFFVp env gene (neo* SFFVp) and the R-SFFV env gene in 
stem cells, which are able to differentiate along the myeloid pathway 
(including the erythroid, N. Ahlers and A. Nowock, pers. commun.). Such 
studies may further define the biological effects of gp55, with respect 
to the erythropoietin independence/dependence of the target cell 
infected by these viruses.
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General discussion
Although F-SFFVp was one of the first highly oncogenic viruses to be 
isolated and indeed molecularly cloned, (Friend, 1957; Linemeyer et 
al., 1980) little of how the virus is able to cause its pathogenic 
effects is known. To add to this there are two types of F-SFFV which 
are able to cause either an anaemia or a polcythaenia in susceptible 
adult aice. Further characterisation of these SFFVs reveals that there 
are four different strains of the polycythaemia inducing SFFVp, three 
of which have been previously molecularly cloned (Linemeyer et al.. 
1980: Yamamoto et al., 1981; Amanua et. al., 1983). In the work 
presented here the fourth strain (Nirand, 1968) was molecularly cloned 
along with its helper virus. The cloning approach utilised in this 
study was novel in that the source of the DNA to be cloned (both F-MuLV 
and SFFVpM) was of extrachromosomal origin whose presence was shown to 
be quantitatively proportional to the differentiation state and also 
the differentiation ability of the Friend cells analysed. This 
phenomenon (first described by Ikawa et. al.. 1980) was shown to be 
confined to Friend cells (as coapared to the other cells used in this 
study) and until recently had only been observed in one other system 
(MMTV infected rat hepatoma cells, Ringold et al., 1978). However 
recently an extracbromosomal form of a retroviral DNA molecule (HTLV-1, 
Hiramatsu et al., 1988) has also been identified within HTLV-1 infected 
human HL60 cells. It was shown by these workers that these 
extracbromosomal DNA molecules (both linear and circular) were able to 
reintegrate into the host cell genome upon passage of these cells. In 
the study described here, no detectable new integration sites could be
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detected within the genoae of F4-6 cells during the DNSO induction of 
these cells or indeed over one year of continuous culture (data not 
shown). However one problea involved in this analysis in F4-6 cells is 
the lack of a specific probe which only detects integrated F-SFFVpM 
sequences and not env related endogenous sequences which are present in 
the DBA/2J genoae froa which these cells originate thus aaking 
detection of new integration site very difficult. This phenoaenon could 
possibly be analysed aore easily now, for as described in Chapter 4 of 
the results. Friend cells tansforaed by a neo* SFFVp are now available 
thus providing a unique hybridisation probe, however it reaains to be 
seen whether extrachroaosoaal ONA molecules are at all present within 
these cells.
Both cloned viral entities were biologically active with the F-MuLV 
being able to cause a lymphatic leukaeaia in new born aice only and F- 
SFFVpH being able to cause an erythroleukaeaia in susceptable adult 
aice, although not with the altered target cell specificity that was 
hoped. Thus the one aspect of the work presented in this thesis to 
aolecularly clone the Mirand strain of F-SFFVp along with its helper 
virus was successful although after encountering aajor difficulties 
with the SFFVp coaponent. That the FV coaplex is regularly used in this 
laboratory aeans that specific molecular probes are now available for 
the molecular analysis of SFFVp in the various experimental cell 
systems exploited here. The molecular clones of the two viruses may 
also be used to further examine the molecular siailarity suggested by 
Nol and co-workers (1981). Such information (i.e. complete nucleotide 
analysis of both of the viral genoaes) would enable one to determine as 
to which recombination events were involved in the genesis of the SFFVp 
genome within this system for these two FV coaponents have remained
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together and have thus co-evolved since their isolation. Comparative 
analysis of the only fully sequenced SFFVp (Clark and Mak, 1983) 
suggests that SFFVp is generated by a complex sequence of 
recombinations involving most likely a minimum of three retroviruses, 
namely an endogenous retrovirus related to AKV, F-MuLV and a virus with 
xenotropic sequences. The recombination point of xenotropic/ecotropic 
SFFV env sequences appears to be similar to that of the F-MCF virus.
The 3‘ end from the 5’ LTR (U5) to the 3' half of the gag gene shows 
more than 95% nucleotide sequence homology between SFFVp and AKV. The 
remainder of the gag region and the non-deleted pol of SFFVp has 75-95% 
homology to both AKV and F-NuLV: More than 90% homology to xenotropic 
and xenotropic derived NCFV sequences is found from the 3' end of pol 
to the middle of the env gene. The 3* end of env is 90-100% homologous 
to F-MuLV.
A second apsect of the work presented here was to develop a 
biologically active SFFVp containing a dominant selectable marker gene, 
which up until now has remained somewhat elusive, (Joyner and 
Bernstein, 1983; Ostertag et al., 1987). The original consideration was 
to use the molecularly cloned F-SFFVpN for this construct, but because 
of the difficulties encountered with the molecular cloning of the virus 
and also for other considerations described earlier the molecular clone 
of the Lilly and Steeves strain was utilised (Linemeyer et al., 1980).
In this thesis it has been shown that using an MPSV based retroviral 
vector as a framework then a biologically active F-SFFVp with a 
dominant selectable marker gene could be constructed and to some extent 
was even more potent than the unmodified wild type SFFVp. Furthermore 
this construct demonstrated that only the env and U3 sequences from F- 
SFFVp are required not only to elicit the erythroproliferative disease,
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but also for the transformation event leading to the isolation of 
Friend cells. Previous workers have used deletion autants and 
genetically engineered recoabinants which bad a SFFV based background, 
thus not disclosing whether other sequences apart froa the env gene may 
indeed contribute to the pathogenicity of the virus, (Lineaeyer et al., 
1982; Ruta et al., 1983; Machida et al., 1984, 1985). The MPSV vector 
which formed the backbone of the neo* SFFVp vector has no pathogenic 
effects in vivo (Ostertag et al.. 1986).
A further construct which differed froa the original neo* SFFVp only 
in the origin of it's U3 region deaonstrated that this region is not 
responsible for the tropisa and pathogenesis of this construct, 
although the initial kinetics of the priaary disease caused by this 
virus soaewhat lagged behind that of the original neo* SFFVp. Direct 
nucleotide sequence coaparison of these two U3 regions along with other 
related viruses, show that within the 03 there is considerable 
nucleotide heterogeneity displayed between the two sequences, (Figure 
58) the aost noticeable of which is the deletion of one direct repeat 
and thus one enhancer in the SFFVp sequences. There is also a 
noticeable nucleotide heterogeneity at the start of the U3 region and 
also at the boundary of the direct repeats whose sequence is a putative 
glucocorticoid receptor binding site. In these regions the MPSV U3 is 
alaost identical to that of the Mo-MuLV LTR which has been shown not to 
alter the biological activity of a recoabinant F-SFFVa (Wolff and 
Ruscetti, 1986).
The reasons for this difference in kinetics is soaevhat unclear 
although effects on transcription levels could be envisaged (either on 
gene products or on progeny viral RMA) when one considers other systeas 
where tissue/cell tropisa and elevated transcription have been shown to

Figure 58. Coaparison of LTR nucleotide sequences of SFFVp and related 
viruses with the LTR sequence of F-MuLV.
Missing nucleotides are indicated by inverted repeat sequences are 
labelled i.r- and direct repeats are labelled d.r. The sequences are 
taken fro«;
Koch et al., 1984: F-SuLV 57, F-MCFV.pFM54B;
Adachi et al., 1984: F-MCFV FrJfx;
Volfi et al.. 1985: F-SFFVa, F-SFFVpLS;
Bestvick et al.. 1984: R-SFFY;
Clark and Mak, 1982: SFFVpAx;
Bosselaan et al.. 1982: H-HCFY cll6;
Stacey et al., 1984: MPSY;
Shinnick et al.. 1981: Ho-MuLV paLVl;
Vogt et al.. 1985; RMCFV-1.
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be dependent upon the cell system.
These vectors may also prove to be useful tools in the dissection of 
various aspects of the pathogenesis of SFFVp for due to their 
selectable marker gene (G418 resistance) cells infected with these 
viruses are easily selected in vitro and are also tagged after 
integration with a sequence which is unique and easily detectable in 
eukaryotic cells. Thus integration sites and target cells may be 
analysed as well as SFFVp specific activities (i.e. directed 
mutagenesis within the env gene. R. Friedrich, University of Giessen 
pers. commun.). A retroviral vector E3 based upon the neo* SFFVp 
construct was also constructed so that sequences apart from the F-SFFVp 
env gene could be analysed. This vector may also prove to be useful for 
high expression of genes within cells of the erythroid lineage or even 
haemopoietic stem cells.
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